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ABSTRACT 
This PhD considered provision of information to potential research participants.  It 
gathered data on the types and detail of information potential participants accessed, 
and determined the feasibility of electronic information provision. 
 
A systematic review found limited empirical evidence to suggest what information 
potential participants want when making a participation decision. 
 
An Information Provision study was designed and embedded in an existing piece of 
low risk interventional research. This had three components; a feasibility study of 
electronic communication; a RCT of an Interactive Information Sheet (IIS); an 
observational study that recorded information accessed by potential participants. 
 
Results suggest electronic communication did not affect consent rate (although study 
was not powered to detect this) and understanding and satisfaction were unaffected 
by level or mode of information provision.  Traditional participation information sheets 
(PIS) may only satisfy 11.4% participants, undersupply 9.1% and oversupply 79.5%.  
Participants were often unable to accurately recall what information they had 
accessed.  
 
In conclusion, the majority of potential participants to this study would have been 
satisfied with a streamlined PIS.  An IIS could provide additional tailored information 
to those who require it, with standardised verbal information provision at consent 
interviews ensuring consent is given in accordance with GCP guidelines.  
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1 INTRODUCTION 
2 
 
Medical research is required for medicine to advance and effective care to be 
provided1;2 but raises ethical concerns when participants are involved3.  It is widely 
accepted that research participants must give their consent before any intervention is 
made (or proxy consent for vulnerable persons, i.e. children and incapacitated 
adults4;5).  This thesis reports studies of one aspect of consent - the provision of 
information.  The studies reported in this thesis are a systematic review of the 
literature to determine the evidence base for what potential participants want to know 
when they are considering participating in research, a feasibility study of providing 
electronic information, a randomised controlled trial (RCT) that explored an 
alternative to the traditional paper based participant information sheet (PIS) and an 
observational study that recorded what information potential participants actually 
accessed when deciding whether to participate in a low risk interventional study. 
 
The overall aim of the thesis was to gather evidence on the topics and level detail of 
study information potential research participants accessed when deciding whether to 
participate in a piece of low risk interventional research, and to determine the 
feasibility of electronic information provision.  This aim was met by answering four 
research questions –  
1. What does the current evidence suggest potential participants want to know 
when they are deciding whether to participate in research?  
2. Is electronic information provision in research feasible?  
3. What information did potential participants access when they made a decision 
about whether to participate in a piece of low risk interventional research? 
4. What are the implications for the future of information provision given answers 
to research questions 2 and 3?   
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The thesis comprises seven chapters; background information, methods and results 
of a systematic review of the literature, the Information Provision study protocol, 
development of an Interactive Information Sheet (IIS), results, a discussion of the 
future for information provision in research in light of the results, and conclusion to 
the thesis. 
 
The background chapter puts the thesis aims into context over three areas.  The first 
outlines the ethical principles driving the process of consent to research participation 
before focusing on what information should be provided to potential participants to 
obtain valid consent.  The second section describes common problems encountered 
when providing study information and reviews research on interventions that have 
been introduced to improve the information provision process.  The final section 
explores the role of the Internet in research and how it could be used to provide 
electronic information to participants.  The chapter finishes with an outline of the 
objectives used to answer the four research questions of the PhD.   
 
The first study conducted for this PhD was a systematic review to answer research 
question 1 and establish the evidence base for what information potential participants 
wanted to know when considering participating in research. Chapter 3 describes the 
methods and results of this systematic review.  The resulting evidence base is then 
compared to the NRES guidance of what to include in a participation information 
sheet (PIS).  This systematic review has been published in BMJ Open and is 
included as Appendix 9.1. 
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Chapter 4 describes the methods for the design and implementation of the 
Information Provision study, the second study of this PhD, which aimed to answer 
research questions 2 and 3.  The chapter begins by describing the process that 
identified a suitable parent study in which to embed the Information Provision study.  
The Information Provision study had three components; a feasibility study of 
electronic information provision in research, a randomised controlled trial (RCT) of an 
IIS compared to a PDF copy of a standard PIS, and an observational study that 
recorded the information accessed when potential participants were considering 
participating in a piece of low risk interventional research.   
 
No established effect size was available on which to calculate a sample size for the 
RCT, so part of Chapter 4 (Section 4.5) outlines how a small study was conducted to 
determine an effect size on which to calculate a sample size.  The novel method 
developed for this study has been published in BMC Research Methodology and is 
included as Appendix 0. 
 
The Information Provision study included an alternative way to provide information to 
potential study participants by using an Interactive Information Sheet.  The IIS 
allowed potential participants to choose the amount and types of information they 
accessed when considering participation in a piece of low risk interventional 
research.  The IIS was based on work by Antoniou et al6 and Chapter 5 outlines the 
development of the IIS for use in the Information Provision study.  The first section of 
Chapter 5 presents the development of the website that hosted the IIS and enabled 
the IIS to unfold and record information accessed into a database.  The second 
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section of Chapter 5 outlines the development of the content included in the IIS.  The 
information in the IIS is included as Appendix 9.2  
 
Chapter 6 provides the results of the Information Provision study.  It reports 
participant numbers and presents demographic data followed by the information 
accessed by participants, the effect of the interventions on recruitment rates, the 
feasibility of using electronic recruitment and electronic information and participant 
understanding of and satisfaction with the information provided.   
 
In order to answer the final research question, the results of the Information Provision 
study were used to develop a streamlined PIS for the parent study.  The streamlined 
PIS incorporated the information that participants accessed when they were deciding 
whether to take part in the low risk interventional study and the information that is 
required by the International Conference on Harmonisation7 (ICH) and the four 
statutory instruments for Good Clinical Practice (GCP) required by UK law.   The 
results of the Information Provision study and the streamlined PIS were then 
presented to the National Research Ethics Service (NRES) expert panel.  They 
provided feedback on these results, their opinions on the streamlined PIS for 
interventional research and how the research could be taken further.  The final 
section of Chapter 6 reports the feedback received at this meeting. 
 
Chapter 7 discusses the results of the thesis.  It considers firstly whether using 
electronic PIS would be feasible in research and looks at the practicalities of 
providing information and recruiting electronically.  The chapter then considers the 
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ethical concerns of information provision regarding consent in light of the results of 
the Information Provision study and offers potential solutions for future research.  
 
In the concluding chapter the key points of the work undertaken for the thesis are 
brought together and it is argued that improvements in information provision for low 
risk interventional research are required.   
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2 BACKGROUND 
8 
 
Three areas of background information are needed to put the thesis aims into 
context.  First, the ethical principles involved in consent (Section 2.1) and the 
information that should be provided to potential research participants (Section 2.2).  
Second, the common problems with providing information to potential participants 
(Section 2.3) and the previously reported interventions in information provision 
(Section 2.4).  The Internet was used in the main project of this PhD as the platform 
to provide study information to potential research participants, so the third area of 
background information explores the role of the Internet in research (Section 2.5) and 
how it can be used to provide study information to potential participants (Section 2.6).  
The chapter concludes with the detailed aims and objectives of this PhD (Section 
2.7). 
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2.1 CONSENT CRITERIA  
 
Consent is a pre-requisite for participation in research and researchers should 
normally obtain the ‘free and informed consent’ of potential participants before they 
enrol8-11.  Gaining participant consent is not merely a legal requirement or formality 
but a moral obligation to ensure that potential research participants fully understand 
and voluntarily make decisions regarding participation.   
 
The requirement for consent prior to research participation comes from a respect for 
autonomy.  Although respect for autonomy is a complicated philosophical concept 
that will not be debated in this PhD, when the research community use ‘respect for 
autonomy’ in terms of consent it is generally understood to mean that potential 
participants make a choice about participation based on their own values, for their 
own reasons and should have that choice respected12-14.  In order to respect a 
potential research participant’s autonomy and for their consent to participate in 
research to be considered valid, it has to fulfil three criteria: 1) The participant is 
given specific detailed information about the study.  2) The participant is capable of 
understanding the information provided and using it to make a decision regarding 
participation.  3) The decision is made voluntarily2;3;15;16.  In addition, potential 
participants should be given sufficient time to make their participation decision.  
Although not compulsory, it is considered good practice to allow participants at least 
24 hours to make a participation decision where appropriate17-19.  Participants should 
be given as much time as they personally require to make a decision - for some 
participants and/or studies this may require much more time and for others much 
less.   
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The consent process should also be on-going and reviewed throughout a research 
study.  Researchers should ensure that even after participants have given their initial 
consent they remain willing to participate, and their consent should be updated if 
changes are made to the study20.  
 
The participant is given specific detailed information about the study 
For the first consent criterion to be fulfilled the participant must be given specific, 
adequate information about the study.  In order to determine what information 
potential research participants need to know to provide their consent we need to 
understand why they should be informed.   
 
The nature of clinical trials often means that the absolute benefit to potential 
participants is unknown, the potential for harm has not been established and there 
may be known and unknown (serious) adverse events or reactions.  In some 
research studies there may also be no expected direct potential benefit to 
participants, for example, an early phase clinical trial where only the safety and 
efficacy of a new drug is tested for the benefit of future patients3. The uncertain 
nature of research means that potential participants put themselves at risk of harm 
(and/or a chance of benefit) in order for medical knowledge to be gathered.  There is 
a greater expectation of unknown toxicity and/or side effects in research than for 
standard treatments, and so the risk is considered greater.  Providing autonomous 
individuals with study information allows them to decide if participating in the 
research is consistent with their values, interests and preferences2;3;14;21-23.   
 
It has been argued that ‘fully informed’ consent can never be achieved because only 
those with expert knowledge can understand all aspects of a research study24.  
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Although consent may rarely be fully informed, it does not mean it cannot be 
adequately informed.  The question to address here is a subjective one of how much 
information needs to be imparted to a potential research participant for it to be 
considered adequate for them to make a participation decision.  To help explain the 
term ‘adequately informed’ the example given by Hewlett3 of a potential customer 
considering a car purchase is useful.  The customer might choose to buy a car based 
on information about its history and performance rather than full information about 
the workings of its engine.  The customer would not be fully informed of the purchase 
if they chose not to understand precisely how the engine works, but they consider 
themselves to be adequately informed because they have the information they 
wanted to know about the car’s history and performance.  Similarly, whilst one 
potential research participant may consider himself adequately informed solely by 
information relating to the potential risks and benefits of participating, the values and 
beliefs of another mean that sources of funding are a significant factor, for example. 
The topics of information important to decision-making are, therefore, likely to differ 
between potential research participants.   
 
Returning to the car sale analogy, the level of detail of information about the car 
considered adequate to make the purchase decision is also likely to differ between 
customers.  A racing driver is likely to be more interested in knowing the specifics of 
a car’s predicted performance than someone buying a car to get to local shops once 
a week.  In this situation, one may accept that the latter does not want or need to 
know information about the car’s performance.  If so, imparting information about the 
car’s performance would not affect the purchase decision, and the customer may not 
understand the information or not be interested in it.  Although the latter buyer is not 
12 
 
fully informed about the car, they are adequately informed because the information 
they have is sufficient to meet their personal requirements.  Similarly, whilst one 
potential participant may neither understand nor be interested in the pharmacological 
actions of a research drug, another may require this level of detailed information 
before they consider themselves adequately informed.      
 
A further point to consider is the level of understanding that is considered adequate 
for a potential participant to be able to make a participation decision.  For anyone to 
have complete understanding of a research study they would need to have the same 
depth and level of understanding as a physician and scientist, since fully 
understanding how a drug works would need in depth knowledge of both anatomy 
and the pharmacological actions of the drug.  To require understanding in the same 
way and to the same extent that a physician and/or scientist understands is an 
unreasonable and impractical expectation to have of potential lay participants14;25 
 
Consent criteria require potential participants to be given ‘adequate’ study 
information on which to make their participation decision.  The amount of information 
considered adequate, however, is likely to differ between research participants.  This 
makes it difficult for researchers to decide exactly what types and how much 
information to include in a PIS.  The IIS used in this PhD aimed to adequately inform 
all potential participants.  Instead of providing a fixed amount of information, it 
allowed potential participants to tailor study information to their individual 
requirements.  
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Other reasons why potential participants should be provided with study information 
relate to protecting the integrity of the research rather than protecting participant 
autonomy.  For example in a clinical trial where a treatment for a chronic disease 
may initially make the participant feel worse before they feel better,  giving potential 
participants information about what to expect may improve the chances of their 
continued co-operation with the study and reduce the dropout rate26.  Reducing the 
dropout rate of a study improves the integrity of the collected data and validity of 
results27.  Since researchers have a responsibility to conduct research in such a way 
that can meet its aims, there may also be ethical connotations if the dropout rate 
biases results to such an extent that results are no longer deemed to be useful28. 
 
The participant is capable of understanding the information provided and 
using it to make a decision regarding participation  
For the second criterion for consent to be fulfilled the potential research participant 
must be capable of understanding the information provided and using it to make a 
decision regarding participation: to have the capacity to make a decision to take 
part29;30.  The Mental Capacity Act (2005)5  states that in order to have capacity the 
person must be able to understand the information provided, retain the information, 
use the information as part of the decision making process and be able to 
communicate their decision.  
 
In order to understand information, a potential participant has to understand the 
consequence of that information.  To have an adequate understanding of the 
consequences of consenting to research does not mean that a potential participant 
needs a deep understanding of, for example, how a study drug works and how it has 
its effects on the body.  Instead, they require an understanding of the types and 
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severity of potential side effects that drug may have and how they can report any 
they experience.  The manner in which information is provided will influence 
adequacy of understanding (Sections 2.3 and 2.4), and since not understanding the 
information is part of the test for incapacity, study information needs to be 
communicated in a way that does not render a potentially competent participant 
incapacitated.   
 
Usually in research, potential participants are provided with information in a paper 
PIS that is verbally reinforced during the consent interview.  Participants’ inability to 
recall information from the PIS at the time of the consent interview does not mean 
they lack capacity to consent.  The Mental Capacity Act5 states that a person is 
unable to make a decision only if they cannot “retain that information, to use or weigh 
that information as part of the process of making the decision” (Section 3, 1b and 1c).  
This means that providing potential participants are able to retain and recall the 
verbal information given at the time they are asked to make a participation decision, 
they are considered to have capacity to consent since they are able to retain the 
information long enough to use it to make a participation decision5.  
 
Finally, after making a decision, the potential research participant needs to be able to 
communicate that decision to researchers.  Their decision may be communicated in 
any way appropriate to their circumstances, for example, using sign language or 
visual aids.  Anyone not able to communicate their decision is rendered incapacitated 
by the Act because they cannot engage in decision-making, even though they do not 
actually lack inherent capacity30-32.  In order to protect, for example, those who speak 
a different language, from being rendered incapacitated, the Act guidance notes33 
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require considerable effort to be made to enable potential participants to 
communicate their decision regarding participation.  Language is a particularly 
challenging area for communication in research since it is often difficult to ensure that 
translations are appropriate.  The Act guidance notes33 stress that there are very few 
participants unable to make a participation decision because they cannot 
communicate it in any way, and the example provided is that of ‘locked in syndrome’ 
where participants can only communicate through blinking.  These participants can 
still communicate and, therefore, should not be rendered incapacitated to consent30. 
 
The decision is made voluntarily  
The final criterion for valid consent is that it is given voluntarily.  This criterion 
requires that potential participants are not coerced into participating, i.e. they are not 
subject to the undue influence of a third party.  For example, if a GP offered a patient 
a particular treatment in return for participating in one of their studies, it would be 
considered coercive and their consent not voluntary14;15;34.   
 
Potential participants may be concerned that they will receive a reduced standard of 
care if they do not ‘comply’ by participating in research they are invited to take part in.  
Participants that agree to take part only because of these concerns for future care 
would not be giving their consent voluntarily as a coercive influence is the overriding 
factor for their decision.  In order for their consent to be given voluntarily, potential 
participants should be assured that they do not have to take part in the research and 
their healthcare would not be affected if they refused to participate.   
 
Another aspect related to voluntariness is the right to withdraw, which ensures 
participants continue to take part in the research voluntarily after they have given 
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their initial consent to participate.  International and UK guidelines state that ‘the 
subject should be informed of the right to withdraw consent to participate at any time 
without reprisal’22;35.  This right to withdraw is meant to reassure potential participants 
that their consent now does not mean that they cannot reduce or withdraw their 
commitment at a later date36.  Participants may wish to withdraw from the study for 
many reasons, for example, they could experience life changes that mean they have 
difficulties meeting the study demands and wish to withdraw completely from the 
study.  Or they could struggle to cope with side effects of a trial drug and no longer 
wish to continue taking it, but agree to be followed up and for their data to be used in 
the study.  There are, however, logistical problems in allowing participants to 
withdraw from the study “at any time”, for example, participants could not withdraw 
their consent for individual results to be used in analyses once study results had 
been published.  The process of and problems with withdrawing consent are outside 
the scope of the thesis and will not be discussed further. 
 
This section has explored what consent is and has shown that it is far more than a 
potential research participant simply agreeing to take part in a study.  In order for 
consent to be valid, a potential research participant has to have sufficient information 
about the study, be able to understand that information and use it to make a 
voluntary decision about whether to take part.  When thinking about consent to 
research it is important to have an understanding of all criteria needed for valid 
consent, but the rest of this PhD concerns only one aspect of consent: the provision 
of information.   
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Key points 
Consent is normally a pre-requisite for participation in health research. 
 
The requirement for consent is based on respect for autonomy that focuses on 
the potential participant making a choice based on their own values, for their 
own reasons. 
 
In order for consent to participate in research to be valid, it has to fulfil three 
criteria –  
1) The participant is given specific detailed information about the study.   
2) The participant is capable of understanding the information provided and 
using it to make and communicate a decision regarding participation.    
3)  The decision is made voluntarily. 
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2.2 THE INFORMATION THAT SHOULD BE PROVIDED TO POTENTIAL RESEARCH 
PARTICIPANTS 
 
This section explores why information provision differs between clinical treatment and 
medical research and then outlines current UK and international guidance and 
guidelines. 
 
Differences between treatment and research  
Guidelines for information provision in clinical care are provided by the General 
Medical Council (GMC) and state that physicians have a duty to engage participants 
in decisions as much as possible, share information and maximise patients’ ability to 
make autonomous decisions for themselves2.  The GMC also acknowledges that no 
single approach to discussions about treatment or care will suit all patients or apply in 
all circumstances, and their guidelines allow the doctor to use specialist knowledge, 
experience and clinical judgement to tailor the amount of information provided (with 
guidance from the GMC2 and Department of Health37).   
 
The conduct of research is controlled by regulatory codes and overseen by ethics 
committees and institutional review boards26 and there are specific guidelines that 
recommend what information should be provided to potential research participants 
that do not exist for clinical care22;35.  Whilst the physician may recommend a 
particular option they believe to be best for the patient, when this is done in research 
there is a question of whether the doctor’s advice constitutes coercion to participate 
and, therefore, undermines autonomy and invalidates consent38.  The other side to 
this argument is that if the researching doctor does not offer advice that would be 
pertinent to the potential participant’s decision-making, even if  it is likely to be 
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coercive, they have not met their clinical obligation of providing the information they 
think is required for their patient to make a decision38.  There are currently no clear 
guidelines as to where the balance between these two points lies.    
 
In research, study information is traditionally conveyed to potential participants by a 
written participant information sheet (PIS) with sufficient time to consider the 
information, before it is reinforced by a verbal consent interview and participants are 
asked to make a consent decision3;22.  The consent process may differ from this 
traditional model - for example, in clinical trials initial information is often provided 
verbally to the patient during a consultation with their doctor, and the patient is then 
provided with a paper PIS to take away39-41. 
 
There are many differences between clinical care and research settings, with the 
biggest difference being in what they aim to do.  Whilst the focus of clinical care is 
solely the well-being of the patient, the goal of research is primarily the acquisition of 
knowledge to benefit future patients26.  Standard therapies are usually well 
understood, are thought to be the best treatment for a particular clinical problem and 
associated risks and potential side effects can often be quantifiable26. Clinical 
research, by virtue of it being research, may put the participant at risk of unknown 
side effects and risks, since the intervention has not been evaluated.  There may, 
however, also be an anticipated or unknown benefit with trial therapies that do not 
exist with the standard therapy.   
 
Researchers are legally required42-45 to disclose more information than physicians 
and some experts argue that this should remain the case46.  A greater level of 
disclosure may be required in research than for clinical care, both because of the 
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greater risk of unknown side effects and toxicities in research, and because the aim 
of research is to benefit future patients rather than being in the best interests of the 
potential participant (even though results may show that participating is beneficial for 
the participant).  For some, a decision to participate may be affected by simply 
knowing how information is being collected and used for research, so a greater level 
of disclosure allows potential participants to access additional information regarding 
research processes that may be decisive to them47. 
 
Physicians are able to make a choice between two treatments where there is clinical 
equipoise48 without telling the patient the risks and benefits of each treatment.  If, 
however, these same two treatments were used in a research study to determine if 
one was superior, the doctor-researcher must inform the potential participant of all 
the potential risks and benefits of both treatments.  Some experts argue that the 
discretion to provide tailored information for clinical care should extend to research 
and the amount of information to be provided to potential participants should remain 
the decision of the doctor-researcher47;49, especially when the drugs being evaluated 
are already available for use in other situations.   
 
Disclosure of information in both the clinical and research setting is supposed to 
facilitate an autonomous decision to be made.  Some experts argue that the amount 
of information to be disclosed in both treatment and research should be based on the 
level of risk likely to occur49, so the amount of information a person considers 
adequate to make a research or treatment decision may be similar.  Research and 
treatments considered low risk arguably require less information to be provided than 
those considered high risk49.  Alternatively it may be that respect for autonomy and 
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protection from harm are paramount in both clinical care and research settings alike 
and guidelines for information provision should be similarly strict in both settings.   
 
There are differences of opinion on whether information provision should differ 
between clinical and research situations.  In order to determine how much 
information should be provided to potential research participants, we need to firstly 
determine what information potential participants actually use to make a participation 
decision.   
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Key points 
Information provision in research is tightly controlled by regulatory codes and 
is overseen by ethics committees and institutional review boards.  In clinical 
care the decision of how much information to provide is left with the treating 
physician. 
 
Health research requires information to be shared with potential participants to 
make a decision, whereas in clinical care it is controlled by physicians. 
 
Information provision differs between research and clinical care due to their-   
 Respective aims.   
o Clinical care focuses on the well-being of the patients.   
o The focus of research is primarily the acquisition of knowledge to 
benefit future patients.   
 Relative risks.   
o A trial therapy may put the participant at risk of potential unknown 
side effects and toxicities since the intervention has not been 
evaluated. 
o Not all research is considered high risk – for example, questionnaire 
based studies. 
23 
 
Current guidelines for informing research participants 
The first published guidelines for informing potential research participants were the 
Nuremberg Code (1949) that occurred as a result of human rights abuses in 
Germany during the Second World War.  The Nuremberg code provides 10 points 
that should be observed for all trials, the first of which concerns voluntary consent of 
participantsii.  Following this, an important international statement, the Declaration of 
Helsinki35, was produced by the World Medical Association in 1964 (with subsequent 
amendments). This provided further guidelines on what information should be 
provided to potential research participantsiii.  In terms of information provision, both 
The Nuremberg Code and Declaration of Helsinki state that potential participants 
should be adequately informed about research but do not provide guidance on the 
detail that should be provided. 
 
Following the Nuremberg Code and Declaration of Helsinki, the International 
Conference on Harmonisation7;50 (ICH) aimed to harmonise clinical research 
processes, in order ensure that research is conducted safely, effectively and in the 
                                            
ii
 Relating to the voluntary consent of participants, the Nuremburg Code states the potential 
participant: 
“should have sufficient knowledge and comprehension of the elements of the subject 
matter involved as to enable him to make an understanding and enlightened decision.  
This latter element requires that before the acceptance of an affirmative decision by the 
experimental subject there should be made known to him the nature, duration purpose of 
the experiment; the method and means by which it is to be conducted; all inconveniences 
and hazards reasonable to be expected; and the effects upon his health or person which 
may possible come from his participation in the experiment.” 
 
iii
 In terms of information provision in research the current version of the Declaration of Helsinki states 
that:  
 
‘In medical research involving competent human subjects, each potential subject must be 
adequately informed of the aims, methods, sources of funding, any possible conflicts of 
interest, institutional affiliations of the researcher, the anticipated benefits and potential 
risks of the study and the discomfort it may entail, and any other relevant aspects of the 
study.  The potential subject must be informed of the right to refuse to participate in the 
study or to withdraw consent to participate at any time without reprisal.’ 
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most efficient and cost-effective manner51.  The ICH gave rise to the first set of Good 
Clinical Practice (GCP) guidance to become mandatory for all commercial clinical 
research.  One aspect of GCP concerns the protection of participants and in part 
covers the information that should be provided to potential participants before 
consenting to a study.  Following ICH guidance, the European (EU) Directive on GCP 
in Clinical Trials (2001/20/EC) aimed to harmonise research processes within the EU 
and covered both commercial and non-commercial research.  The EU Directive first 
became UK law on 1st May 2004 by use of statutory instrument ‘The Medicines for 
Human Use (Clinical Trials) Regulations 2004 (SI 1031)42’.  There are currently four 
statutory instruments that regulate clinical trials in the UK – 1. Medicines for Human 
use (Clinical Trials) Regulations 2004 (SI 1031)42.  2. Medicines for Human use 
(Clinical Trials) Amendment Regulations 2006 (SI 1928)43.  3. Medicines for Human 
use (Clinical Trials) Amendment No. 2 regulations 2006 (SI 2984)44 4.  Medicines for 
Human use (Clinical Trials) and Blood Safety and Quality (Amendment) Regulations 
2008 (SI 941)45. 
 
One part of GCP concerns information provision to research participants and the ICH 
GCP provides a list of information that potential participants must be provided with 
before they consent to research.  The National Research Ethics Service (NRES) 
provide guidance22 to help researchers write PIS’s that meet the requirements of the 
ICH GCP.  NRES guidance suggests headings (Figure 1) of information that should 
be provided in a PIS (where relevant).  The guidance suggests that one size of PIS 
will not fit all and the length should be matched to the complexity and risk of the 
individual study. It also notes the concern that PIS are becoming increasingly long 
and complex.   
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Even with the extensive NRES guidance, researchers often find it difficult to decide 
how much detail to include in a PIS52;53 since each potential participant is likely to find 
different types of information important and require different levels of detail before 
they are able to make a participation decision.  It is often particularly difficult to know 
how much information to include in PIS for low risk studies, in particular 
questionnaire-based studies where less information is likely to be provided in a PIS 
since reading the questionnaire itself provides information on the types of questions 
being asked.   
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Figure 1 - NRES suggested PIS headings22 
What is the purpose of the study? 
Why have I been invited to participate? 
Do I have to take part / What will happen if I do not want to carry on with the 
study? 
What will happen if I take part / What will I have to do?  
Will I be paid expenses or payments for participating? 
What are the alternatives for diagnosis and/or treatment? 
What are the disadvantages and risks of taking part / Side effects of any 
treatment received? 
Information relating to the radiation and Ionizing Radiation Regulations. 
Could participating could cause harm to an unborn child? 
What are the benefits of taking part? 
What will happen when the research study stops? 
What will happen if there is a problem? 
Will participation be kept confidential? 
What will happen if relevant new information becomes available? 
Will by GP/family doctor be involved? 
What will happen to any samples I give? 
Will any genetic tests be done? 
What will happen to the results? 
Who is organising and funding the research? 
Who has reviewed the study? 
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Key points 
Research in the UK must adhere to four statutory instruments. 
 
One aspect of GCP is the provision of information to potential participants. 
 
The National Research Ethics Service (NRES) provides extensive guidance 
on how to write PIS that adhere to statutory instruments. 
 
Even with the extensive guidance provided by NRES, researchers often find it 
difficult to decide on the level of detail to provide in a PIS, especially in low risk 
interventional research and questionnaire based studies. 
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2.3 PROBLEMS WITH READING AND UNDERSTANDING PARTICIPANT 
INFORMATION SHEETS 
 
This section outlines the problems associated with writing and communicating study 
information and the following section describes the reported interventions that have 
aimed to improve these processes. 
 
It is essential that a PIS is readable and understandable to research participants (or 
their representative) if it is to be used to aid decision making.  The average reading 
age of the UK population is estimated to be around that of an educated 9 year old 
and the need to write PIS’s at a suitable level has been noted for decades54.  Despite 
this, PIS often contain complex language that is above the recommended reading 
age55;56.  Potential participants often struggle with the language and content of a PIS 
with even a low level of readability57 and the general population finds medical and 
scientific language particularly difficult to read57, so the task of writing a readable PIS 
can be difficult.  The readability of a PIS is directly linked to a potential research 
participant’s understanding of the study58.  A PIS that requires a high reading level or 
contains excessive clinical jargon is more difficult to understand than a simple 
disclosure and participants particularly struggle to grasp scientific concepts such as 
‘randomisation’, ‘equipoise’, ‘risk’ and ‘probability’57;59;60.  Participant demographics 
can also have an effect on understanding with lower educational levels and reading 
ability linked to poor levels of understanding61-63.  There are many other aspects of a 
PIS that can influence participant understanding, for example the layout, presentation 
and length64-66.  Investigators have long been required to disclose relevant 
information to participants, but ethical guidelines make little explicit reference to the 
need to test understanding. 
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There are problems with ensuring and demonstrating that potential participants 
understand the study they are asked to participate in.  Firstly, research questions and 
study details vary between studies and study specific methods limit the ability to 
generalise or compare consent processes1.  As such, most studies of participant 
understanding have used measurement strategies tailored toward the individual 
study and no standardised measure to demonstrate understanding exists1.  
Secondly, determining the distinction between recall and understanding of study 
information is a difficult task.  Understanding information suggests an ability to apply 
the information, whereas recall is the ability to reproduce specific pieces of 
information58.  Most methods to assess understanding test the short-term recall of 
technical information, which cannot be equated with understanding since the ability to 
repeat information is not the same as being able to apply the information to 
appreciate the consequences of the decision, i.e. understanding the information23.  
Differentiating between recall and understanding is a significant problem and this, 
together with the lack of a standardised tool, means that most assessments of 
understanding of study information actually measure recall.  As we have already 
seen, the reason potential participants are provided with study information is so they 
can use it to make a participation decision. 
 
Another method of assessing understanding is to ask participants if they believe they 
have a good understanding of the information.  Studies reporting this as an outcome 
often found the majority of participants were satisfied with the consent process and 
considered themselves well informed.  Further examination, however, showed that 
many were unaware of particular features of research (including the unproven nature 
of the treatment and uncertainty of benefits to themselves) and were considered to 
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have low levels of understanding60;67-69.  If participants often believe they understand 
the information when, in reality, they have not fully grasped the ideas, this poses a 
further problem for determining potential participant understanding.  The reason for 
this difference could be explained by potential participants not actually wanting to 
know all of the information provided in a PIS and so consider themselves to be well 
informed because they understand the aspects of the study they wish to know.  It 
may be that the information researchers think participants need to make an informed 
decision differs from the information that participants think they need to make a 
decision70. 
 
A potential participant’s level of understanding requires a compromise between 
knowing basic study elements and having sufficient knowledge to understand the 
finer methodological points that are required for someone to fully understand what 
taking part means25.  Potential participants should understand the information 
sufficiently well enough be able to make a choice that makes sense for them, in the 
manner in which they would normally make similar choices25.  Allowing potential 
research participants the chance to ask questions and gather further information to 
use in the formulation of their decision has been shown as one way to improve their 
understanding67.   
 
There are clear limits to what written information alone can do to overcome the 
complex barriers to understanding and the quality of communication between the 
person obtaining consent and the potential participant is fundamental to the consent 
process71.  Methodologies that assess the consent procedure require greater 
attention.  Without a standardised method to assess understanding, interventions 
that aim to improve potential participant understanding cannot be meaningfully 
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compared.  Despite this, the next section shows that there have been many attempts 
to improve participant understanding. 
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Key points 
Potential participants have to be able to understand the information in the PIS 
in order to make a consent decision. 
 
Potential participants are more likely to understand information in a PIS when 
its readability level is lower. 
 
It is difficult to determine whether participants have understood the study:  
 There are no standardised methods to measure understanding. 
 Recall, rather than understanding, is often measured by researchers.   
 
Participants think themselves to be well informed but when tested are often 
considered by researchers to have low levels of understanding. 
 
The information researchers think participants need may differ from what 
participants think they need. 
 
Different potential participants are likely to want different types and amounts of 
information in order to consider themselves adequately informed. 
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2.4 PREVIOUS EFFORTS TO IMPROVE PIS’S 
 
There have been many attempts to design interventions that improve the readability 
and understanding of PIS.  Two systematic reviews; by Flory and Emanuel (2004)64 
and Cohn and Larson(2007)65; have been published that aimed to evaluate these 
interventions.  In this section, the methods for each of the two systematic reviews are 
compared and then the results from both reviews are combined and reported 
together. 
 
Flory and Emanuel (2004)64 aimed to determine what interventions actually work to 
improve potential participant understanding and how well they work.  They included 
all trials published between 1966 and March 2004 that quantitatively compared the 
understanding of research participants who had undergone a standard consent 
process (as defined by the individual study; most commonly a PIS followed by a 
verbal consent interview) with the understanding of participants who had received an 
intervention.  Thirty publications reporting 42 trials were identified and included in the 
review.  Each study reported four quality criteria; if it was randomised, included a real 
or simulated consent process, number of participants and whether it was published in 
a peer-reviewed journal.  Peer-reviewed randomised trials in a real setting with 
relatively large enrolment (size not defined) were given the greatest validity.  The 
primary outcome was the significance of differences (p<0.05 = statistically significant) 
between understanding scores for control and intervention groups. 
 
Cohn and Larson (2007)65 aimed to critically analyse studies published between 
1996-2007 about potential participants’ understanding of study information in 
research and to identify promising intervention strategies.  Each study was given a 
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quality score based on its performance on six quality indicators; sampling method, 
use of controls/comparison group, response rate, outcome measurement, clear 
description of the intervention/comparison and method and using a statistical method 
appropriate to the study.  Ten interventional studies were identified, although eight of 
these were included in the review by Flory and Emanuel.  
 
Interventions from the two reviews were categorised into five groups; multimedia, 
enhanced PIS, extended discussion, test/feedback and other approaches.  The 
intervention could be in place of or in addition to the standard PIS.  All studies aimed 
to improve the level of understanding of participants.  As discussed previously 
(Section 2.3), it is likely that these studies do not report the level of understanding of 
participants since current tools to measure ‘understanding’ actually measure recall.  
The term ‘understanding’ (rather than ‘recall’) will remain the term used to report 
results in this PhD, however, since studies report what is currently understood (with 
the current tools available) by most researchers to be the measure of understanding.   
 
Multimedia interventions 
Multimedia interventions used any form of computer or video technology to present 
information to potential participants.  Twelve multimedia interventions were compared 
to standard PIS/consent processes to determine if the intervention increased the 
potential participants’ understanding of the study.  Seven interventions were 
supplementary videos72-76, three were computerised presentations72;76;77, one a 
supplementary touch screen computer presentation72 and one an interactive 
computer program78.  Studies of these twelve interventions provided little evidence to 
suggest that a multimedia presentation of study information improved potential 
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participant understanding since only one study found a statistically significant 
improvement (p=0.01)77. 
 
Enhanced PIS interventions 
Interventions were classed as ‘enhanced PIS’ interventions if the study PIS was 
thought to be improved in some way.  Sixteen enhanced consent form interventions 
were compared to standard PIS/consent processes to determine if participant 
understanding of the study was improved.  Five PIS were enhanced by re-arranging 
the information in the PIS but not removing any information72;76;79;80, three by 
improving readability alone81-83, three by improving readability, providing less detailed 
information and re-formatting information63;84;85, two by reformatting and providing 
less detailed information (but not improving readability)86;87, two by providing less 
detailed information88;89; and one by allowing a consumer group to revise the study 
PIS90.   
 
Understanding was thought to be improved by reformatting the PIS and/or improving 
readability to be more accessible79;81;86;87, by providing less detailed information88;89 
and allowing patient input to the design of the PIS90.  Interestingly, none of the 
interventions that combined improving readability, providing less detailed information 
and re-formatting the information in the PIS improved understanding63;79;84.  Of the 
seven interventions that showed a statistically significant improvement in 
understanding (p<0.00186-8, p<0.00581, p<0.0289, p=0.0390, p<0.0579), five evaluated 
hypothetical consent processes where the PIS was the only means to convey study 
information to participants.  In most real situations potential participants also receive 
verbal information about the study, which may dilute the effect of the PIS on 
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understanding.  Any effect of improvement to understanding in the hypothetical 
studies, then, is more likely to be indicative of the effects of the PIS on level of 
understanding. 
 
Extended discussion interventions 
Extended discussion interventions evaluated the use of a meeting with a researcher 
or neutral educator to discuss the information in the PIS.  Six62;73;91-94 extended 
discussion interventions were tested that aimed to improve study understanding.  
Interventions tested were a 30 minute semi-structured telephone conversation with a 
research nurse91, detailed repetition of clinical trial information92, three 40 minute 
meetings with a counsellor93, a meeting with an independent educator73, a meeting to 
discuss the trial with the enrolling physician94 and a video followed by discussion with 
a consent educator62.  Three interventions showed a statistically significant 
improvement in understanding (p<0.00191-93) and two showed a trend towards 
improved understanding (p=0.05473; p=0.0894).  It is likely that encouraging potential 
participants to have an extended discussion about the information included in a PIS 
improves their understanding of that information. 
 
Test and feedback interventions 
Five interventions80;95-97 tested participants’ understanding of study information, 
provided feedback for incorrect answers and then repeated the understanding 
questionnaire.  Understanding was shown to be improved in all five studies80;95-98.   
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Any other approaches 
A series of five other interventions72;80;98-100 not classifiable into any other category 
were identified, two of which were combinations of other approaches (extended 
discussion, computerised presentation and other simple teaching aids100, and 
extended discussion, additional pamphlet and other teaching aids98).  These both 
showed a statistically significant improvement in understanding (p<0.0598, 
p=0.001100.  The other three interventions included allowing potential participants to 
experience the tests (multi-frequency bioelectrical impedance analysis and 
questionnaires) used in the study before deciding whether to participate99, to have a 
neutral facilitator present at the potential participant’s meeting with investigator80 and 
educational vignettes included with the PIS72, all of which did not show a statistically 
significant improvement in understanding. 
 
Of all the tested interventions in the two reviews, re-arranging the information in a 
PIS, providing less detailed information and allowing potential participants to have 
extended discussions with researchers showed an improvement in understanding 
that was both clinically relevant and statistically significant.  Part of this PhD tested a 
developing intervention - an interactive participant information sheet (IIS) - that 
allowed participants to choose the level of detail of study information they wanted.  
Since results from these reviews showed that reformatting and providing less 
detailed information improves a potential participant’s understanding of study 
information, it was hypothesised that this intervention would also improve participant 
understanding.   
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The IIS intervention utilised the Internet to recruit and provide information to potential 
participants, so the next section of this chapter outlines current use of the Internet in 
research. 
 
Key points 
Two published systematic reviews64;65 evaluated interventions that aimed to 
improve the readability and understanding of PIS. 
 
Understanding was found to be improved by –  
 Re-arranging the information in a PIS. 
 Providing less detailed information. 
 Allowing potential participants to have extended discussions with 
researchers. 
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2.5 THE ROLE OF THE INTERNET IN RESEARCH  
 
This section of this chapter explores the use of the Internet in medical research and 
outlines the advantages and disadvantages of conducting research online when 
compared with traditional non-Internet based methods.  The interactive nature of the 
Internet makes it an attractive method for conducting research and there are many 
advantages, as well as some disadvantages, of using the Internet to facilitate 
research.  
 
The last 15 years have seen a substantial increase in the proportion of the population 
using the Internet.  According to data collected between 2000 and 2012 by the Office 
for National statistics (ONS)101-103 99.3% of 16-24 year olds now use the Internet (up 
from 69% in 2000) and 80% of households in the UK have an Internet connection (up 
from 25% in 2000).  Internet use declines with increasing age (Figure 2) and use is 
affected by location (85.9% London and the South East vs. 72.7% Northern Ireland), 
marital status (92% single vs. 81% married), occupation (91% 
managerial/professional occupations vs. 67% semi-routine/routine occupations), 
health (86% healthy vs. 61% disabled), education (97% >degree level vs. 45% with 
no formal qualifications) and income (98% >£41,000 vs. 69% income <£10,399).  
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Figure 2 – Internet use by age group101 
 
 
 
 
 
 
 
 
 
 
 
 
As the proportion of the population using the Internet has increased so have its uses 
and many day to day tasks such as banking are now carried out online101;104.  A 
growing number of people search the Internet for health related information and often 
use this to self-diagnose and self-medicate ailments105;106.  The Internet is also used 
regularly in medical research with tasks from writing a protocol to data entry utilising 
the Internet107-119. Since one of the earliest pieces of online research, a web-based 
survey on the effects of ulcerative colitis on quality of life by Soetikno et al in 1996120, 
Internet research methodology has advanced substantially.  Clinical drug trials have 
been conducted electronically where participants were recruited, completed study 
questionnaires, had study medication automatically dispensed to them (via mail) and 
logged adverse events online118;121-123.    
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Designing research and writing a study protocol often uses information sourced from 
the Internet.  Online medical literature databases are routinely used to review current 
literature107-110, requirements for ethical approval can be located111 and experts in the 
field can be contacted for advice on specialised matters112.  The Internet can be used 
to recruit potential participants, for example, via websites that list clinical trials by 
disease type113-116, by putting links to a research websites on social network 
sites112;117, or by using email mailing lists to send study information to large numbers 
of addresses112. 
 
There is also scope for using the Internet to provide study information to potential 
participants.  Once potential participants are directed to a study website it can be 
used to provide them with study information and screen them for eligibility112.  A PIS 
presented online may have many advantages over a paper one.  It could, for 
example, be made to be interactive so those who want lots of background 
information could easily access it, or potential participants with sight problems could 
increase the size or change the colour of the text to allow them to see it more 
easily117.   
 
Once the potential participant has read the information and decided they would like to 
take part, an online eligibility-screening questionnaire112;118 may be used to 
automatically determine if they are eligible, which could reduce trial personnel 
involvement and related costs112.  Traditionally, study participants have signed 
consent documents by hand, but, new technologies mean digital signatures124-126 
could be used for Internet based studies.  This would make all aspects of participant 
recruitment achievable online. 
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Many aspects of study administration are already conducted using the Internet, for 
example, randomisation, communication and data collection.  In randomised 
controlled trials where it is common to use a central co-ordination centre for 
randomisation, the Internet often replaces expensive 24-hour phone services with an 
online service where participants have a study group randomly allocated to them by a 
computer112.  Study websites may be used by potential participants and study 
personnel to access study information, contact details and download required 
paperwork and a section is often made secure (by password protection) to allow trial 
personnel/participants to communicate112;118;119.  Data can be remotely entered into a 
central database using Internet technology and advantages of this include the data 
being immediately accessible for analysis, time savings due to fewer steps in the 
data collection process and reduce handling and storage costs due to the near 
elimination of paper source documents112;127. 
 
There are functionality benefits to conducting research online.  For example, web-
based forms used to collect participant responses to online questionnaires have 
advantages over their paper-based alternative, such as automatic collating of 
information112;128;129.  The ability of web-based forms to be interactive allows 
questionnaires to be actively tailored towards population subgroups; for example, text 
can be translated at the click of a button.  Missing data can be minimised by 
configuring web-based forms to automatically reject incomplete questionnaires130;131 
and scripting language can build dynamic questionnaires that randomise certain 
items to minimise the risk of systematic influences of the order of items upon 
responses132. 
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Online research can be conducted confidentially and anonymously, providing the 
correct electronic safeguards are in place.  Web-based forms can allow 
questionnaires to be completed anonymously as technological identifiers (such as IP 
addresses) can remain uncollected, or they can be placed in a password protected 
area of the Internet to protect personal information.  Previous research has shown 
that Internet completers skipped fewer sensitive questions and were less likely to 
conform to social desirability when compared with those completing a mailed 
questionnaire128;133;134.  Participants may feel more comfortable completing personal 
questions online than for a postal survey because of the “increased perception of 
anonymity”133. 
 
Online questionnaires can also speed up the research process; for example, study 
information and questionnaires can be distributed to large numbers of potential 
participants very quickly and at a lower cost than traditional paper 
ones112;118;128;129;135;136, and they allow rapid prototyping and pilot testing of 
instruments (for example an automatic time stamp can be used to calculate the time 
needed to complete the questionnaire)131.   
 
Response rates and participation rates can be calculated by assigning a unique ID to 
every questionnaire viewer (a cookie) and multiple responses from the same user 
can be filtered out by removing questionnaires completed at the same computer131.  
Calculating response rates to online questionnaires can be tricky, however, and there 
are many concerns over who has received, opened and completed the 
questionnaire137. 
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With potentially reduced costs, global access and real time data collection, the 
potential size of research studies that can be practically implemented is increased by 
using the Internet and global studies could be run in shorter time frames.  There are, 
however, disadvantages to conducting research online. The most significant 
disadvantage is the potential for selection bias due to the non-representative nature 
of the Internet population101;138;139.  Considering whether the topic chosen for study is 
suitable for the Internet population should be the first consideration when deciding 
whether to conduct online research.  An online questionnaire would be unsuitable if 
the target population were elderly with major morbidities, for example.  Several 
studies have tested the validity of Internet-based surveys by comparing their results 
to identical traditional paper-based studies and they seem to suggest that the validity 
and reliability of data obtained online are comparable to those collected by 
conventional methods140;141.  This may mean results can be collected online that are 
generalisable to the population as a whole, but this is only likely to occur when the 
majority of the study sub group population have Internet access.  The generalisability 
of results collected using Internet technologies remains a limitation for research in 
populations where the majority do not have Internet access.   
 
In a population where most were competent computer and Internet users, Pealer et 
al133 found no statistically significant differences in participants’ demographics or 
response rate between those completing a postal questionnaire and those 
completing an Internet survey and other studies have shown similar results139;142.  It 
can be expected that if the trend of increasing Internet access continues, it will 
eventually reach a point where Internet access is as common as postal access.  
When this point is reached, conducting research online would have no greater risk of 
un-generalisable results than conducting the survey by post or by telephone.   
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Paul et al112 outline other potential disadvantages of conducting research using the 
Internet.  Online communications may not be as secure as more traditional means 
(telephone, fax and mail) and some participants and study centres may decline 
involvement because of concerns over the security of online data.  Internet studies 
often require experienced computer professionals to set up and maintain the online 
system.  If the study experiences problems with the online system, potential 
participants may be deterred from participating if they are unable to access the 
website the first time they try.  Studies may need to have paper-based back-ups for 
all aspects of research conducted online, in-case Internet connection and/or online 
systems fail.  Finally, the expense of developing an online system may not be 
feasible for smaller studies. 
 
There are many advantages to conducting research online that make it an attractive 
prospect.  This PhD considers two aspects of Internet research; electronic 
communication and provision of electronic study information.  
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Key points 
Many people use the Internet for a variety of daily tasks and use of the 
Internet in research is a growing area. 
 
Whole research studies can now be conducted online; from writing a study 
protocol to analysing data; and tasks are often much quicker using electronic 
methods. 
 
There are many advantages to using the Internet in research including 
flexibility of data provision, automatic collating of information, minimising 
missing data, and reduced costs of distribution, completion and return of 
research items such as questionnaires. 
 
Disadvantages of conducting research online include the generalisability of 
the online population, potentially less secure communications and the need for 
experienced computer professionals to set up and maintain online systems.  
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2.6 USING THE INTERNET TO PROVIDE STUDY INFORMATION TO PARTICIPANTS 
– A STUDY BY ANTONIOU ET AL 
 
A study by Antoniou et al6 piloted a new way to provide study information to potential 
participants and aimed to explore how information is used to make a decision about 
whether to participate in research.  The study was embedded within a nation-wide 
population-based study investigating the development of twins during early childhood 
and involved the completion of an electronic questionnaire accessed via the study’s 
website by a study participant.  Participants of the ‘development of twins’ study were 
either parents or legal guardians of twins. 
 
Before deciding whether to participate in the development of twins study, potential 
participants were directed to an interactive PIS that allowed them to access up to 
three levels of information ‘unfolding’ on request from each of six frequently asked 
questions (FAQ’s).  Participants clicked a (+) sign next to the FAQ in order to access 
the information.  Level one gave them a broad understanding of the project and what 
would be required of them if they chose to participate.  The information in level two 
was longer and comparable to the level of detail required in a standard REC 
reviewed PIS.  Level three was more sophisticated and contained links to external 
sources of information, such as academic articles.  The information that potential 
participants chose to access, along with how long they spent on it, was tracked. This 
allowed the authors to determine what information was accessed by each participant 
deciding whether to complete an online questionnaire and to apply average reading 
times to the time spent on each level.  Demographics collected enabled the amounts 
of information accessed to be compared between sub groups of the population.  
Results showed that whilst the first level of information (for at least one FAQ) was 
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accessed by 70 to 82% of participants, only 9 to18% accessed level two (for at least 
one FAQ) despite this being the level of information RECs suggest participants 
should be given and only 3 to 12% accessed all three levels of information in any 
FAQ.  On average participants spent more time reading information about why the 
survey was being conducted.  No overall statistically significant differences were 
seen in the pattern of accessing and the time spent reading the information between 
ethnic groups, the educational level of participants, age or gender, although a trend 
was seen for some individual FAQ’s. 
 
As well as collecting information about what information participants accessed, 
participants were asked questions about the information they read in the PIS and 
were asked to choose options that applied to them from a list provided.  The results 
of this questionnaire often conflicted with what participants actually did.  For example, 
4% (20/552) said they did not click any of the (+) sign options whereas the activity 
monitored showed this to be 18%.  Interestingly, 20% (93/552) said they wanted 
more information about what would be done with the results of the study, even 
though only 9% chose to click through to the second and 6% to the third level of 
information for the corresponding FAQs. 
 
The majority of the potential participants sought very little information before making 
a decision about whether or not to participate in the questionnaire-based study, and a 
clinically significant minority (18-30%) had accessed no information at all.   
 
This study by Antoniou et al provided useful information as to what information 
participants want to know when they are deciding whether to participate in 
questionnaire-based research where completing the questionnaire itself provides 
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direct information about what participating entails.  As the authors acknowledge, 
study results are not readily generalisable to all potential participants in clinical 
research since the study population were all parents of young twins and were mostly 
white, well-educated women.  The authors also acknowledge that the study also only 
collected the information from those who took part in the study and not those who did 
not choose to participate, and results may differ for these two groups6.   
 
Results from this study also only concern what information participants of low risk 
questionnaire-based studies wanted to know and the amount of information 
participants of other studies - particularly those involving an intervention or greater 
risks - want to know may be very different.  Further research needs to be conducted 
to determine if these results are generalisable to the whole research participant 
population.  This PhD aims to add to this knowledge base by developing the 
Interactive Information Sheet (IIS) used by Antoniou et al and using it to collect the 
information accessed by participants deciding whether to participate in low risk 
interventional research. 
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Key points 
Antoniou et al designed an ‘unfolding’ electronic information sheet that 
enabled them to observe the information accessed by potential participants 
before they participated in an Internet-based questionnaire study. 
 
The participants chose to access very little information before participating. 
 
Reported and actual patterns of information access differed, suggesting that 
asking participants what information they use to make a participation decision 
may not be an accurate way of determining what they did use. 
 
Results of this study are not generalisable and further research is required.  
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2.7 AIMS AND OBJECTIVES OF THE PHD  
 
Aims of the PhD: 
To gather further evidence of the topics and level of detail of information potential 
participants access when deciding whether to participate in a piece of low risk 
interventional research, and to determine the feasibility electronic information 
provision. 
 
Research questions: 
1. What does the current evidence suggest potential participants want to know 
when they are deciding whether to participate in research? 
2. Is electronic information provision in research feasible? 
3. What information did potential participants access when they made a decision 
about whether to participate in a piece of low risk interventional research? 
4. What are the implications for the future of information provision given answers 
to research questions 2 and 3? 
 
Objectives: 
1. Systematically review the literature on what information potential participants 
want to know when they are deciding whether to participate in research by: 
i. Devising a systematic review study protocol 
ii. Using the protocol developed in (i) to conduct a systematic review of 
the literature 
 
52 
 
2. Devise and conduct a study that allows a) participants to be contacted 
electronically b) study information to be provided electronically and c) collects 
data on what information potential participants accessed when making a 
participation decision for a piece of low risk interventional research by: 
iii. Identifying a suitable parent study in which to embed the study 
iv. Calculating a sample size for the information provision study 
v. Developing a study protocol 
vi. Designing a website to host the IIS and develop programming code 
required to record the information accessed 
vii. Testing the website designed in (vi) for errors and participant usability  
viii. Identifing the information to be included in the IIS using the results of 
the systematic review (1), interviews with potential participants and key 
research staff and discussion with experienced academics 
ix. Designing a questionnaire to determine understanding and satisfaction 
of participants with the information provided  
x. Obtaining ethical approval for conducting the study 
xi. Collecting and analysing data on the feasibility of electronic information 
provision and the information accessed by potential participants 
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3. Consider the implications of study results from objective 2 by 
xii. Designing a PIS using the information potential participants wanted to 
know from results collected from objective 2 and the information current 
guidance stipulates participants need to know, for the parent study 
identified in (iii) 
xiii. Gathering expert opinions on how to take forward the research 
conducted for this PhD  
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3 SYSTEMATIC REVIEW OF THE LITERATURE 
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This chapter will answer the first research question of the thesis and meet objective 
one. It will establish the evidence base for the information that research participants 
want to be included in a PIS.  As was discussed in the previous chapter, valid 
consent to research requires potential participants being given the information they 
need to make a decision.  The information potential participants want to know may be 
different to the information experts think they want to know70.  The systematic review 
reported in this chapter identified all literature reporting what information research 
participants wanted to know before they were able to make a participation decision.  
It then compared this evidence base to the information that NRES22 guidance 
suggests should be included in a PIS. 
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3.1 AIMS 
 
To assess the level of detail and the types of information potential research 
participants report they should be given in order to make a decision regarding 
participation in medical research. 
 
To assess how this evidence compared with the kinds of information that NRES 
guidance suggests participants should be given. 
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3.2 METHODS 
 
Methods, including inclusion criteria and analysis plan, were specified in advance 
and documented in a protocol as detailed below. 
 
 
3.2.1 INCLUSION CRITERIA 
 
Any primary research published between 1950 and 27th October 2010 with no limit to 
language, participant age, medical condition or participant group (including 
vulnerable participants).  Literature was included if it asked potential research 
participants to indicate how much/which types of information they wanted to be told 
about a research study or to rate the importance of a specific piece of information.   
 
Studies reported in multiple journals were included only once with the latest known 
reference used.  Where reports noted different aspects of the research, results were 
included from all publications.  The review was limited to studies of participant 
opinion, excluding studies of health care professional or other expert opinion.  
 
 
3.2.2 OUTCOME MEASURES 
 
The percentage of participants that wanted to know a specific item of information 
about a study (spontaneous and prompted responses) or rated a piece of information 
as important.  Qualitative information, for example from focus groups, where 
participants indicated what information they wanted to know. 
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3.2.3 SEARCH METHODS 
 
Electronic databases 
An information specialist from the University of Birmingham library helped to design 
the search strategy used for this systematic review.  The search of electronic 
databases combined Mesh terms ‘Patient’, ‘Research Subjects’, ‘Consent forms’, 
‘Informed Consent’ and ‘Research ethics’ with terms relating to information provision 
(Figure 3).  The search was applied to Medline (Ovid platform)143 and adapted for 
Web of Science144, Applied Social Sciences Index and Abstracts on the Web 
(ASSIA)145, Sociological Abstracts146, The Health Management Information 
Consortium (HMIC)147 and the Cochrane Library148.  The last search ran on the 27th 
October 2010.   
 
The types of literature included in each electronic database were: 
 
1) Medline (Ovid)143: A database of life sciences and biomedical literature that 
includes medical journals and literature from academic journals within the 
subjects of medicine, nursing, pharmacy, dentistry and health care.  It includes 
literature from 1950 to the present day.   
2) Web of Science (WoS)144: A platform providing access to seven databases 
covering journals, book-based and journal conference proceedings within the 
subjects of science, technology, social sciences, arts and humanities.  It 
includes non-medical journals not indexed by Medline.  It includes literature 
from 1900 to the present day. 
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3) ASSIA145: Includes topics of literature such as social services, psychology, 
sociology, economics, politics, race relations and education not indexed by 
Medline or WoS.  It includes literature from 1987 to the present day.  
4) Sociological abstracts146: A database of literature from disciplines within social 
and behavioural sciences not indexed by other databases.  It covers literature 
from 1952 to the present day. 
5) HMIC147: A platform that provides access to the Department of Health’s 
Library and Information Services, and the King’s Fund information and Library 
Service.  It includes literature relating to health and social care management 
information, health service policy that is not included in other databases 
searched.  The majority of the literature included in this database ranges from 
1983 to the present day.  
6) The Cochrane Library 148:The Cochrane Library is a collection of six 
databases that contain evidence to inform healthcare decision-making 
(Cochrane Database of Systematic Reviews, Cochrane Central Register of 
Controlled Trials, Cochrane Methodology Register, Database of Abstracts of 
Reviews of Effects, Health Technology Assessment Database and the NHS 
Economic Evaluation Database).  It covers literature from 1988 to the present 
day. 
7) Index to Theses’149: A comprehensive listing of around 500,000 thesis titles 
and abstracts that have been accepted for higher degrees by universities in 
Great Britain and Ireland, since 1716.   
8) Grey literature includes papers, reports, technical notes or other documents 
produced and published by governmental agencies, academic institutions and 
other groups that are not distributed or indexed by commercial publishers but 
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nevertheless may include information relevant to this review.  The following 
sources of grey literature were accessed: 
a) System for Information on Grey Literature in Europe (SIGLE)150: An 
open access database of bibliographical references of reports and 
other grey literature produced in Europe.  Examples of grey Literature 
included in this database are technical or research reports, doctoral 
dissertations, conference papers and official publications.  It covers 
topics of pure and applied science and technology, economics, other 
sciences and humanities. 
b) GreyNet International; The Grey Literature Network Service151: 
Provides listings of potential places to search for grey literature. 
c) Health Information Resources (formerly National Library for Health)152: 
Provides access to medical documents, including evidence based 
reviews, guidance documents and reports, specialist collections for 
specific areas of medical practice, health care databases (for example 
HMIC and Medline), collections of medical images, and up-to-date drug 
libraries (for example the British National Formulary (BNF)). 
d) UBIRA153: The ePapers repository contains research material produced 
by members of the University of Birmingham.  It includes working 
papers, images and contains material that has not been through a 
formal peer-review process. 
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Figure 3 - Search strategy: MEDLINE (OVID) 
 "research patient*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 exp Patients/ 
 "participant*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 exp Research Subjects/ 
 1 or 2 or 3 or 4 or 5 or 6 
 exp Consent Forms/ 
 "information leaflet*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "information sheet*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 (consent adj4 form*).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 8 or 9 or 10 or 11 
 exp Informed Consent/ 
 exp Ethics, Research/ 
 "medico legal".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "medicolegal".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 exp Disclosure/ 
 (informed adj4 consent*).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 (research adj4 ethic*).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "disclos*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
 "want to know".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "want*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "information*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "require*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "desire*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "need*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 "choice*".mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
 23 or 24 or 25 or 26 or 27 or 28 
 7 and 21 and 29 
 12 or 22 or 30 
 31 and "Humans" [Subjects] 
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References and cited article lists 
Secondary citations were identified from reference lists of included papers.  Medline 
(Ovid Platform) was also used to search for any literature citing articles identified for 
inclusion in the review, and all returned references were included as secondary 
citations.  
 
Expert authors 
Expert authors were identified as authors of papers included in the review.  A list of 
expert authors was compiled (from authors of identified included papers) and 
contacted by email.  They were asked to identify articles relevant to this systematic 
review and identify further expert authors to contact. A reminder email was sent after 
one month if they did not respond.   
 
Key Journals 
Some ethics and law journals may not be indexed on the electronic databases 
searched because they are not classed as medical journals. Given the nature of the 
review topic, these types of journals had the potential to include relevant articles and, 
therefore, needed to be searched.  Relevant journals were identified though Internet 
search engines ‘www.google.com’ and ‘www.google.com/scholar’, with searches 
using the key words ‘consent’ and ‘research’.  Any journal that published papers 
within the subject of research ethics was classified as a relevant journal for this 
review.  Of the 33 relevant journals identified (Table 1) thirteen were not indexed on 
electronic databases, although tables of contents were available electronically and 
were reviewed (from the first issue available or from 1950, whichever was earlier) to 
identify papers for inclusion. 
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Table 1 - Key Journals identified 
 
Journal Title 
Indexed in an 
electronic 
database? 
 
Database 
Acta Bioethica Yes Web of Science 
American Journal of Bioethics Yes Medline 
Bioethics Yes Medline 
Bioethics Bulletin No - 
BMC Medical Ethics Yes Medline 
Cambridge Quarterly of Healthcare Ethics Yes Medline 
Community Ethics No - 
Eubios journal of Asian and International 
Bioethics (EJAIB) 
No - 
Ethics and Behaviour No - 
Ethics and Medicine No - 
Hastings Centre Report Yes Medline 
Health Ethics Today No - 
Health Expectations Yes Medline 
JONA’s Healthcare Law, Ethics and Regulation Yes Medline 
Journal of Clinical Ethics Yes Medline 
Journal of Law and Medicine Yes Medline 
Journal of Law, Medicine and Ethics Yes Medline 
Journal of Medical Humanities Yes Medline 
Journal of Medicine and Philosophy Yes Medline 
Journal of Medical Ethics Yes Medline 
Kennedy Institute of Ethics Journal Yes Medline 
Medical Law Review Yes Medline 
Medicine, Health Care, and Philosophy Yes Medline 
New Zealand Bioethics Journal No - 
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NTM: International Journal of History and Ethics 
of Natural Sciences, Technology and Medicine 
Yes Medline 
Nursing Ethics: An International Journal for 
Health Care Professionals 
Yes Medline 
Online Journal of Health Ethics No - 
Penn Bioethics Journal No - 
Philosophy, Ethics and Humanities in Medicine Yes Medline 
Princeton Journal of Bioethics No - 
Theoretical Medicine and Bioethics Yes Medline 
American Medical Association Journal of Ethics No - 
 
 
 
Internet search engines 
Other relevant articles were identified by searching two Internet search engines 
(Google and Google Scholar) using the key words ‘Patients’, ‘Informed consent’ and 
‘Research’. Only the first 30 results (3 pages) of each search were reviewed because 
article relevance diminishes substantially with each page of results154. 
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3.2.4 STUDY IDENTIFICATION 
 
Given the unspecific nature of search terms in the research questions, a broad 
searching strategy was implemented to maximise the possibility of identifying all 
relevant literature.  For example, editorials and letters were not eligible for inclusion 
in the review but were included in the search to identify expert researchers in the 
field. 
 
MeSH terms were used in conjunction with key words and wildcards.  The first 500 
references retrieved from Medline were reviewed to identify any key words that 
commonly appeared in relevant papers and the search strategy was refined.  There 
were no key words found consistently across irrelevant papers that could be 
incorporated to narrow the searching strategy.  Figure 3 shows the search strategy 
that was used to conduct the Medline search and adapted for other electronic 
databases.   
 
Due to the broad search strategy implemented there was a large number (n=11,943) 
of unique references retrieved.  Decisions for inclusion, therefore, utilised three 
phases of screening with irrelevant references being excluded at each phase. Phase 
one involved reviewing reference titles alone, phase two involved reviewing abstracts 
and phase three involved reading full papers to determine if they met study inclusion 
criteria.  
 
66 
 
Phase one – Title reading 
Titles were scanned for an indication the paper met the inclusion criteria.  References 
were included in phase two if they appeared to refer to any of the following topics: 
1. Information research participants wanted to know. 
2. Information patients wanted to know about treatment.  
3. Ways to alter or improve informed consent procedures. 
4. Addition of information to consent forms/patient information sheets (e.g. 
adding a rare complication to an information sheet). 
5. Ways to improve recruitment. 
6. Participants/patients asked to help with the design of a participant/patient 
information sheet. 
 
Phase two – Reviewing Abstracts 
Phase two involved reading the abstracts of references that had not been excluded in 
phase one.  References were marked for inclusion in the next phase of screening if 
they appeared to meet the inclusion criteria for the full review (where inclusion could 
only be confirmed once the full paper had been read), if no abstract was available, or 
it was not clear from the abstract whether it met inclusion criteria. 
 
Phase three – Reading full papers 
Full papers of the references identified from phase two for inclusion in phase three 
were accessed and reviewed and those meeting the inclusion criteria were marked 
for data extraction.  
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3.2.5 VALIDATION OF SCREENING 
 
Validation was independently conducted on approximately 10% of the references 
identified from electronic databases.  Reference Manager was used to store citations, 
and give each reference a unique ID.  Figure 4 shows the agreement rate between 
the two reviewers.  The two reviewers agreed that 91 references should be included 
(thereby excluding 870 papers) in the next phase of screening.  A kappa calculation 
determined an inter-rater agreement of 80.0%155.  Using figures from Table 1, the 
equation used to calculate kappa was: 
 
К = [Pr(a) – Pr (e)] / [1-Pr (e)] = [0.96-0.8] / [1-0.8] = 0.16/0.2 = 0.80 = 80.0% 
Pr (a) = [91+870]/997 = 0.96 
Pr (e) = p(++) + p(--) = 0.01+0.79 = 0.8 
  p(++) = ([91+16]/997) x ([91+20]/997) = [107/997] x [111/997] = 0.01 
  p(--) = ([20+870]/997) x ([16+870]/997) = [890/997] x [886/997] = 0.79 
 
There were 36 references where the reviewers disagreed about inclusion.  
 16 references were marked for inclusion in the next phase of screening by 
reviewer one but excluded by reviewer two. Since reviewer one (the author of 
this thesis) completed the full screening process on all references, if this 
reviewer included more papers in each round of screening, it would not have 
meant relevant papers were missed.  These papers, therefore, needed no 
further consideration.   
 20 references were excluded by reviewer one but included by reviewer two. 
This initially suggested a potential 2% error rate (20/997) but when the 
abstracts were reviewed, none of the papers were relevant.
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Figure 4 – Agreement rate between reviewer one and two for phase one 
reference screening  
 
  Reviewer 1 (HK) 
  + - 
Reviewer 2 (TK) + 91/997 20/997 
- 16/997 870/997 
 
Key:  
+ indicates the reviewer thought the paper should have been included 
-  Indicates the reviewer thought the paper should have been included 
 
 
3.2.6 DATA EXTRACTION 
 
Data were extracted from papers using a pre-defined data extraction sheet, designed 
to extract quality indicators from papers (Appendix 9.3).  Items extracted were year of 
publication, country of study, study design, study setting, sampling strategy, 
participant group, analysis procedure, number of participants, response rate and 
results relevant to this systematic review.  The data was extracted (by the author of 
the thesis) and 10% were checked for accuracy by a colleague (Thomas Keeley).   
Disagreements were resolved by discussion. 
 
Themes used to categorise the data were based on NRES recommended headings22 
with similar headings combined to make one variable. 
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3.2.7 STUDY SELECTION 
 
Figure 5 provides an overview of how many references were identified from each 
source. 
 
Electronic Databases 
The breakdown of the references identified by each electronic database is presented 
in Table 2 and shows that each of the electronic databases identified unique 
references.  Once the latest update was conducted (on 27th October 2010), a total of 
10838 unique references were identified from searching electronic databases.  
Fourteen of these references were identified for inclusion in the review. 
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Table 2 - References identified from each electronic database 
Database 
Name 
No. 
references 
identified 
No. after 
duplicates 
deleted 
% Unique 
references 
No. papers 
included in 
review 
Medline 6322 6322 Reference 
source 
13 
ASSIA 953 833 87.4% 1 
Sociological 
abstracts 
1181 957 81% 0 
HMIC 695 550 79% 0 
Web of Science 2884 1380 47.9% 0 
Grey Literature 204 204 100% 0 
Thesis 592 592 100% 0 
Total 12831 10838  14 
 
 
References and cited article lists 
Searching reference lists of relevant articles provided 404 references and an 
additional 69 were identified by reviewing the cited article lists of relevant articles.  All 
473 reference titles were examined for relevance and 42 met phase two inclusion 
criteria.  Twenty-two were duplicates of references identified by the electronic 
database search and a further twenty were excluded after reviewing the abstract.  No 
unique references meeting inclusion criteria were identified by this method. 
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Expert authors 
Fourteen expert authors were identified (corresponding authors from included 
papers) and written to.  Twelve responded to an email request with relevant papers 
and three identified three further expert authors who all responded to our 
correspondence.  Thirty-seven references were identified; 13 were duplicates from 
the electronic database searches and 24 did not meet inclusion criteria.  No unique 
references meeting inclusion criteria were identified by this method. 
 
Key Journals 
Eight potentially relevant articles were identified from hand searching journal content 
pages of the 13 key journals not indexed on electronic databases (Table 1); none 
met inclusion criteria once full papers were read. 
 
Internet search engines 
The search engines Google Scholar (returned 896,000 results) and Google (returned 
11 million results) returned 11,896,000 results.  The first 30 results from each search 
engine were reviewed for relevance; however, none of the articles or websites 
retrieved identified any papers relevant to the review that had not been identified 
from other sources. 
 
Total number of references identified from all sources 
A total of 13379 citations were identified.  Once duplicates had been deleted there 
were 11943 unique references to be screened (Figure 5).  Of these, 11291 were 
discarded on the basis of the title alone (phase one screening), for example, ‘Should 
non-invasive ventilation be used with the do-not-intubate patient?156’ and ‘Sex 
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offender re-entry courts: a cost effective proposal for managing sex offender risk in 
the community157’. 
 
There were 652 references included in phase two, of which 620 (95.1%) were 
discarded because the abstracts confirmed that they did not meet the inclusion 
criteria.  Types of studies discarded at this phase included those asking patients to 
comment on what information they wanted to know about their treatment in routine 
clinical care, studies asking health professionals what information they thought 
participants should be told and studies that determined readability of participant 
information sheets and participant understanding of them.  
 
There were 32 papers that proceeded to phase three, of which 11 papers met the 
inclusion criteria (and 21 were excluded).  An example of a paper excluded at this 
phase was entitled ‘Consent of use of personal information for health research: do 
people with potentially stigmatizing health conditions and the general public differ in 
their opinions?158’ On reading the abstract it seemed the paper may meet inclusion 
criteria, but when the full paper was read the study aim was to determine whether 
patients thought they should have to give their consent for their details to be used in 
various different types of research; it did not ask them what they wanted to know 
about the research in order for them to give that consent.  Exclusion reasons for the 
21 papers are included in Table 3. 
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Table 3 – Reasons for full paper exclusion 
Reason Number of 
studies excluded 
Determine participant understanding of the study or satisfaction 
with the information provided.  These studies did not ask 
participants if they wanted to know the information or rate how 
important the information was to know, and so did not meet 
inclusion criteria for the systematic review 
5 
Reasons why participants may refuse/consent to participate in 
research 
4 
Concerned only whether research participants would want 
results of the study to be returned to them following completion 
of the study 
3 
Expert opinions of what should be included in a PIS 3 
Asked participants if they would be happy for their details to be 
given out for other research studies without their consent 
2 
What patients wanted to know about treatment 1 
Who should convey study information to participants 1 
Asked participants to talk about ethically important processes in 
research, but did not if they would want to know them when 
deciding whether to participate in research 
1 
Asked participants if they wanted a long or short PIS but not 
what information they wanted included in it 
1 
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Figure 5 – Number of citations identified at each round of screening  
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3.2.8 STUDY CHARACTERISTICS 
 
Table 4 shows the study characteristics and results for each of the eleven studies 
included in the review.  No papers were published before 1994 and most (n=8) were 
published after 2005.  Most (n=7) were conducted in the USA with only one study 
conducted in the UK159.  Five studies used questionnaires to produce quantitative 
results, four used qualitative semi-structure interview and two used focus groups. 
 
 
3.2.9 ANALYSIS 
 
A meta-data analysis used basic thematic analysis to split results from identified 
papers into themes (topics of information).  Where more than one quantitative study 
reported the proportion of participants wanting to know a topic of information, results 
were pooled with random effects.   
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Table 4 - Summary of studies included in the systematic review 
 
Lead 
author / 
Country / 
Year  
Inclusion / 
exclusion criteria 
Participant 
illness 
Participant 
demographics 
Total 
number of 
participants 
(response 
rate) 
Study design Sampling 
strategy 
Analysis Key Themes 
explored 
Study strengths Study limitations 
Walkup
160
 
USA 
2009 
None provided 
 
 
None Gender:  Not 
reported 
Age: Not 
reported 
Education / 
deprivation: Not 
reported 
Ethnicity: Not 
reported 
57  
(not 
provided) 
Exploration of 
conversation 
and 
questionnaire 
Convenience  Descriptive 
summary 
statistics 
Study 
purpose, 
voluntariness, 
study method, 
risks, benefits, 
confidentiality, 
review board 
approval 
Participants approached in 
a public setting and invited 
to complete a 
questionnaire and 
researcher recorded study 
information spontaneously 
requested  
 
Did not specify a disease 
group 
No inclusion/exclusion 
criteria  
 
Participant demographics 
not reported 
 
Participants questions 
may have been answered 
by looking at the 
questionnaire 
Bento
161
 
Brazil 
2008 
Female 
participants 
aged 18-49 who 
had taken part in 
a clinical trial of 
women’s health 
in the previous 
12 months and 
lived in 
Metropolitan 
area of 
Campinas, Sao 
Paulo, Brazil 
Women’s 
health 
Gender: Only 
women 
Age: 18-49 
Education / 
deprivation: 4 
focus groups 8
th
 
grade or less, 4 
focus groups 
above 8
th
 grade 
education 
Ethnicity: Not 
reported 
51 
participants 
8 focus 
groups  
(not 
provided) 
Focus groups Convenience Framework 
analysis 
Study 
methods, risks 
and benefits  
Participants of different 
ages and educational level 
likely to have different 
needs and opinions 
regarding topic  
 
Focus groups 
homogenous for age and 
educational level; suitable 
to ensure they were 
comfortable expressing 
opinions 
 
Recruitment continued 
until data saturation point 
 
Demographics not 
representative of the 
general population as the 
study only included 
women and was limited to 
participants from a trial of 
a contraceptive 
intervention 
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Casarett
16
2
 
USA 
2001 
Participants with 
a current 
telephone 
number, enrolled 
at a pain clinic, 
who had chronic 
non-malignant 
pain, were 
taking scheduled 
opioids and had 
experienced the 
pain for at least 
6 months 
Chronic 
pain 
Gender: 40% 
male 
Age: Mean age 
47 [range 30-86] 
Education / 
deprivation: 
Range of 
backgrounds 
Ethnicity: 85% 
White 
40/86 
(46.5%) 
 
Semi 
structured 
telephone 
interviews 
Convenience  Descriptive 
summary 
statistics 
and 
Bivariate 
analysis with 
non-
parametric 
tests 
Voluntariness, 
study 
methods, 
expenses, 
risks and the 
drug/device/pr
ocedure being 
tested 
Validated interview topic 
guide  
 
Questions spontaneously 
asked by participants were 
recorded 
Demographics not 
representative of general 
population as participants 
were more often male and 
limited to chronic pain 
patients 
 
Maslin
159
 
UK 
1994 
Attending a 
breast unit and 
were patients 
with a breast 
cancer diagnosis 
or asymptomatic 
women with a 
family history of 
breast cancer 
Cancer  Gender: Only 
women  
Age: Median 47 
[range 24-81] 
Education / 
deprivation: Not 
reported 
Ethnicity: Not  
reported 
213/300 
(71%) 
Postal 
questionnaire 
Random Simple 
descriptive 
statistics 
Study 
purpose, 
voluntariness, 
study 
methods, 
risks, benefits 
and 
confidentiality 
Participants chosen at 
random but from a subset 
of those attending a breast 
unit 
Demographics not 
representative of general 
population as the study 
only included females and 
was limited those with 
breast cancer  
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Sand
163
 
Norway 
2008 
Participants 
eligible for the 
parent study (all 
lung cancer 
patients) 
Cancer Gender: 57% 
male 
Age: Median 
age 69 [range 
44-84] 
Education / 
deprivation: 
Range of 
backgrounds 
Ethnicity: Not 
reported 
21/33  
(64%) 
Semi 
structured 
interviews 
Convenience Identification 
and 
categorisatio
n of themes 
and analysis 
based on 
deductive 
and 
inductive 
categories 
Voluntariness, 
study methods 
and treatment 
alternatives 
 
 
No inclusion/exclusion 
criteria stated but 11 
potential participants were 
not invited  
 
Technical problems with 3 
recordings 
 
Demographics not 
representative of the 
general population as 
participants were more 
often male, had a median 
age of 69 years and were 
limited to lung cancer 
patients 
Hutchinso
n
164
 
Australia 
2008 
Participants of 
clinical trials of 
COPD, asthma, 
diabetes, 
osteoporosis, 
rheumatoid 
arthritis and the 
influenza 
vaccine.  
Excluded if 
clinical trial for 
acute, life 
threatening or 
debilitating 
conditions with 
inadequate 
therapy 
Chronic 
illness 
Gender: 52% 
male 
Age: Median 
age 70 [range 
not reported] 
Education / 
deprivation: 
Range of 
backgrounds 
Ethnicity: Not 
reported 
259/324 
(80%) 
Questionnaire Convenience Descriptive 
summary 
statistics 
and 
multivariate 
logistic 
regression 
Conflicts of 
Interest 
(CoI)/organisat
ion and 
funding of the 
research 
 Demographics not 
representative of the 
general population as 
median age of 70 
Gray
165
 
USA 
2007 
Participants 
enrolled onto a 
phase I research 
trial, spoke 
English, and 
were medically 
and mentally 
capable of 
participating 
Phase I 
research 
trial 
Gender: 52% 
male 
Age: Median 
age 61 [range 
26-82] 
Education / 
deprivation: 
Range of 
backgrounds 
Ethnicity: 81% 
White 
102/119 
(86%) 
Semi-
structured 
interviews 
Consecutive 
participants 
enrolling onto 
parent trial  
Descriptive 
summary 
statistics, 
Chi squared 
tests and 
Multivariate 
logistic 
regression 
Conflicts of 
Interest 
(CoI)/organisat
ion and 
funding of the 
research  
Same interviewer 
conducted all interviews 
 
Demographics not 
representative of the 
general population as the 
median age was 61 and 
was limited to cancer 
patients participating in an 
early phase clinical trial 
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Grady
166
 
USA 
2006 
Participants of 
HIV, Hepatitis, 
Arthritis and 
Surgical 
Oncology Trials 
who were >18 
years and 
English 
speaking 
Various Gender: 61% 
male 
Age:  Not 
reported 
Education / 
deprivation: 
Range of 
backgrounds 
Ethnicity: 70% 
White 
33  
(not 
provided) 
 
Face to face 
semi 
structured 
interviews 
Convenience Transcripts 
coded and 
themes and 
major 
concepts 
identified 
Conflicts of 
Interest 
(CoI)/organisat
ion and 
funding of the 
research 
Open questions used 
during interviews 
 
Data collection continued 
to saturation point 
 
Two authors 
independently conducted 
analysis 
 
Used hypothetical 
scenario 
 
Demographics not 
representative of general 
population as participants 
were more often male and 
limited to adults 
participating in HIV, 
hepatitis, arthritis or 
surgical oncology trials 
 
Hampson
1
67
 
USA 
2006 
Participants with 
cancer and 
enrolled in a 
clinical trial who 
were English 
speaking and 
>18 years 
Cancer Gender: 56% 
male 
Age: 24% < 50, 
32% 50-59, 26% 
60-69, 16% >70  
Education / 
deprivation: Well 
educated and 
financially 
secure 
Ethnicity: 92% 
White 
252/272 
(93%) 
Structured 
face to face 
interviews 
Not provided Descriptive 
summary 
statistics 
and Fishers 
exact test / 
Kruskal-
Wallis test 
Conflicts of 
Interest 
(CoI)/organisat
ion and 
funding of the 
research 
Validated interview 
questions 
 
Demographics not 
representative of general 
population as the study 
population were well 
educated, financially 
secure and limited to adult 
participants of a clinical 
trial 
 
 
Weinfurt
16
8
 
USA 
2006 
Healthy adults or 
those with a mild 
chronic illness.  
Excluded if they 
had participated 
in another focus 
group within the 
previous 6 
months or were 
working or had 
worked for an 
organisation 
involved in the 
conduct of 
clinical trials 
Healthy Gender: 42% 
male 
Age: 12% 18-29, 
51% 30-49, 37% 
>50 
Education / 
deprivation: Well 
educated and 
financially 
secure 
Ethnicity: 56% 
White 
16 focus 
groups  
(not 
provided) 
Focus groups Convenience Initial 
content 
codes based 
on 
transcripts 
developed 
that were 
summarised 
and 
reviewed to 
identify main 
themes 
Conflicts of 
Interest 
(COI)/organisa
tion and 
funding of the 
research 
Participants not limited to 
disease group 
 
Only one moderator 
conducted focus groups 
 
Non-verbal communication 
not recorded 
 
Demographics not 
representative of general 
population as the study 
population were well 
educated, financially 
secure and the majority 
had previously shown 
interest in research 
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Kim
169
 
USA 
2004 
 
Potential 
research 
participants >18 
years, 
diagnosed with 
heart disease, 
breast cancer or 
depression, and 
listed on the 
Harris 
Interactive 
Chronic Illness 
Database 
Various Gender: 50% 
male 
Age: 4% 18-29, 
16% 30-44, 61% 
45-64, 19% 65+ 
Education / 
deprivation: 
Range of 
backgrounds 
Ethnicity: 92% 
White 
5478/20205 
(27%) 
Internet-based 
questionnaire  
Random 2-way 
ANOVA 
modified for 
ordinal data 
and 
multinomial 
logistic 
regression 
Conflicts of 
Interest 
(CoI)/organisat
ion and 
funding of the 
research 
Validated questionnaire 
 
Participants chosen at 
random but from the 
subset of those registered 
on the Harris Interactive 
Chronic Illness Database 
 
Demographics not 
representative of general 
population as it was 
limited to Internet users 
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3.3 RESULTS 
 
A meta-data analysis used basic thematic analysis to split results from the 11 papers 
into themes based on the FAQ titles provided in NRES guidance.  Individual results 
were coded based on their relevance to each theme and then collated and used to 
report results (Table 5). 
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Table 5 - NRES recommended headings against papers that report evidence 
NRES Heading* Evidence from literature 
 
What is the purpose of 
the study? 
 
2 studies provided relevant data
159;160 
 
Between 51% (29/57; 95% CI 38%;63.9%)
160
 and 94%(200/213; 95% CI 90.7%;97%)
159
 wanted to know about the 
scientific purpose of the study. 
 
Pooled results (with random effects) showed that 80.0% (229/27; 95% CI 83%; 91%) of participants wanted to 
know about the scientific purpose of the study. 
 
Why have I been invited? No studies reported this 
 
Do I have to take part? / 
What will happen if I 
don’t want to carry on 
with the study?* 
4 studies provided relevant data
159;160;162;163 
 
Between 0% (0/57)
160
 and 95% (202/213; 95% CI 91.9%;97.8%) wanted to know
159
 about this.  One study reported 
that participants thought it was the most important piece of  information to be included in a participant information 
sheet
163 
 
Pooled results (with random effects) from the 3 quantitative studies
159;160;162
 showed that 38.8% (215/310; 95% CI 
2.5%;99.5%) participants wanted to know this. 
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What will happen to me if 
I take part? / What will I 
have to do?* 
3 studies provided relevant data
159;160;162 
 
Two studies showed that around 40% of participants wanted to know the time needed to complete the study (42% 
[17/40; 95% CI 27.2%;58.8%]
162
; 37% [21/57; 95% CI 24.3%;49.4%
160
], whilst the third study had conflicting results 
and showed that 96% (204/213; 95% CI 93.1%;98.5%) wanted an indication of the nature and extent of the time 
commitment
159 
 
Pooled results (with random effects) showed that 61.4% (242/310; 95% CI 15.7%; 96.9%) participants wanted to 
know this. 
 
1 study provided relevant data
162 
 
68% (27/40; 95% CI 53%;82%) wanted to know the frequency of additional study visits
162 
 
Only one study provided results, so no pooled results could be calculated 
 
No studies reported this 
 
Two studies reported relevant data
162;163 
The proportion of people wanting to know what would happen to them ranged from 9.5% (2/21; 95% CI 
0%;22.1%)
163
 to 20% (8/40; 95%CI 7.6%;32.4%)
162
 depending on what the specific information was.  For example, 
20% (8/40; 95% CI 7.6%;32.4%) wanted to know about burdens to friends or family caused by study 
participation
162
, 12% (5/40; 95% CI 2.3%;22.8%) wanted to know how much work they would miss because of 
study participation
162
, 10% (4/40; 95% CI 0.7%;19.3%) wanted to know how much time would be spent waiting in 
clinic during study visits
162
, and 9.5% (2/21; 95% CI -3%;22.1%) wanted to know practical information about trial 
procedures
163 
 
Specific information types varied considerably between studies, so no meaningful pooled results could be 
calculated 
Expenses and payments 1 study provided relevant data
162 
 
25% (10/40; 95% CI 11.6%;38.4%) wanted to know if free medication would be available during or after trial
162 
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What is the drug, device 
or procedure that is 
being tested? 
Two studies provided relevant data
106 
 
One qualitative study showed that participants wanted to know how to use the intervention
106 
 
One study 
115
 showed that specific questions about the medication regime ranged from 25% (10/40; 95% CI 
11.5%;38.4%) that wanted to know what control they had over medication dose during the study to 70% (28/40; 
95% CI 55.8%;84.2%) that wanted to know the frequency with which study medication must be taken
115 
 
The same study showed that 62% (25/40; 95% CI 47.5%;77.5%)  wanted results of previous studies of safety and 
45% (18/40; 95% CI 29.5%;60.4%)  of efficacy, and 15% (6/40; 95% CI 3.9%;26.1%) wanted to know if study 
medication had been approved for clinical use
115
  
What are the alternatives 
for diagnosis or 
treatment? 
1 study provided relevant data
116 
 
5% (1/21; 95% CI 0%;13.9%) wanted as much information about  treatment alternatives as they received about the 
study medication
116 
 
What are the possible 
disadvantages and risks 
of taking part? / What are 
the side effects of any 
treatment received when 
taking part?* 
4 studies provided relevant data
104;10516106 
 
Results ranged from no participants that asked about study risks (0/57)
105
, to 97% (207/213; 95% CI 95%;99.4%) 
who wanted to be informed about any possible emotional or physical discomforts and side effects
104 
 
Specific information types varied considerably between studies, so no meaningful pooled results could be 
calculated 
 
Radiation and the 
Ionizing Radiation 
Regulations 
No studies reported this 
Harm to the unborn child: 
therapeutic studies 
No studies reported this 
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What are the possible 
benefits of taking part? 
Three studies provided relevant data
104-106 
  
Results ranged from 0% (0/57)
105
, to 98% (209/213; 95% CI 96.3%;99.9%) that wanted to know about study 
benefits
104
. 
 
Pooled results (with random effects) of the two quantitative studies
104;105
 suggest that 57.2% (209/270; 95% CI 
7.2%; 98.4%) wanted to know about study benefits 
 
Two studies provided relevant data relating to specific benefits
115;116 
 
Specific requests ranged from 14% (3/21; 95% CI -0.7%;29.3%) that wanted to know about hopes for better 
treatment
116
 to 55% (22/40; 95% CI 39.5%;70.4%) that wanted an opportunity to learn about condition or 
medication under study
115
  
 
Specific information types varied considerably between studies, so no meaningful pooled results could be 
calculated 
 
 
What happens when the 
research study stops? 
1 study provided relevant data
115 
 
55% (22/40; 95% CI 39.6%;70.4%) wanted to know about the availability of medication after the study is over
115 
What if there is a 
problem? 
No studies reported this 
Will my taking part in the 
study be kept 
confidential? 
2 studies provided conflicting data
104;105 
 
2% (1/57; 95% CI 0%;5.2%) asked about data privacy
105
 and no participants asked about data maintenance (0/57) 
in one study
105
, whereas the other study showed that 75% (160/213; 95% CI 69.3%;80.9%) wanted to be assured 
that all information concerning them would be kept confidential
104
, and 66% (141/213; 95% CI 59.9%;72.6%) 
wanted to be given information on the protection of their privacy
104 
 
Pooled results (with random effects) showed that 43.7% (302/483; 95% CI 9.8%; 8.2%) participants wanted to be 
given information about confidentiality and the protection of their privacy 
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Involvement of the 
GP/family doctor 
No studies reported this 
What will happen to any 
samples I give? 
No studies reported this 
Will any genetic tests be 
done? 
No studies reported this 
What will happen to the 
results of the research 
study? 
No studies reported this 
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Who is organising and 
funding the research? 
4 studies provided relevant data
107;109-111 
 
There was general disagreement over whether patients wanted to be told about financial COI.  Pooled results 
showed that 65% (95% CI 64%;66%) wanted to know about any type of COI. 
 
3 studies provided relevant data relating to what participants wanted to know about specific aspects of COI
110;113;117 
 
When financial COI were broken down into subcategories, 82.5% (4519/5478; 95% CI 81.48%;83.5%) wanted to 
be told about commercial funding
113
, 69% (3779/5478; 95% CI 67.8%;70.2%) about personal income
113
, between 
41% (105/259; 95% CI 34.6%;46.5%) and 82% (4492/5478; 95% CI 81%;83%) about patents and stocks and 
shares 
113;117
, and 40% (101/253; 95% CI 34%;46%) thought researchers should have told participants only about 
the oversight system
110 
 
One study reported that participants wanted to know specifically how money was spent, with proportions ranging 
from 25% (65/259; 95% CI 19.8%;30.4%) that wanted to know how much of the funding was spent on 
administration
117
, to 38% (98/259; 95% CI 31.9%;43.8%) that wanted to know how spare accrued funds were used 
at study completion
117 
 
One qualitative study reported that participants wanted to know the name of the sponsor
111
, and one quantitative 
study reported that 57% (148/259; 95% CI 51.1%;63.2%)
117
 wanted to know the name of the funder.  
 
Some participants wanted help understanding the potential consequences of COI, some did not
111 
 
Specific information types varied considerably between studies, so no meaningful pooled results could be 
calculated 
 
Who has reviewed the 
study? 
1 study provided results
105 
 
No participants asked about institutional review board approval (0/57)
105 
 
 
*Similar headings have been merged 
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3.3.1 CATEGORIES WITH NO STUDIES REPORTING RELEVANT RESULTS 
 
Of the twenty NRES suggested headings for inclusion of information in a PIS, there 
were seven categories where no research evidence was identified to suggest what 
information potential research participants wanted to know.  These were: 
 Why have I been invited? 
 Radiation and the Ionizing Radiation Regulations 
 Harm to the unborn child: therapeutic studies 
 What if there is a problem? 
 Involvement of the GP/Family doctor 
 What will happen to any samples I give? 
 Will any genetic tests be done? 
 
Four of these categories (‘Radiation and the Ionising Radiation Regulations’, ‘harm 
to the unborn child: therapeutic studies’, ‘will any genetic tests be done?’ and ‘what 
will happen to any samples I give?’) are very specific and NRES suggests their 
inclusion only for relevant studies.  There were four other categories where no 
studies reported relevant results (‘why have I been invited?’, ‘what if there is a 
problem?’, ‘involvement of the GP/family doctor’ and ‘what will happen to the results 
of the research study?’) and these categories of information are likely to be relevant 
for the majority of research studies. 
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3.3.2 CATEGORIES WITH STUDIES REPORTING GENERAL RESULTS 
 
Six studies considered what potential participants wanted to know about investigator 
conflicts of interest (COI).  Six studies reported research participants’ preference for 
information about investigator COI in a research study.  When the results of the four 
qualitative studies were pooled (with random effects) (Figure 6), 65.2% (95% CI 
64.0%; 66.4%) wanted to know about any type of COI.  The forest plot (Figure 6) 
showed that individual study results varied widely with one large study providing the 
majority of the weight.  The two studies that produced substantially different results 
to the pooled percentages164;167 had problems with generalisability to the wider 
research population and the use of defined sub populations may account for the 
differences seen.  Given that the one study providing the majority of the weight in the 
calculation169 agreed with results of the two qualitative studies (most participants 
wanted to be informed of any COI166;168), this is likely to be the best evidence of 
where the true value lies, given the limited data available. 
 
All six studies collected only hypothetical opinions of what participants wanted to 
know.  It is generally held that hypothetical opinions may not reflect real opinions170-
172 and participants may think differently when they are considering what information 
they require to decide to participate in an actual study.  
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Figure 6 - Forest plot of the proportion of participants that wanted to know 
about investigator COI (random effects) 
 
 
Of the remaining eleven categories, pooled results were calculated for four 
categories.  Results showed that participants wanted to know about the purpose of 
the study (84.8%; 229/270), voluntariness (69.4%; 215/310), what they would have 
to do (78.1%; 242/310), and confidentiality (62.5%; 302/483).  There were seven 
categories where pooled results could not be calculated because they included 
qualitative results, only one study provided results or studies reported specific 
information types that varied considerably between studies.   
 
Only five studies looked generally at what potential research participants wanted to 
know when deciding whether to participate in research (the remaining six studies 
looked at what potential participants wanted to know about conflicts of interest).  The 
proportion of participants that wanted to know study information varied according to 
0.2 0.4 0.6 0.8 
combined 0.65 (0.64, 0.66) 
Kim et al. 0.68 (0.67, 0.69) 
Gray et al. 0.55 (0.45, 0.65) 
Hutchinson & Rubinfield 0.39 (0.33, 0.45) 
Hampson et al. 0.31 (0.25, 0.37) 
proportion (95% confidence interval) 
91 
 
the topic.  Results ranged from 5% (1/21) that wanted to know about alternative 
treatments163 to 98% (209/213)159 that wanted to know about potential benefits.  
Different study methodologies may account for this variability.  For example, studies 
that asked participants if they wanted to know specific information often reported 
high proportions (i.e. 75% [160/213] wanted to be assured that all information 
concerning them would be kept confidential159), whereas studies that reported 
spontaneous information requests generally reported low proportions (i.e. only 2% 
[1/57] wanted to know about data privacy160).  One study was a qualitative focus 
group study and did not report proportions161.  There were also limitations to 
generalisability of findings in all studies.    
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3.4 DISCUSSION   
 
Of the eleven papers identified; six only provided information on what participants 
wanted to know about COI in research165;164;166-169.  Only five looked more broadly at 
what research participants want to know159-163.  All eleven studies were shown to 
have limitations when applying their findings to the wider research population (Table 
4).  This systematic review, therefore, found no good quality evidence to suggest 
what information the general research population wants to know before they decide 
whether to participate in research.  Table 6 shows a summary of the number of 
studies providing evidence for each category of information with pooled results 
where they could be calculated. 
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Table 6 - Number of studies providing evidence for each category of 
information with pooled results 
NRES suggested title  Number 
quantitative  
(/ total number) 
studies  
Pooled results  
(%) 
Study purpose  2/2 Yes (84.5) 
Why they have been invited  0/0 No 
Voluntariness  3/4 Yes (69.4) 
What will happen to them   3/3 No 
Expenses and payments  0/0 No 
What is being tested  0/1 No 
Alternatives   1/1 No 
Disadvantages, risks and side effects  0/0 No 
Radiation and the Ionizing Radiation 
Regulations 
 0/0 No 
Harm to the unborn child: therapeutic 
studies 
 0/0 No 
Benefits  2/3 Yes (77.4) 
When the research study stops  0/0 No 
If there is a problem  0/0 No 
Confidentiality  2/2 Yes (62.5) 
Involvement of the GP/family doctor  0/0 No 
Samples  0/0 No 
Genetic tests   0/0 No 
Results   0/0 No 
Organising and funding of the research  2/4 Yes (65) 
Ethical review  1/1 No 
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Incomparable study methodologies 
Of the five studies that looked more broadly at what research participants wanted to 
know159-163, differences in research methodology and design meant that that 
application of pooled results was also limited.  An example of this is the category 
‘What is the purpose of the study?’ where two studies provided relevant results.  The 
study by Walkup and Bock160 was an observational study and reported what 
information participants spontaneously requested about a questionnaire survey, 
whilst the study by Maslin159 asked participants to indicate if they wanted to know 
each of a series of prompted pieces of information.   Walkup and Bock reported a 
much lower proportion of participants that wanted to know the study purpose (51%160 
vs. 94%159).  When asked directly if they wanted to know this information, as in the 
Maslin study, participants said they did want to know the information because they 
found it interesting.  In the study by Walkup and Bock, however, they did not ask for 
that information spontaneously.  The differences in results caused problems when 
trying to determine if participants wanted to know this information, as the studies 
were not comparable.  Ideally, a separate meta-analysis would have been conducted 
for each type of methodology, but the limited literature meant this could not be done. 
 
A second potential cause of the variability in study results could be attributed to 
differences between hypothetical studies and collecting actual opinions.  Walkup and 
Bock160 reported what participants wanted to know about a real study, whereas 
Maslin159 reported what participants said they wanted to know about a hypothetical 
study.  It is generally held that what people say they want to know in a hypothetical 
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situation differs to what they would actually do when presented with a real 
scenario170-172. 
 
The final difference between these two papers lies in the level of risk in the studies 
participants were asked about.  Walkup and Bock160 conducted a low risk 
questionnaire study, compared with Maslin’s159 high-risk breast cancer trial.  It would 
be reasonable to expect that participants wanted to know more information when 
being asked to participate in a higher risk study.  This again makes comparisons 
between the two study results difficult. 
 
These differences in the design of the studies papers may account for the different 
proportions of participants that wanted to know about the purpose of the study.  
Given these differences in the study designs, data could not be pooled to determine 
an overall proportion of how many people wanted to know each piece of information 
about a study.   
 
Similar problems were seen with other NRES categories, for example ‘Do I have to 
take part? / What will happen if I don’t want to carry on with the study?’  Two papers 
reported the questions that participants asked about a study when they were being 
invited to take part105;115 and both reported that few participants wanted to know 
information about whether they had to take part in the study (0% [0/57] and 32% 
[13/40; 95% CI 18%;47%] respectively).  In comparison, the two studies that asked 
participants if they wanted to know specific pieces of information159;163 both reported 
a very high proportion of participants that wanted to know this information (95% 
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[202/213; 95% CI 91.9%;97.8%]159 and “it being the most important piece of 
information to be included in a PIS”163).   
 
Level of detail 
There were also problems with the level of detail provided by the five studies that 
reported generally what participants wanted to know.  Most papers asked participants 
if they wanted to know pieces of information or recorded what information they 
requested, but the methodologies used did not allow information to be collected on 
the level of detail potential participants want.  Real time observational studies need to 
be conducted that track the level of detail of information accessed by potential 
participants when they are given a choice. 
 
Generalisability 
A further problem with the studies identified for inclusion in this review was the 
selected populations used in the studies.  Many studies used specific subsets of the 
population, such as cancer patients, and did not look broadly at what all research 
participants might want to know about research.  Given that NRES guidance provides 
general guidance to writing a PIS (i.e. not guidance specific to subgroups), the views 
of the overall research population need to be taken into account when writing 
guidance on how much information to include in a PIS.  This would suggest that work 
needs to be conducted with a range of key stakeholders to address differing needs, 
i.e. to ensure that future PIS are written in such a way as to provide the information 
that potential participants want, meet regulatory requirements and also provide 
information to legally protect researchers.  Given that this systematic review provided 
little evidence to suggest exactly what information research participants wanted to 
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know, PIS may not currently include the information they want to make a participation 
decision. 
 
Limitations 
The unspecific nature of the topic and the broad search strategy used in this 
systematic review led to the identification of a large number of citations (n=11943) 
and it was not feasible to review all abstracts.  The sifting process included scanning 
titles for relevance in the first instance, so there is a possibility that relevant papers 
were excluded where a title was not sufficiently informative.  Whilst this is a limitation 
to the review, the lack of overall evidence means it is unlikely that many (if any) 
relevant papers were missed. 
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3.5 CONCLUSIONS 
 
This systematic review has demonstrated differences between what participants 
wanted to know before they decide to take part in research, depending on the 
methodologies, context and population used in the studies.   
 
The studies showed that participants spontaneously requested less information than 
they said they wanted to know when they were prompted.  It is difficult to conduct 
future research to determine what information potential participants want, since 
asking potential participants what information they want to know may not accurately 
reflect what information they will use when faced with a participation decision170-172.  
Future research should focus on real time observational studies that collect the 
information accessed by participants when making a participation decision.    
 
A paper by Dixon-Woods et al (2007)173 is worth discussing in relation to the results 
of this systematic review.  Embedded within the genetic GRAPHIC trial, interviews 
were undertaken with 29 healthy participants to explore their views and experiences 
of research.  They found that participants often decided to participate without a great 
deal of thought and the decision was not based on the information included in the 
PIS, but rather based on four other main factors: a positive attitude towards medical 
research; a desire to do good; a possibility of some personal gain in the form of a 
health check; and confidence in the research process and its governance and a 
perception of low risk.  Participants suggested that the precise nature of the study 
was unimportant so long as the research appeared to be worthwhile and well run; 
something they attributed to recognising funders and organisers of the research i.e. 
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an issue of trust.  This research sheds a new light on the meaning participants may 
give to information included in a PIS, and whilst they may not need to know all of the 
information included in a PIS, they may use it to form an overall opinion of whether 
the study is worthwhile participating in. 
 
For firm conclusions to be drawn from the speculations made in this systematic 
review, further research is needed.  There is real need for a large, good quality study 
to determine what information research participants actually want to know about a 
research study, so that information provided in the PIS can be tailored towards what 
participants feel they need to know in order to arrive at an informed decision. 
 
This systematic review has been published in the BMJ Open174 and is included as 
Appendix 9.1. 
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Key points 
There is limited evidence about what information potential participants want to 
know at the time they are deciding whether or not to participate in research. 
 
Asking potential participants what information they want to know may not 
accurately reflect what information they will use when faced with a 
participation decision. 
 
Real-time observational studies need to be conducted to explore what 
information potential participants access when given a choice.  This will 
enable us to determine exactly what information research participants want to 
know and could, in addition to other sources such as expert opinion, help tailor 
PIS towards specific population subgroups and enable appropriate high-
quality information to be provided to meet individual needs. 
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4 INFORMATION PROVISION STUDY PROTOCOL 
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The second objective of the PhD was to devise and conduct a study (from henceforth 
referred to as the Information Provision study) to collect data on what potential 
participants want to know to be able to participate in low risk interventional research.  
This chapter provides the protocol for the Information Provision study.   
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4.1 STUDY DESIGN 
 
The Information Provision study had three components.  The first addressed the 
feasibility of electronic information provision, comparing electronic information 
provision to standard paper format.  The second was an RCT (IIS RCT) that 
compared responses to a PDF file of a standard PIS (PDF-PIS) with an IIS.  The third 
component was an observational study of participants randomised to the IIS arm of 
the IIS RCT.  This recorded the study information accessed by each participant. 
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4.2 AIMS 
 
Feasibility component:  
Primary aim 
To determine if it was feasible to provide electronic information in low risk 
interventional research 
 
Secondary aims 
 To determine the proportion of potential research participants that had access 
to the Internet and were willing to use it to access study information and 
whether this varied within subsets of the population 
 To determine if participants were satisfied with the way in which information 
was provided and whether satisfaction varied within subsets of the population 
 To determine what proportion of the population had a good understanding of a 
study after reading the PIS and whether method of information provision 
affected level of understanding  
 
IIS RCT:  
Primary Aim 
To determine if an IIS could improve consent rates to research 
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Secondary aim 
To allow assessment of satisfaction and understanding as a component of the 
observational study 
 
Observational study:   
Primary Aim 
To determine what information potential participants accessed about a low risk 
interventional study when given the choice of the type and level of detail of 
information 
 
Secondary Aims 
 To determine if informational needs differed within subsets of the population 
 To determine if the type and amount of information used by potential study 
participants differed between those who consented and refused to participate 
in the study and whether this differed within subsets of the population 
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4.3 PARENT STUDY (IN WHICH THE INFORMATION PROVISION STUDY WAS 
EMBEDDED) 
 
4.3.1 IDENTIFICATION OF A SUITABLE PARENT STUDY  
 
Antoniou et al6 demonstrated the feasibility of using an IIS in an Internet 
questionnaire-based study.  When conducting research on consent procedures, there 
are concerns that new interventions may mean participants will enter research 
without being properly informed if the introduced intervention does not appropriately 
inform potential participants.  For this reason, it was decided that the next challenge 
for the IIS was to use it in low risk interventional research where the risks and 
disadvantages of participating would be minimal.  Accordingly, the information 
provision study needed to be embedded within a low risk intervention study (non 
questionnaire-based) that had a large number of participants (Section 4.5) with a 
range of ages and the capacity to recruit participants and distribute participant 
information electronically.  Clinicians and academic researchers at the University of 
Birmingham were approached to see what planned or on-going trials were available, 
but finding a study that met all criteria proved difficult. 
 
A consultant at the Queen Elizabeth Hospital, Birmingham offered three potential 
studies.  The first two studies (a RCT of chronic colitis patients randomised to active 
topical treatment vs. no topical treatment, and a randomised non blinded controlled 
study of a new form of oral iron for anaemic inflammatory bowel disease patients)  
were excluded because of small sample sizes (n=50).  The third study (a RCT to test 
a new formula of cyclosporine) was industry-based and the clinical research 
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organisation was unwilling to embed a methodological question into their protocol.  
Several potential leads with other hospital consultants were also explored but no 
suitable study was identified. 
 
Principal Investigators (PIs) within the School of Health and Population Sciences and 
the Clinical Trials Units at the University of Birmingham were then approached via 
email (and sometimes in person where appropriate).  A summary of the Information 
Provision study was included in emails and PIs were asked to identify potentially 
suitable studies in which it could be embedded.  Professor Richard McManus, a 
researcher with several prevalence studies in primary care, expressed an interest.  
After discussion with Professor McManus, a suitable observational study, the ‘Blood 
Pressure Monitoring in Different Ethnic Groups (Bp-Eth)’ study was identified.  Bp-
Eth was a large study (n=800), recruiting over 24 months, it included a range of 
participants and was suitable for electronic recruitment.  The limitation to embedding 
in this study was the older participant age range (40-74) but as young people were 
more likely to use the Internet102, if the study found that providing study information 
electronically was acceptable to an older cohort of participants, it was reasonable to 
hypothesise that it would also be acceptable to a younger cohort.  
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4.3.2 OUTLINE OF THE PARENT STUDY 
 
Study aims 
The tri-phase “Blood Pressure Monitoring in Different Ethnic Groups Study (Bp-Eth)” 
(Appendix 9.4) conducted at the University of Birmingham aimed to answer three 
research questions:  
 
1. How often and in what ways does monitoring of blood pressure occur and how 
does it differ between White and minority ethnic populations?  
 
2. Are the thresholds for diagnosis and management of hypertension comparable 
for White and minority ethnic populations using three different measurement 
modalities: office blood pressure, ambulatory blood pressure monitoring 
(ABPM) and self monitoring?  
 
3. What preferences for blood pressure measurement do people from White and 
minority ethnic populations have? 
 
Outline of the three research phases 
Phase I was a cross-sectional survey of 8000 participants and included 
representative samples from four ethnic groups, (White, Irish, Asian, and African-
Caribbean) with both normotensive and hypertensive blood pressure ranges.   
 
Phase II was a validation study to compare different modes of blood pressure 
measurement in diagnosing hypertension and to detect thresholds for when 
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medication doses should be altered.  Blood pressure readings (recorded by 
ambulatory 24 hour blood pressure monitors; self monitored blood pressure and 
research office measurements) were used to ascertain whether differences in 
readings between methods of measurement were similar between ethnic groups.  
Participants were eligible for phase II if they were aged between 40-74 years and 
belonged to one of the four ethnic groups under investigations (White, Irish, Asian, 
African-Caribbean).  Participants were excluded if they were unable to self monitor or 
use an ambulatory blood pressure monitor, were pregnant, unable to consent, had a 
terminal disease or their GP felt they were not suitable.   
 
Phase III was a focus group study that included participants from each ethnic group.  
It considered participant preferences for, and experiences of, blood pressure 
measurement in each of the three ways considered in phase II. 
 
 
4.3.3 HOW THE INFORMATION PROVISION STUDY WAS EMBEDDED 
 
Participants (8000 in total) were recruited into phase I of the Bp-Eth study.  At the 
end of the phase I questionnaire participants were asked to provide contact details if 
they would be willing to participate in phase II.  Of the participants who returned the 
phase I questionnaire and expressed an interest in participating, 800 (200 White, 200 
Black, 200 Asian and 200 Irish) were recruited take part in phase II of the Bp-Eth 
study.   
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To embed the Information Provision study an additional email address field was 
added to the contact details participants were asked to provide if they were interested 
in Phase II of Bp-Eth.  All those who provided an email address were potentially 
eligible to participate in the Information Provision study.  
 
The full protocol for the Bp-Eth study is provided as Appendix 9.4. 
 
For the remainder of the thesis, phase II of the Bp-Eth study, where the information 
provision study sat, will be referred to as the parent study.  The questionnaire for the 
phase I Bp-Eth study will be referred to as the questionnaire for the parent study.  
This is for clarity to distinguish between the Bp-Eth and Information Provision study. 
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4.4 PARTICIPANTS 
 
Feasibility of electronic information provision 
All participants who wished to continue with the parent study were included.  
Participants were asked to provide an email address with their contact details.  If they 
did, they were sent an electronic invitation letter (via email) (Appendix 9.5) and link to 
the parent study website.  If no email address was provided they were sent the 
standard parent study information through the post. 
 
IIS RCT 
All those who provided an email address were sent the invitation to participate in the 
parent study in which they were asked to click on a hyperlink to the parent study 
website.  If they did so, they were randomised either to receive a PDF copy of the 
paper PIS (PDF-PIS) or the IIS. 
 
Participants were assumed to have opened the email if they returned a read receipt, 
replied to the email, made a consent appointment or accessed the study website.  
Participants who appeared not to have opened the email within 3 days were 
contacted by telephone to verify their email address.  Up to 10 attempts were made 
to contact participants at different times of the day; in the morning (9-12pm), 
lunchtime (12-2pm), afternoon (2-6pm), evening (6-9pm) and weekends; over a 
seven day period.  If they did not answer the telephone after ten attempts they were 
deemed un-contactable and sent a postal invitation and paper PIS.   
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If participants made an appointment with the research nurse they were perceived to 
have consented for the purpose of this Information Provision study.  Following this 
perceived consent, the potential participant still may not have participated in the 
parent study and changed their decision either prior to the appointment (and so did 
not attend the appointment) or after speaking with the research nurse.  In these 
cases, the information in the PIS/IIS was not decisive for their final decision.  This 
study aimed to consider only the effect of the PIS/IIS on consent, and so perceived 
consent was used as the outcome.   
 
The email invitation contained contact details for researchers if participants were 
interested in taking part.  Participants were able to make an appointment without 
clicking on the hyperlink to access the study website.  These participants were 
perceived to have consented to take part without accessing any PIS. 
 
Observational study 
Participants randomised to IIS were included in an observational study that captured 
the information accessed by each participant using a database connected to the IIS.   
 
Demographic data for all participants were collected by the parent study, which was 
made available for use in the Information Provision study. 
 
Figure 7 provides an overview of how participants were recruited to the Information 
Provision study. 
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Understanding and satisfaction questionnaire 
All participants who agreed to participate in the parent study were asked to complete 
a questionnaire to determine their understanding of the study and their satisfaction 
with the way in which information was provided.  Participants randomised to PDF-PIS 
or IIS were directed to complete the questionnaires after they indicated if they wished 
to participate in the parent study.  If they did not complete the questionnaire at this 
time, did not take part in the IIS RCT or were sent a paper PIS, the questionnaires 
were sent through the post at the time they made an appointment with the research 
nurse for the parent study.  All participants receiving a postal questionnaire were sent 
a reminder and duplicate questionnaire if they did not respond within two weeks. 
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Figure 7 – Recruitment flow chart 
Potentially eligible from parent study 
No email address 
Supplied = 
Paper PIS group 
Provided email 
address = 
Electronic PIS 
Incorrect email address - 
verify by telephone 
Email delivered 
Opened email Did not open email 
Accessed website for 
more info 
Did not access website 
= No PIS group 
Randomised to IIS = 
IIS group 
Randomised to PDF 
= PDF group 
Did not 
Book parent 
study 
appointment 
Booked 
parent study 
appointment 
Did not 
Book parent 
study  
appointment 
Booked 
parent study 
appointment 
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4.5 SAMPLE SIZE CALCULATIONS 
 
Sample size calculations were based on the IIS RCT component of the Information 
Provision study. 
 
 
4.5.1 ESTIMATING AN EFFECT SIZE 
 
The primary outcome measure of the IIS RCT was consent rate to the parent study.  
Since the IIS had never been used as the intervention for a RCT and there was 
insufficient evidence to predict the likely effect size, it was not known how much of a 
difference its use would have on the consent rate.  Without this estimate of effect size a 
sample size calculation could not be made175-177.  Another way to estimate the effect 
size is to gather expert opinion and then use effect size that is required to change 
practise, to inform sample calculations178.  This method was used to establish an effect 
size for the IIS RCT. 
 
Researchers were identified and invited (by email) to participate in an online 
questionnaire.  The questionnaire described the IIS and asked how much they would 
need to see recruitment rates increased by, based on 90%, 70%, 50% and 30% 
baseline rates, before they would consider using the IIS in their research.  The 
questionnaire was sent to 122 people; 7 responded to say they were not involved in trial 
design and could not complete the questionnaire, 64 attempted it and of these 26 failed 
to complete it.  Thirty-eight completed the questionnaire and were included in the 
analysis (response rate 33%; 38/115).  Depending upon the baseline recruitment rates 
presented in the questionnaire participants wanted recruitment rate to increase from 
6.9% to 28.9% before they would consider using the IIS (Table 7). This study has been 
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reported in the BMC Medical Research Methodology Journal179 and the full study is 
included as appendix 0. 
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Table 7 - Results from the effect size questionnaire 
Expected consent rate without 
using the IIS (baseline consent 
rate) 90% 80% 70% 50% 30% 
 
Mean percentage increase  
experts wanted  7.4 10.9 13.8 19.6 27.0 
Standard deviation 
 3.19 5.61 24.05 8.53 18.13 
Median percentage increase  
wanted  9 10 11 20 25 
Inter quartile range 
 5 5 10 17.5 30 
Range of responses seen 
 0-10 0-20 0-30 0-50 0-70 
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4.5.2 SAMPLE SIZE CALCULATIONS FOR THE IIS RCT 
 
A variety of sample sizes were calculated assuming study baseline consent rates of 
90%, 80%, 70%, 50% and 30%, powers (β) of 90% and 80% and effect sizes of 
7.4%, 10.9%, 13.8%, 19.6% and 27% respectively (Table 7) using the calculation: 
 
N = [ (α +β)² x (p1q1+p2q2) ] / effect size² 176    
 
With a predicted type I error of 5% and a type II error of 10-20%, the calculated 
sample sizes ranged from N=122 to N=442 (Table 8). 
 
Pilot work for the parent study (n=7) suggested that consent rate was likely to be 
around 70% so this was used as an estimate of the main parent study consent rate. 
Table 9 shows a further range of sample sizes based around a 70% consent rate for 
the range of effect sizes collected from the effect size questionnaire. 
 
The sample size estimate for the IIS RCT component of the Information Provision  
study was 382 participants, but given the uncertainty of the effect size the study was 
implemented as quickly as possible to recruit the maximum number of participants 
from those invited to the parent study.  The maximum number of participants that 
could have been approached was 1200 (given that 840 participants were sought for 
the parent study and assuming a 70% consent rate). 
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Table 8 - Estimate sample sizes for the range of baseline consent rates 
Effect size Consent rate Power N (per arm) N (total) 
7.4% 90% 90% 221 442 
  80% 165 330 
10.9% 80% 90% 214 428 
  80% 160 320 
13.8% 70% 90% 191 382 
  80% 143 286 
19.6% 50% 90% 126 252 
  80% 94 188 
27% 30% 90% 66 132 
  80% 61 122 
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Table 9 - Sample sizes for a consent rate of 70% 
Effect size Consent rate Power N (per arm) N (total) 
1% 70% 90% 43660 87319 
  80% 32653 65306 
7.5% 70% 90% 717 1435 
  80% 536 1073 
13.8%* 70% 90% 191 382 
  80% 143 286 
15% 70% 90% 157 315 
  80% 118 236 
22.5% 70% 90% 58 116 
  80% 43 87 
30% 70% 90% 24 49 
  80% 18 37 
 
*Effect size required to change practice 
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4.6 RANDOMISATION 
 
Participants were randomised to receive either a PDF-PIS or be directed to the IIS 
website.   
 
Randomisation could have led to a chance imbalance in prognostic characteristics 
and biased results.  In order to balance known prognostics between groups, 
randomisation was stratified by age and gender.  Randomisation was stratified to 
three age groups: (1) those under 50 years, as previous literature showed response 
rate was likely to differ between those below and above the age of 50180;  (2) those 
over 65, since ‘The Office for National Statistics Statistical’ Bulletin “Internet Access 
Households and Individuals 2009” stated that Internet usage was low in this age 
group181; and, (3)  those aged between 50 and 65.    One inclusion criteria for the 
parent study was being aged 40 to 74, so these three age groups used for 
stratification also split the IIS RCT participants into approximately equal groups 
spanning between 10 and 15 years.  
 
Blocking is a method of preventing unequal group sizes in randomised trials and 
guarantees that at any point in study recruitment, the imbalance in numbers between 
the study arms will be small (dependant on block size)182.  Blocks of four were used 
for the IIS RCT, meaning that at any one time there could be a maximum difference 
of two participants per subgroup.  A blocking group of four was chosen because a 
larger blocking size would potentially create a bigger difference between subgroup 
sizes.  Since this study relied on participants choosing to enter themselves, 
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recruitment could stop at any time.  If this happened before the end of the parent 
study blocking would ensure that the resulting groups were of equal size.   
 
Blocks were assigned in random groups of four.  There were, therefore, six 
sequences to which participants could have been allocated to group A (PDF-PIS) or 
B (IIS).  The possible blocks were: 
 
AABB 
ABAB 
ABBA 
BAAB 
BABA 
BBAA 
 
Each of these blocks was given a number from one to six and the random number 
generator function in Excel generated a random list using only these six numbers.  
Each random number in this list was replaced with the corresponding blocking 
sequence and a random list of allocations blocked in groups of four was produced. 
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4.7 INTERVENTIONS 
 
PDF-PIS 
The PDF-PIS was an electronic copy of the parent study paper PIS.   
 
IIS 
The IIS was the intervention in the IIS RCT and is described fully in Chapter 5.  The 
IIS was developed based on the unfolding PIS intervention described by Antoniou et 
al6.   
 
The IIS presented the reader with a screen containing a list of frequently asked 
questions (FAQ) about the parent study that corresponded to NRES suggested titles 
for a PIS.  Behind each FAQ were up to four levels of information accessed by 
clicking on hyperlinks embedded in each level.  Level one contained less detailed 
information than the parent study paper PIS (minimal information), level two an exact 
copy of the paper PIS (standard information), level three was more detailed than it 
(extended information) and level four contained links to external sources, for example 
scientific papers evidencing the information provided (external information).   
 
Understanding and satisfaction questionnaire 
Participant understanding and satisfaction were captured online or by postal 
questionnaire. 
 
Since some participants would take part in at least two phases of the parent study it 
was undesirable to burden them with an additional lengthy questionnaire to answer, 
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so the questionnaire to determine understanding and satisfaction was designed to be 
completed in less than ten minutes.   
 
There is no standardised measure of level of understanding of participants1 but 
‘Quality of Informed Consent tool’ (QuIC)1, was adapted for use in this study.  The 
QuIC was appropriate since it is a validated self-administered questionnaire that 
takes less than 10 minutes to complete183.  It tests participants on their knowledge of 
research and questions could be easily adapted to include specific aspects of the 
parent study without altering the questionnaire and, therefore, its validity.  The final 
questionnaire is included as Figure 8. 
 
Antoniou et al6 asked participants about their satisfaction with the way in which their 
study information was provided.  Their questions were adapted to determine 
satisfaction for this study.  Figures 9 shows the satisfaction questionnaire sent to 
those randomised to IIS, and Figure 10 shows the satisfaction questionnaire sent to 
those randomised to PDS-PIS or paper PIS. 
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Figure 8 - Questionnaire to determine understanding 
 
Part A 
Below you will find several statements about the blood pressure monitoring study.  Thinking about the 
study, please read each statement carefully.  Then tell us whether you agree with the statement, you 
disagree with the statement, or you are unsure about the statement by marking in the appropriate 
response box.  Please respond to each statement as best you can.  We are interested in your opinions. 
 
1.  You have been asked to measure blood pressure with 
different machines. Do you think this is for a piece of 
medical research? 
 
Yes1 No Don’t know 
2. Is this study to see if differences between blood 
pressure measured at home and blood pressure 
measured at the GP surgery are the same for different 
ethnic groups? 
 
Yes1 No Don’t know 
3.  Have you been chosen to take part in this study 
because you have high blood pressure?   
 
 
Yes No1 Don’t know 
4. Do you have to take part in this study? 
 
 
Yes No1 Don’t know 
5.  If you take part in this study will you be involved in the 
study for 8 days? 
 
 
Yes1 No Don’t know 
6. If you take part in this study, will you have to measure 
your blood pressure yourself at home? 
 
 
Yes1 No Don’t know 
7. Will your GP be told you are taking part in this study?  
 
 
Yes1 No Don’t know 
8. Will the research nurse for this study offer you 
treatment for high blood pressure? 
 
Yes No1 Don’t know 
9. Will we keep information about you confidential if you 
agree to take part in this study? 
 
Yes1 
 
 
 
No Don’t know 
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10. If you decide to pull out from the study, will it affect 
your care from your GP?  
 
 
 
Yes 
 
No1 
 
Don’t know 
11. Will statisticians involved in this study be able to see 
your name, address and other personal details? 
 
 
Yes No1 Don’t know 
12. If you don’t want your GP to know you are taking part 
in this study will you still be able to take part? 
 
 
Yes No1 Don’t know 
13. Is this study is being organized by professional 
researchers at the University Of Birmingham?  
 
 
Yes1 No Don’t know 
14. When we publish the results of this study, will we 
identify you in any report? 
 
 
Yes No1 Don’t know 
15. Has this study been looked at and approved by a 
research ethics committee? 
 
 
Yes1 No Don’t know 
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Figure 9 - Questionnaire to determine satisfaction for those randomised to IIS 
 
 
We would like your comments about the information you read about the Blood Pressure Monitoring Study.  
Please tick any of the following statements that apply.  
  
 
 I did not click on any of the (+) signs. 
 
 I found the information under the (+) signs useful and it influenced my decision to take part in this 
study. 
 
 I clicked on the (+) signs to see what was there but did not read the information. 
 
 I clicked on the (+) signs and skimmed through the information.  I did not read it fully. 
 
 I clicked on the (+) signs and skimmed through the information.  I picked out and read only parts 
which were important to me. 
 
 I found the information under the (+) signs interesting but it didn’t influence my decision to 
participate in the Blood Pressure Monitoring study. 
 
 I would have been happy with just the first piece of information from each section.  I did not need to 
read any of the information under the (+) signs to make a decision about whether I wanted to take 
part in the Blood Pressure Monitoring study. 
 
 
 
I would not have agreed to take part in the Blood Pressure Monitoring study without being able to 
read the information under the (+) signs. 
 
 
 
I would have liked more information about the study. 
 I didn’t need as much information about the study as I was given. 
 
 I would prefer to have information provided electronically if I took part in research again. 
 
 
 I would prefer to have information provided on paper if I took part in research again. 
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Figure 10 - Questionnaire to determine satisfaction for those randomised to 
PDF-PIS or paper PIS 
 
We would like your comments about the information you read in the information sheet you were given about 
the blood pressure monitoring study.  Please tick any of the following statements that apply.   
 
 
 I read all of the information sheet I was given about the Blood Pressure Monitoring study. 
 
 I read some of the information in the information sheet I was given about the Blood Pressure 
Monitoring study. 
 
 I skimmed through the information in the information sheet I was given about the Blood Pressure 
Monitoring study and read only the bits that were important to me. 
 
 I did not read any of the information in the information sheet I was given about the Blood Pressure 
Monitoring study. 
 
 I read some of the information in the information sheet but it did not help me to decide whether or 
not I wanted to take part in the Blood pressure Monitoring study. 
 
 The information sheet was important to read and helped me to decide whether or not I wanted to 
take part in the Blood Pressure Monitoring Study 
 
 I found the information in the information sheet about the Blood Pressure Monitoring Study 
interesting but it did not influence my decision to take part. 
 
 I would not have agreed to take part in the Blood Pressure Monitoring study without being able to 
read the information in the information sheet 
 
 
 
I would have liked more information about the study. 
 I did not need as much information about the study as I was given. 
 
 I would prefer to have information provided electronically if I took part in research again. 
 
 
 I would prefer to have information provided on paper if I took part in research again. 
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4.8 OUTCOMES 
 
Primary outcomes 
The primary outcome measure for the feasibility component was the proportion of 
participants that provided an email address.  The primary outcome measure for the 
IIS RCT was consent rate to the parent study.   
 
The primary outcome measure for the observational study was the amount and type 
of information accessed.  The proportion of people clicking on each link within levels 
of the IIS FAQ was used as the proxy for determining what information potential 
study participants accessed when they were deciding whether to participate.   
 
Secondary outcomes 
Secondary outcome measures were email address provision and level of study 
understanding and satisfaction with the information provided. 
 
Feasibility study and IIS RCT 
Demographic information was collected by the parent study for all participants who 
expressed an interest in taking part.  These data were anonymised to participant ID 
number, so they could be matched to the participant ID number of participants in the 
Information Provision study.  Each participant was given an Index of Multiple 
Deprivation (IMD) score184, based on postcode and calculated using the GeoConvert 
tool available through the official Census website185.  These data were used in 
conjunction with the other outcome measures to determine if informational 
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requirements, access to the Internet and acceptability of the IIS varied between 
subsets of the population. 
 
The proportion of participants who provided an email address was used as a proxy 
measure of accessibility to the Internet, which was then used as a measure of 
feasibility of using an IIS.   
 
A comparison of responses to the satisfaction and understanding questionnaire was 
made between those who received the IIS and those who received the standard PIS 
(electronic or paper) to determine if satisfaction or understanding were affected by 
method of information provision. 
 
Observational study 
The proportion of people clicking on each link within the levels of the IIS FAQ was 
also used in conjunction with the proportion that consented to participate in the 
parent study to determine if the type and amount of information accessed differed 
between those who consented and refused to participate in the parent study.   
 
The time spent within each level of the IIS was used to judge whether participants 
had read the information presented when they accessed an area.   
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4.9 STATISTICAL ANALYSIS 
 
All analyses were carried out using SAS version 9.2  
 
Feasibility study 
The relationship between subject characteristics (gender and age [<49, 50-65, >66]) 
and the variables presented below were evaluated using a non linear effect model 
(with practice as a random effect)186.  The relationship between patient demographics 
and the following outcomes were assessed: 
 
 Provided/did not provide an email address 
 Accessed/did not access information online 
 Level of understanding 
 
IIS RCT 
The RCT analyses were based on intention to treat (ITT)187.  The primary analysis for 
the IIS RCT intended to assess the impact of IIS on consent rate using a mixed 
model with a logit link and binomial error accounting for baseline age and gender and 
with practice as random effects186.  Odds ratio 95% CI and p value were also 
presented188. 
 
Observational study 
Each time a participant clicked on a link to request information about the study from 
the IIS it was recorded and used to produce a list of what information was accessed 
by each individual and the proportion of participants that accessed each level of 
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information189.  The proportion of people that clicked on each link was used to show 
which levels of information were commonly read and which were not.  This, along 
with how much time was spent on each piece of information was used to determine 
what information was regarded as important to participants. 
 
The number of words an average person can read in one minute was used to 
determine how long it would take the average person to read each piece of text on 
the IIS190;191.   This calculation was then used to make a best guess as to whether the 
participant had read the text, skimmed through it, or opened up the level of 
information without attempting to read it at all. 
 
The proportion of people that accessed each level of information was used to 
determine if there were particular questions on the IIS where participants were more 
likely to read the extended information available.  Exploratory analyses using 
frequency and proportion were undertaken to assess whether different socio-
demographic groups were more likely to access and read each piece of information.  
Frequencies and proportions were examined to see if any clear patterns emerged. 
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4.10 ETHICAL APPROVALS AND CONSIDERATIONS 
 
Ethical approval was sought from The Black Country REC as an amendment to the 
parent study before commencement of data collection (REC reference 
09/H1202/114). 
 
This study was an electronic version of an observational study.  Observational 
research presents methodological challenges because telling participants they are 
being watched can alter behaviour thereby biasing the results192;193.  For this reason 
we did not inform participants of this IIS RCT that we would record the type and 
amount of information they accessed.   Participants were told of all aims that were 
not likely to invite bias into the study, for example, that we wanted to evaluate and 
pilot a new way of providing study information to participants.   
 
Based on the results reported by Antoniou et al, it was anticipated that some 
potential participants would not choose to read information on the website and that 
still more would not access all of the information provided on the paper PIS. They 
would not, therefore, be fully informed about the parent study when they made a 
decision regarding participation.  Moreover, we would be able to identify those 
participants who had read little or no information. Given the ethical significance 
placed on information in decisions regarding research, this presented an ethical 
challenge for the research team. Our justification for continuing was as follows: 
1.  The parent study was a low risk study unlikely to result in any physical harm to 
participants. Thus the participants who did not choose to access information were not 
‘blindly’ consenting to significant risk.   
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2. There is always a danger that participants will not read the PIS, even when it is 
presented to them in full and on paper.  The consent interview acts as a safeguard 
against this danger. GCP suggests that the person gaining consent should go 
through the information provided and the opportunity for the potential participant to 
ask questions. We confirmed that this was indeed the practice on the parent study, 
and that consent would not be gained until the research nurse was sure that the 
participant understood what they were agreeing to before gaining consent.  
Accordingly, we judged that the risk of ill-informed consent being gained from our 
participants was in fact quite small. 
 
3. We, as researchers, were aware that some individual participants had not 
accessed study information prior to the first appointment, although in terms of the 
participants’ experience, this is no different to them not reading a PIS sent through 
the post.  The first ethical issue of the research lies here since tracking participants 
online activities moved the boundary from uncertainty (in the case of traditional 
versions of PIS) to near certainty (in the case of IIS) that individuals did not read 
study information before the appointment. UK NRES guidelines22 do acknowledge 
that PIS are only one part of the consent process and suggests the platform for 
presenting information (for example, verbal/written information) should be considered 
for every study.  In the parent study we regarded the reading through of the PIS at 
the first appointment as a sufficient safeguard if participants had not read any (or 
‘sufficient’ levels of) information prior to the appointment.  Given this safeguard and 
NRES guidance, the researchers involved in the IIS study did not fail in their duty to 
ensure informed participation.   
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Finally, we accessed demographic information (not names or addresses) about 
participants in the parent study who either did not choose to participate in the 
information provision study or who were ineligible to participate because they did not 
include an email address.  The PIS for the parent study stated that: “personal data 
will be kept separately from study results.  Anonymised data from the study will used 
in the main analysis and may be used in future work.”  This meant that participants 
were informed that anonymised data may be made available for other research, such 
as this Information Provision Study.  Demographic data anonymised by participant ID 
number for statistical analysis purposes in the parent study was made available for 
use in this Information Provision study.  This information was then tied, by ID 
number, to participants in the Information Provision study.   For this reason, we do 
not think that consent was exceeded. 
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4.11 CHANGES MADE TO THE PROTOCOL AFTER COMMENCEMENT OF THE 
STUDY 
 
The parent pilot study (n=7) estimated a consent rate of 70% but the actual rate of 
recruitment was around 30%.  Sample size calculations for the IIS RCT assumed a 
baseline consent rate of 70% and so were amended to take into account the lower 
rate.  For a 30% baseline consent rate the required effect size was 27.0% (Section 
4.5), so with 90% power the sample size estimation was n=132 (Table 8).  
 
The proportion of parent study participants accessing the study website was much 
lower than anticipated, with only 29.7% (86/290) randomised.  There were also an 
unexpectedly high number of people that participated in the parent study without 
accessing any study information (63/106; 59.3%).  Based on results by Antoniou et 
al6 we anticipated that around 25% of our participants would not access any study 
data, but the actual figure was 59.3%.  The lower than predicted parent study 
consent rate and high number of participants choosing to access no study 
information had an effect on uptake to the IIS RCT and so recruitment was slow.  By 
the end of the recruitment period only 86 participants had been randomised in the IIS 
RCT.   
 
Average recruitment to the IIS RCT for these 86 participants was 8.6 participants per 
month.  Recruitment rate of ethnic minority groups to the IIS RCT was shown to be 
much lower than for White participants; 36% (62/172) White, 23.7% (14/59) Black 
Caribbean and 13.9% (6/43) South Asian were randomised to the IIS RCT.  At the 
end of the IIS RCT planned recruitment period the parent study began to focus on 
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recruiting South Asian participants since they had recruited sufficient White 
participants.  The recruitment of South Asian participants to the IIS RCT was 2.5 
times slower than for White participants.  It was expected that continuing the IIS RCT 
once the parent study began to focus on recruiting South Asian participants would 
only recruit 3.4 participants per month.  It was estimated that the sample size would 
not be met in a timely manner if recruitment continued.  For this reason, the trial was 
stopped on 12th December 2011 at the end of the planned recruitment period.  
 
We also planned to compare the information accessed by participants using a logistic 
regression model to account for age and gender with GP practice as random effects.  
Due to the small numbers seen in each of the demographic groups, this model would 
have been overfitted194, meaning results would not be reliable.  Since this modelling 
work was not used to meet a primary aim, it did not need to be conducted to satisfy 
ICH Topic E 9 Statistical Principles for Clinical Trials Guidelines195.  Instead of this 
modelling work, exploratory subgroup analysis determined the proportion of 
participants in each demographic group that accessed each piece of information.  
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Estimate of costs 
An exploratory retrospective analysis of costs was undertaken for the Information 
Provision study as described below.   
 
Cost of invitations 
Costs for electronic and postal invitations were calculated using a combination of 
actual and estimated costs.  Stationery, printing, and phone call costs were 
accurately identified from invoices and used to calculate cost per item.  
Administrator’s time was estimated, from the time it took to do the listed jobs in the 
Information Provision study (e.g. to print letters, fill envelopes, call participants, etc).  
The cost for administrator’s time was then estimated using the middle of a band 400 
salary grade at the University of Birmingham.  For the postal invitations, the total cost 
per person was calculated by adding together the total cost for printing, stationery 
and administrator’s time.   
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The estimated cost of sending electronic invitations was calculated using both the 
cost of administrator’s time to send the invitations, and the cost of follow-up phone 
call to encourage participants to open the email.  The cost of sending the email was 
calculated by estimating the administrator’s time.  The cost to call each participant 
who answered was calculated using the cost of the estimated average duration of the 
phone call, and estimated administrator’s time to talk to participants and to call 
participants when they did not answer.  The percentage of participants who 
answered was calculated from the actual percentage that did so in the Information 
Provision study.  The cost to call each participant who did not answer was calculated 
using the estimated administrator’s time to call participants when they did not 
answer.  The percentage of participants who did not answer was calculated from the 
actual percentage that did so in the Information Provision study.  The total average 
cost per invited participant was calculated by: (Total cost to send email to each 
participant) + ([cost to call participant when they answered] x 28.5% of total 
participants) + ([cost to call participants when they did not answer] x 16.9% of total 
participants) 
 
Cost of developing the IIS 
The cost to develop the IIS needs to be considered in relation to the costs associated 
with the standard PIS.  The level two information was the REC favourably reviewed 
information and would have to be written for any research study involving humans 
anyway, so the costs in relation to this information would not increase for an IIS.  The 
additional costs in developing the content of the IIS came with writing the information 
in levels one and three. 
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If an IIS was to be developed for a future low risk interventional study it is likely that 
the first draft would be written by a member of staff appointed at band 6 (i.e. research 
associate), it would be reviewed by a more senior member of the research team 
appointed at band 7 (i.e. research fellow) and then the principal investigator would 
undertake a final review of the information.  The wages used in the cost estimate for 
the IIS were based on the average wage for the appointed band at the University of 
Birmingham.   
 
Researchers involved in development of the IIS were asked to estimate how long it 
had taken them to review documents at each stage of the development process.  The 
total cost of developing the IIS was then estimated with the calculation: ([Estimated 
total hours it took the Grade 6 staff member to develop the IIS] x [the approximate 
wage per hour for Grade 6 staff]) + ([estimated total hours it took the Grade 7 staff 
member to develop the IIS] x [the approximate wage per hour for Grade 7 staff]) + 
([estimated total hours it took the Grade 9 staff member to develop the IIS] x [the 
approximate wage per hour for Grade 9 staff]). 
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5 DEVELOPMENT OF THE INTERACTIVE INFORMATION 
SHEET (IIS) 
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5.1 CONTRIBUTORSHIP OF CHAPTER 5 
 
 
Antoniou et al6 developed an unfolding electronic PIS and used it in participants of a 
Internet questionnaire-based study, and this work formed the basis of the IIS 
intervention (Section 2.6). 
 
Whilst the design and writing of the website used to host the IIS was carried out by 
the author, all programming of the website was undertaken by Christopher Withers 
who is part of the Education Technology Team at the University of Birmingham.  
 
The information to be included in the IIS was drafted by the author of the thesis, but 
was reviewed and comments provided by Professor Heather Draper, Dr Melanie 
Calvert, Professor Sue Wilson and Professor Richard McManus. 
 
 
5.2 DESIGN AND IMPLEMENTATION 
 
Design of the IIS Website 
 
Outline 
The layout of the IIS website was consistent across each page and its basic design 
consisted of three parts:  
 
1. A header across the top of each page that provided participants with the name 
of the research study, the University logo and the parent study emblem.  This 
allowed participants to identify that they had entered the correct URL.  
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2. A menu bar down the left side of each page contained a list of the FAQ’s 
where participants were able to click to access information (Section 5.3 gives 
and explanation of how FAQ titles were chosen).  When participants clicked 
on an FAQ, the initial information relating to that FAQ appeared in the ‘content 
box’ on the right hand side of the webpage.   
3. At the bottom of this initial information was a ‘button’ they could click to access 
more information relating to that FAQ.   Participants could access information 
relating to a different FAQ by clicking the hyperlink over the FAQ in the menu 
bar.  When they did this, the information in the content box was replaced with 
information relating to the selected FAQ.   
 
When designing the website the outline (Figure 11) of each page was written first 
using the master page function in ASP.net196.  The master page function allowed the 
same page design to be applied to each webpage and provided continuity and 
reading ease.   
 
The menu bar formed a site navigation pane that provided access to all parts of the 
website containing study information.  It included links to all of the FAQ’s and 
enabled participants to click on the FAQ in which they were interested and access 
information relating to it.  Participants were able to click on as many questions, in any 
order, as many times as they required.  This allowed participants to access only the 
types of information they needed to meet their individual informational requirements.  
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Figure 11 – Outline of the IIS website 
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The website was written using a variety of computer languages197.  The layout of the 
pages used HTML (Hypertext Markup Language), the standard language for writing 
Internet pages.  The design aspects were written using CSS (Cascading Style 
Sheets), which allowed a level of design detail greater than is achievable using 
HTML alone.  Master pages cannot currently be written using HTML and CSS alone 
so this function was coded using ASP.net196 (Active Server Pages language for 
Microsoft).  Christopher Withers programmed the website and linked it to a database 
to collect study data using his preferred languages (C+ [C plus] and MySQL [My 
Structure Query Language]). 
 
Allowing the information to ‘unfold’ 
ASP.net language, specifically ‘Asp.Panel’ and ‘Asp.Button’ tags and the ‘Onclick’ 
functions198, allowed the website to be written in such a way that each page could be 
programmed to unfold.   Visual Basic (VB) programming code199 linked these 
‘buttons’ and ‘panels’ and added functionality to allow the information to unfold as 
buttons were clicked by participants. 
 
Each level of information was written in a different ‘Panel’ and ‘Panels’ of text could 
be hidden or shown depending on code linked to it.  Level one information was 
included in ‘Panel 1’, level two information in ‘Panel 2’ and level three information in 
‘Panel 3’.   
 
Under the first level of information was ‘button 1’, that, when clicked, allowed the 
level two information to be seen.  VB code added meant that when this button was 
clicked, Panel 1 (level one information) and Panel 2 (level two information) were 
visible, but Panel 3 (level three information) and Button 1 were hidden.  A new 
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Button, ‘Button 2’, also appeared at the bottom of the level two information once 
‘Button 1’ had been clicked.   
 
When button 2 was clicked, the VB code told the website that Panel 1, Panel 2 and 
Panel 3 should be visible, but Buttons 1 and 2 should be hidden (see Figures 12 and 
13 for pictorial representation of this process).   
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Figure 12 – Unfolding content of the IIS website 
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Figure 13 – Images of the unfolding content of the IIS website 
 
 
 
Level one 
 
 
 
 
 
 
 
Level two 
 
 
 
 
 
 
 
Level three 
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Hosting  
The IIS was hosted on the University of Birmingham website under the study title 
URL (http://medweb4.bham.ac.uk/bloodpressurestudy).  Participants randomised to 
receive the IIS were provided with access to the IIS part of the website and could use 
their participant ID number (provided when they were invited to participate) to log 
onto the website as frequently as they liked.   
 
How participants accessed the website 
Potential parent study participants who provided their email address when they 
returned their questionnaire were invited to take part by an email invitation.  Included 
in this email was a link to the study website where, they were told, they would find 
information that would help them to decide whether or not to take part.  If they chose 
to access parent study information online, the link took them to the login page of the 
study website where they were prompted to enter their participant ID provided on the 
email.  On successful login a webpage explained that providing information online 
was a departure from standard paper-based practice and was being evaluated as an 
alternative and novel way of providing study information to potential participants.  
Participants were given the choice of opting into or out of the IIS RCT at this point.  If 
they did not wish to participate they were automatically sent a paper PIS in the post 
and were not contacted electronically again.  If they agreed to participate in the IIS 
RCT they were directed to a webpage that asked them for their age and gender 
(used for stratification during randomisation).  Once participants clicked on the submit 
button at the bottom of this page they were randomised, automatically by the 
database connected to the website, to receive either the PDF-PIS (control arm) or 
the IIS (intervention arm).  The information provided in the PDF-PIS was identical to 
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the paper PIS already approved for the parent study and could be saved and/or 
printed.   
 
How information accessed by each participant was recorded 
Christopher Withers programmed the website to allow information about the following 
participant actions to be stored in a database: 
 
1. If they logged onto the website 
2. If they agreed to participate in the IIS RCT 
3. Age and gender 
4. The arm randomised to 
5. For those participants randomised to the IIS, the levels of information 
accessed and the time spent on each 
6. If they were interested in participating in the parent study.  Responses to the 
understanding and satisfaction questionnaire 
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5.3 DEVELOPMENT OF CONTENT 
 
How titles for the FAQ were chosen 
The parent study already had a PIS approved by the local REC (REC reference 
09/H1202/114).  The titles used in the paper PIS were also used as the titles in the 
IIS to ensure consistency between the two.  Clicking on the links over the FAQ’s 
allowed participants to choose what types of information they accessed. The FAQ 
titles used were: 
1. What is the purpose of the study? 
2. Do I have to take part? 
3. Why have I been chosen? 
4. Expenses and payments 
5. What will happen to me if I take part? 
6. What are the possible disadvantages and risks of taking part? 
7. What are the possible benefits of taking part? 
8. What if there is a problem? 
9. Will my taking part in the study be kept confidential? 
10. What will happen if I don’t want to carry on with the study? 
11. Involvements of the General Practitioner/Family doctor (GP)What will happen 
to samples I give? 
12. Will any genetic tests be done? 
13. What will happen to the results of the research study? 
14. Who is organising and funding the research? 
15. Who has reviewed the study? 
16. Further information and contact details 
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Explanation of the type of information included in each level 
The information in the IIS was split into three levels: level one contained less detailed 
information than in the parent study PIS (minimal information), level two contained an 
exact copy of the information in the parent study PIS (standard information) and level 
three contained more detailed information than the parent study PIS (extended 
information) (Figure 13).  The objective was to determine if potential participants 
chose to access less detail, the same detail, or more detail about the study than was 
provided in the standard PIS.   
 
Level one contained a short, easily digestible piece of study information.  For 
example, if a participant clicked on the FAQ “Will my taking part in this study be kept 
confidential?”’, they would simply have received information that stated “Yes, your 
taking part in this study will be kept confidential”.  
 
Level two provided the same information as the paper PIS. 
 
Those who wanted more information were invited to click a second button at the 
bottom of this level two information to access more detailed information (level three).  
This third level of information was the most detailed available on the IIS website, 
although it sometimes contained hyperlinks directing participants to external 
information sources, for example, to websites that explained terms used in the 
explanation, or linked to scientific papers evidencing information provided.  All 
external links opened in a new window so participants could easily navigate back to 
the study website. 
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How content was decided  
 
Parent study PIS  
The information in the paper PIS was split into two parts as suggested in NRES 
guidance22 - part one gave basic information, and part two provided further 
information.  All of the information in the parent study paper PIS was included in the 
IIS, generally in level two.  Exceptions occurred when information topics were 
included in both parts of the paper PIS.  An example of this is the FAQ ‘What if there 
is a problem?’  Part one stated: 
 
“Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed.  The detailed 
information on this is given in Part 2.” 
 
 Part two then stated: 
 
“If you have a concern about any aspect of this study, you should ask to 
speak to the researchers who will do their best to answer your questions:  
Dr Richard McManus (T: 0800 234 6 432). If you remain unhappy and 
wish to complain formally, you can do this by contacting Ms Sarah 
Bathers, Primary Care Clinical Trials Unit Manager, Primary Care Clinical 
Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT (T: 
0121 414 3323).  
 
In the event that something does go wrong and you are harmed during the 
research and this is due to someone‘s negligence then you may have 
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grounds for a legal action for compensation against The University of 
Birmingham but you may have to pay your legal costs.” 
 
Information on the same FAQ was sometimes included in both parts of the PIS.  In 
these cases, part 1 information from the parent PIS was included in level two of the 
IIS and part 2 information from the parent PIS was included in level three of the IIS.    
 
Interviews with parent study pilot participants and research nurses to inform the IIS 
The parent study conducted some pilot work on phase II of their study that involved 
seven participants, each of whom made three appointments with the research nurse.  
After appointment two, all seven participants were asked if they would be willing to 
take part in a short interview about their experiences of the consent process to help 
inform the design of the IIS RCT.  Three participants agreed to be interviewed.  All 
were provided with written information about the pilot work to describe what would be 
required of them (Appendix 9.6). 
 
This pilot interview study did not require NHS permission because it was pilot work 
intended to inform the design of the main Information Provision study (which would 
be reviewed by NRES). This small IIS design pilot study did require further University 
review and was given favourable opinion prior to commencing (reference number 
RG_10-119).   
 
Interviews were conducted with three parent study participants. A research nurse 
who was not involved in the parent study but had extensive experience in blood 
pressure monitoring research also agreed to be interviewed.  Interviews lasted 
around 40 minutes each, during which participants were asked questions about each 
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section of the parent study PIS.  Participants were asked to indicate which part of the 
information provided they thought was the most important to know.  The data 
collected were used to inform what information would be included in level one of the 
IIS (Table 10). 
 
Interviewees were also asked to describe what further information they would like to 
have for each FAQ in the PIS.  For the most part, participants were unable to provide 
an answer to this question and simply stated that the information provided was 
already comprehensive.   
 
Level three information was based on the information that participants from 
interviews wanted to know or thought that others might want to know (Table 11).   
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Table 10 - The minimal information participants thought should be included in a PIS 
Question Pt1 Pt2 Pt3 Nurse 1 
What is the 
purpose of the 
Study 
None ……. I think the measurement 
at home which gives you, 
probably gives you a more 
accurate reading, er as long as 
you do it 
Right, but what interested me 
was the fact that erm you get 
differences with home 
measurements than when you 
come to the doctors  
None 
Why Have I been 
chosen? 
None None None None 
Do I have to take 
part? 
We’ll  ask for permission to look 
at your records.   
None I would think perhaps to 
someone, some people, they 
may not be too willing to give 
permission for you to delve into 
their medical records 
None 
What will happen 
to me if I take part? 
Er, you’ll be involved in it for 8 
days, erm, and in that time you’ll 
be asked to have a 24 hour 
monitor, and, er to take your own 
blood pressure for a week 
I wouldn’t want to see it 
reduced I don’t think 
None I think probably, the less 
that’s inclusive the better, 
because the more information 
you give sometimes the less 
it’s too overpowering isn’t it? 
Expenses and 
payments 
None None None None 
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What are the 
possible benefits 
of taking part? 
I suppose that they’re going to 
pass it onto your GP would, 
perhaps impress you 
I just think the results basically 
are the most important 
None None 
What are the risks 
of taking part? 
None None None None 
What if there is a 
problem? 
None That you’ve got a telephone 
contact number if you’ve got a 
problem 
None None 
Will my taking part 
in the study be 
kept confidential? 
Just the fact thatit’s being kept 
er ......... private really 
I think the, the probably the 
telephone number and contact 
is, is probably the probably the 
most important 
None None 
Involvement of 
your General 
Practitioner/Family 
doctor (GP) 
We will ask your permission to 
inform to your GP regarding the 
results of this study? 
None None None 
Who is organising 
and funding the 
research? 
None No I, I would, the research is 
all gonna happen at 
Birmingham...... [pause]  .... I 
don’t know on this one.  I really 
I think you only need to put the 
National Institute of Health 
Research or just the 
department, is funded by the 
Department of Health 
None None 
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What will happen 
to the results of 
the study? 
None Just the fact that you, you’re 
going to publish the results of 
the study in medical journals 
None None 
Who has reviewed 
the study? 
I suppose the last sentence, ‘this 
studies been reviewed and given 
favourable opinion by the 
research ethics committee’ 
I think that all research in the 
NHS is looked at by an 
independent group 
None None 
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Table 11 - Extended information participants thought should be included in the PIS 
Question Participant 1 Participant 2 Participant 3 Nurse 
What is the 
purpose of the 
Study 
None None Why the measurement at home 
is lower?I’m not really into why 
you’re studying British, Asian, 
White, Irish.  The sort of 
technical details of how it [blood 
pressure] works 
The most common method is to have 
your blood pressure measured at the 
GP practice by a doctor or nurse, but 
that you can also have it measured at a 
pharmacy.  Substantiate why you’re 
looking at the differences between 
ethnic minority groups 
Why Have I 
been chosen? 
I think if it came out 
the blue, and I, I’d 
think well who’s giving 
out my information? 
I did want to know why 
I’d been chosen but I 
took it that erm I’d been 
chosen because I’d had 
problems before 
None None 
Do I have to 
take part? 
None None None This will not affect the care that you 
receive from your GP.  I’m just 
wondering if you need to say where 
they will sign that consent form 
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What will 
happen to me if 
I take part? 
you see they said if 
you shower or 
anything erm, you 
could unplug it, but 
they didn’t mention 
going to the toilet or 
anything like that 
There’s a phone number 
for queries, it might be 
worth putting erm the 
times that that phone I 
think they need to know 
why their blood pressure 
is unstable 
None To say where you write them down, are 
you going to give them a book, or write 
them down, are you going to provide 
that?Details of what the, the kinds of 
things that the questionnaire will be 
asking themHow much teaching they 
will have about how to take their own 
blood pressure because it may seem 
like a big thing to some people to take 
their own blood pressure.  Say why it’s 
good to have an acceptable blood 
pressure reading in terms of prevention, 
of the illness, yeah, and preventing 
problems in the long term.   I think it’s 
important to mention actually that if your 
bp is over the NICE guielines or the 
accepted limits, you feel probably very 
well.  Right, so you might need to 
elaborate on that, will they be able to 
shower, will they be able to sleep? I 
think you will need to give a bit more 
information on that 
Expenses and 
payments 
None None None You might want to ask if they’ll bring a 
receipt if they use a taxi 
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What are the 
possible 
benefits of 
taking part? 
None None Information about what high 
blood pressure does and what it 
can lead to and all that 
None 
What are the 
risk of taking 
part? 
None None None So it might be useful to just say, what 
uncomfortable is 
What if there is 
a problem? 
None None None  
Will my taking 
part in the 
study be kept 
confidential? 
What’s R&D audit? None None Well I think it’s worthmentioning that, 
that they will be assigned an ID 
numberStored securely, yes you 
could elaborate on stored securely, 
either in locked cabinets or a password 
protected database, something like that 
Involvement of 
your General 
Practitioner/Fa
mily doctor (GP) 
None None None None 
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Who is 
organizing and 
funding your 
research? 
None None None None 
What will 
happen to the 
results of the 
study? 
Yeah, in a sort of 
simplified form, I 
mean I don’t want to 
know all the official 
stuff would yaI 
think you’ll have 
probably people who 
are really interested or 
people who want to 
know all the details 
None None Some might want to know what the 
function of a research ethics committee 
is 
Who has 
reviewed the 
study? 
None None None None 
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Results from systematic review 
It was expected that the systematic review (Chapter 3) of existing literature 
would inform the development of the IIS.  The review, however, identified no 
studies that looked in detail at what participants wanted to know, so could not 
be used to determine what further information to include in level three of the IIS. 
 
Expanding on the information in the paper PIS 
The pilot interviews and the systematic review did not provide sufficiently 
detailed information about areas that could be usefully expanded, so each 
sentence of level two information under each FAQ was read to identify places 
where further information could be included.  Detailed information was collected 
from scientific papers, credible websites and lay publications/leaflets for this 
level.   
 
The level three information was then re-searched to identify key words that 
could be used to link to external sources for further explanation.  An example of 
this was the key word ‘blood pressure’ that was externally linked to the British 
Heart Foundation website where participants could find an explanation of what 
blood pressure is.  This was done for as many key words as possible and only 
websites published by expert groups such as NHS Direct, scientific papers 
where appropriate and electronic lay information leaflets produced by credible 
sources were used as hyperlinks. 
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The readability of the first draft of level three information was assessed using 
the Flesch Reading Ease and the Flesch-Kincaid Grade Level200-202.  The 
wording of the information was adjusted until it was below Grade 8 level (i.e. 
comprehensible by the average 13 year old) and had a reading ease greater 
than 60%. 
 
Review and comments from supervisors 
The first draft of the IIS was assessed and discussed by all three academic 
supervisors - Professor Heather Draper, Professor Sue Wilson and Dr. Melanie 
Calvert - and the PI of the parent study (Professor Richard McManus), all of 
whom are senior academics at the University of Birmingham and experienced in 
the design of PIS.  They ensured the information was scientifically and ethically 
sound and easy to understand and suggested appropriate places to add further 
information.  The draft was updated to take into account their feedback and then 
included in website coding to allow it to be uploaded to the server and made 
available online.   
 
The full information from the IIS is included as Appendix 9.2. 
 
Testing of the content 
Once the content of the IIS had been developed it was loaded onto the website 
and made live, which allowed the website to be de-bugged and user tested. 
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De-bugging and content testing with competent computer users 
The website was first checked for errors by competent Internet users.  Five 
volunteers were asked to log on to the website, navigate around it and report 
any problems they found and attempt to ‘break’ the website using methods such 
as pressing the back button on the Internet browser.  Errors reported included 
CSS coding not working on some pages (meaning the page did not display 
properly), broken external website links, links to some external websites not 
being brought up in a parent window and the ability to ‘trick’ the website into 
allowing a user to be randomised twice.  All errors were fixed and the same five 
volunteers re-reviewed the website and identified no further problems.  
 
User testing with low computer users 
Once the de-bugging of the website had been completed, it was then tested 
with low computer users (defined as using the Internet less than twice a week).  
It was expected that if potential participants provided an email address they 
would have at least some computer literacy.  Three users (one male, aged 68; 
one female aged 45; and one female aged 54) were asked to log onto the 
website and follow the online instructions.  All were able to follow the 
instructions correctly and successfully navigate the website.  When asked how 
the website could be improved they suggested making text larger and darker.  
They also suggested that a link to the ‘how to use this website’ page should be 
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included at the bottom of each page.  All three suggestions were incorporated 
into the website and the updated version was uploaded to the server.  
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6 RESULTS 
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This chapter provides detailed results of the Information Provision study.  It begins by 
providing recruitment numbers for both the parent study and Information Provision 
study, and key results from the study.  It then presents demographic data for 
participants, information accessed by participants and the time spent reading it, the 
effect of the IIS on consent rates, the level of participant understanding and 
satisfaction with the way information was provided, and finally, an estimation of costs.  
A streamlined PIS for the parent study is then presented, which was developed using 
the information accessed by participants in the Information Provision study and the 
information that guidelines states participants ought to know.  The results of the 
Information Provision study and streamlined PIS were presented to the NRES expert 
panel, and so the chapter concludes with their feedback of this work. 
  
169 
 
6.1 PARTICIPANT RECRUITMENT 
 
Data were collected for the Information Provision study between 5th February and 
12th December 2011.  Table 12 gives the number of participants included at each 
stage. 
 
1160 participants returning the parent study questionnaire (phase I) were happy to be 
contacted about taking part in phase II of the parent study (63% response rate) 
(Figure 14).  Of these, only 290/1160 (25%) provided an email address.  All 290 
participants were sent electronic invitations to participate in the parent study.  Of 
these, 14/290 (4.8%) provided an incorrect email address and could not be contacted 
by telephone for the correct information (7 did not provide a valid telephone number 
and 7 did not answer the telephone after ten attempts).  These 14 participants were 
sent a standard postal invitation letter and paper PIS to the parent study but 
remained in the electronic information arm for Intention To Treat (ITT) analysis.    In 
total, 276/290 (95.1%) emails were assumed to have been delivered to the correct 
participants. 
 
Of the 146/290 (50.3%) participants who were assumed not to have opened the 
email within 3 days, 83/146 (56.8%) were successfully contacted by telephone and 
resent the electronic invitation (Figure 15).  Of the 83 participants successfully 
contacted by telephone, 61/83 (73.5%) responded to the email that was resent 
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following the telephone conversation, so a total of 191/290 (65.7%) of participants 
were known to have opened the email invitation to participate in the parent study. 
 
A total of 85/290 (29.3%) participants were assumed not to have opened the email 
(although they may also have opened, read and deleted the email and so not 
responded).  22 of these (25.9%) were contacted by telephone, 13 (15.3%) had no 
valid telephone number and 50 (58.8%) did not answer the telephone.   
 
Of the 290 IIS study participants, 101/290 (34.8%) accessed the website and 86/290 
(29.7%) entered their age and gender into the website and were randomised to IIS or 
PDF-PIS (Figure 16).  86 participants were randomised and included in the Intention 
To Treat analysis for calculations of consent rate to trial arms IIS and PDF-PIS 
information.    
 
99/290 (34.1%) Information Provision study participants booked a parent study 
appointment.  A contact number to book a consent appointment for the parent study 
was provided in the invitation email and 63/106 (59.4%) participants booked a parent 
study appointment without first accessing any study information.  Of those 
randomised in the IIS RCT (and, therefore, receiving study information), 36/86 
(41.9%) participants booked a consent appointment.   
 
  
171 
 
Participants were divided into five study groups for analysis purposes; ‘IIS’ includes 
those randomised to IIS and ‘PDF-PIS’ includes those randomised to the PDF PIS; 
‘No PIS’ is where participants opened the invitation email but did not access the 
study website and, therefore, received no PIS.  The ‘email address’ group are those 
that provided an email address on the parent study phase I questionnaire and, 
therefore, were eligible for electronic communication, and the ‘No email address’ 
group were those that did not provide an email address and were sent a standard 
postal invitation and paper PIS.   
 
Table 12 – Participants included at each stage of recruitment 
 
 
N % 
Eligible from parent study 
 
1160  
Provided an email address 
 
290/1160  25% 
Opened invitation email 
 
191/290 65.7% 
Booked parent study appointment 
 
99/290 34.1% 
 
Participants in each analysis group 
 
Randomised to IIS 
 
44  
Randomised to PDF 
 
42  
No PIS 
 
106  
Paper PIS 
 
870  
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 Figure 14 - Distribution of participants through the Information Provision study 
Total number phase I (questionnaire) parent study participants willing to take part in 
Phase II of the parent study 
n=1160 
Provided an email 
address  
n=290/1160 (25.0%) 
Did not provide an email address 
n= 870/1160 (75.0%) 
 
Invitation letter sent via 
email  
n=290/290 (100%) 
Booked parent study 
appointment  
n= 271/870 (31.1%) 
Incorrect email address 
n=37/290 (12.8%) 
Correct email address 
n= 253/290 (87.2%) 
Email address updated after 
phone call 
n=23/290 (7.9%) 
Could not be contacted by telephone  
n=14/290 (4.8%) 
_____________________________ 
 
No valid telephone number  
n=7/14 (50%) 
 
Did not answer  
n=7/14 (50%) 
Total number of emails delivered 
n= 276/290 (95.1%) 
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Figure 15 – Proportion of participants that opened the email. 
 
Total number of emails delivered 
n= 276/290 (95.1%) 
Opened email without 
telephone call prompt 
n=130/290 (44.8%) 
Did not open email 
within 3 days 
n=146/290 (50.3%) 
Contacted by 
telephone 
n=83/146 (56.8%) 
Unable to contact by 
telephone  
N=63/146 (43.2%) 
_____________ 
 
No valid telephone 
number N=13/63 
(20.6%) 
 
Did not answer 
N=50/63 (70.4%) 
 
Opened 
email 
n=61/146 
(41.8%) 
Total that did not open email 
n=85/290 (29.3%) 
Did not open 
email 
n=22/146 
(15.1%) 
Total that opened email 
n=191/290 (65.7%) 
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  Figure 16 – Number of participants that took part in the IIS RCT 
Total that opened email 
n=191/290 (65.7%) 
Randomised 
n=86/290 
(29.7%) 
Randomised to 
PDF 
n=42/290 (14.5%) 
Did not book 
parent study 
appointment 
n=22/42 
(52.4%) 
Booked parent 
study 
appointment 
n=20/42 
(47.6%) 
Randomised to IIS  
n=44/290 (15.2%) 
Did not book 
parent study 
appointment 
n=28/44 
(63.6%) 
Booked parent 
study  
appointment 
n=16/44 
(36.4%) 
Accessed 
website 
n=101/290 
(34.8%) 
Opened email but did not 
access website 
n=90/290 (31.0%) 
Did not book parent 
study appointment 
n=33/90 (33.7%) 
Booked parent 
appointment 
n=57/90 (63.3%) 
 
Accessed website but 
were not randomised 
n=15/290 (5.2%) 
Booked parent 
study 
appointment 
n=6/15 (40.0%) 
Did not book parent 
study appointment 
n=9/15 (60.0%) 
  
175 
 
6.2 KEY RESULTS 
 
An executive summary of findings is provided here and the following sections will 
provide detailed results of the Information Provision study. 
 
The consent rate to the parent study was similar for all participants, whether they 
received information electronically or through the post.  For parent study participants 
who did not provide an email address (and received information through the post) 
271/870 (31.1%) booked a consent appointment.  Of those that did provide an email 
address and so took part in the Information Provision study, 99/290 (34.1%) booked 
a consent appointment.  A large proportion of participants consented to the parent 
study without accessing any study information (59.3% [63/106]).   
 
11.4% of study participants randomised to IIS accessed the level of detail of 
information provided in the paper PIS for the parent study.  9.1% read more 
information than the paper PIS provided and 79.5% of participants read less than 
was provided in the paper PIS.  Participants mostly accessed information about the 
practical aspects of taking part in the study, such as what they would have to do if 
they took part.  Despite a high proportion of participants accessing no study 
information, the level of understanding was common across all study arms.  
Participants across all study groups were generally satisfied with the level of 
information they received, regardless of how much they chose to access. Those who 
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received information electronically were, however, less likely to want more 
information about the parent study.  
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6.3 DEMOGRAPHICS  
 
Demographic data were collected for the study population and split by study groups 
(Table 13).  Compared to those who did not provide an email address, those that did 
provide an email address were younger (email address=51 years and no email 
address=59 years), more commonly White (email address=172/290 [59%] and no 
email address=470/870 [54%]) and less deprived (email address=IMD 35.4 and no 
email address=IMD 38.6, where a higher IMD score indicates a higher level of 
deprivation).  The three Information Provision study sub-groups (IIS, PDF-PIS and No 
PIS) were a similar age (median age 54.0, 53.5 and 50.5 respectively), but there 
were more males in the PDF-PIS group (24/44 [54.6%], 25/42 59.5%] and 52/106 
[49.1%] respectively).  Of those with an email address, a higher proportion of Asian 
and Black participants chose not to access the study information (no PIS group) 
(White 57/172 [33.1%]; Asian 19/43 [44.2%]; Black 25/59 [42.4%]) and those in the 
‘no PIS’ group were more deprived (IMD 34.6, 34.3 and 38.2 respectively).   
 
Participants who consented to the parent study were more deprived (IMD 39.2 and 
33.3 respectively) and more commonly Black (Black 33/256 [12.9%]; Asian 14/218 
[6.4%]; White 54/642 [8.4%]) than those who did not participate in the parent study.   
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Table 13 – Baseline data for study population   
 Information provision study groups Electronic or paper 
Consent status to parent 
study (those with an 
email address)  
 IIS* PDF-PIS* No PIS 
Email 
address 
No email 
address 
(Paper PIS) 
Consent  
Did not 
consent 
Age 
Mean age 
(SD) 
54.5 (9.3) 53.9 (9.8) 54.3 (9.7) 53.4 (9.28) 58.5 (9.5) 54.26 52.91 
Median 
age (IQR) 
54.0 (14) 53.5 (15) 50.5 (17.0) 51.0 (16) 59.0 (16) 52.5 51.0 
Gender 
Male 
24/44  
54.6% 
25/42  
59.5% 
52/106  
49.1% 
157/290  
54.1% 
430/870 
49.4% 
53/102  
52.0% 
104/188 
55.3% 
Female 
20/44  
45.5% 
17/42  
40.5% 
54/106  
50.9% 
133/290  
45.9% 
440/870 
50.6% 
49/102 
48.0% 
84/188 
44.7% 
 
* denotes a randomised group in the IIS RCT 
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 IIS PDF-PIS No PIS 
Email 
address 
No email 
address 
(Paper PIS) 
Consent 
Did not 
consent 
Ethnicity 
White 
31/44 
70.5% 
31/42 
73.8% 
57/106 
53.8% 
172/290 
59.3% 
470/870 
54.0% 
54/102 
52.9% 
118/188 
62.8% 
Asian 
2/44  
4.5% 
4/42 
9.5% 
19/106 
17.9% 
43/290 
14.8% 
175/870 
20.1% 
14/102 
13.7% 
29/188 
15.4% 
Black 
5/44  
11.4% 
5/42  
11.9% 
25/106  
23.6% 
59/290  
20.3% 
197/870 
22.6% 
33/102 
32.4% 
26/188 
13.8% 
Deprivation 
Mean IMD 
Score 
(SD) 
 
34.6 (17.8) 34.3 (17.8) 38.2 (16.6) 35.4 (16.9) 38.6 (17.2) 39.2 (18.3) 33.3 (15.8) 
Median 
IMD Score 
(IQR) 
32.0 (29.5) 30.1 (35.5) 36.0 (30.5) 32.1 (27.5) 37.2 (31.8) 36.7 (35.1) 31.2 (25.4) 
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Table 14 shows the proportion of the participants in phase II of the parent study that 
provided an email address, broken down into the demographic groups of age, gender 
and ethnicity.  Younger, White participants were the most likely to provide an email 
address.  As age increased, the proportion of participants with an email address 
decreased.  South Asian participants were the least likely to provide an email 
address. 
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Table 14 – Proportion with an email address broken down into demographic 
groups (age, gender, ethnicity) 
 
  Parent study 
participants that 
provided an email 
address  
General population 
that use the Internet 
Age 45-55 174/508  34.3% 89.5% 
 
55-65 69/303  22.8% 78.8% 
 
65+ 47/350  13.4% 57.0% 
 
 
Gender Male 157/571  27.5% 84.6% 
 
Female 133/588  22.6% 79.8% 
 
 
Ethnicity White 172/639  27.0% Unavailable 
 
Asian 43/218  19.7% Unavailable 
 
Black 59/256  23% Unavailable 
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6.4  INFORMATION ACCESSED BY PARTICIPANTS 
 
One aim of this thesis was to determine what types and the level of detail of 
information potential study participants used to make a decision regarding 
participation in research.  Only data from participants who were randomised to 
receive the IIS (n=44) in the IIS RCT contributed to this aim.  This section describes 
what information participants accessed from the IIS.   
 
The information in the IIS was available in an unfolding manner, meaning that 
participants could only access a higher level of information once they had accessed 
the previous level of information.  Each time a participant clicked to access a piece of 
information; it was recorded in a database along with the amount of time they spent 
accessing it.  
 
Table 15 shows the proportion of participants accessing (and not accessing) each 
piece of information. Where a higher level of information was not available, this is 
indicated by ‘n/a’.     
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Table 15 – Proportion of participants accessing each level of information for each FAQ 
 Level one Level two Level three External information  
Purpose of the study 
 
18/44  40.9% 4/44 9.1% 2/44 4.6% 2/44 4.6% 
Have to take part 
 
8/44  18.2% 0/44 0% 0/44 0% 0/44 0% 
Why been chosen 18/44  40.9% 4/44  
9.1% 
 
1/44 2.3% n/a* 
Expenses 22/44  50% 5/44 11.4% 2/44 4.6% n/a* 
What will happen 22/44 50% 4/44 9.1% 2/44 4.6% 2/44 4.6% 
Risks 22/44 50% 7/44 15.9% 2/44 4.6% 0/44 0% 
Benefits 21/44 47.7% 5/44 11.4% 1/44 2.3% 0/44 0% 
Problems 16/44 36.4% 1/44 2.3% 0/44 0% n/a* 
Confidentiality 10/44 22.7% 1/44 2.3% 0/44 0% 0/44 0% 
Don’t want to carry on 7/44 15.9% 0/44 0% 0/44 0% n/a* 
GP 14/44 31.8% 3/44 6.8% 1/44 2.3% 0/44 0% 
Samples 15/44 34.1% n/a* n/a* n/a* 
Genetic tests 10/44 22.7% n/a* n/a* n/a* 
  
184 
 
Results 11/44 25% 3/44 6.8% 2/44 4.6% 0/44 0% 
Organising and funding 11/44 25% 4/44 9.1% 2/44 4.6% 0/44 0% 
Reviewed study 11/44 25% 4/44 9.1% 2/44 4.6% 0/44 0% 
Further info/contact 9/44 20.5% n/a* n/a* n/a* 
 
Participants not 
accessing any 
information  
18/44  40.9% 35/44 79.5% 40/44 90.1% 40/44 90.1% 
 
* There was no information available for the FAQ under that level 
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Of those randomised to the IIS, 18 (n=44; 40.9%) participants did not read any study 
information.  Seventeen participants (n=44; 38.6%) only accessed the minimal 
information provided in level one and 5 participants (n=44; 11.4%) only the 
information the REC favourably reviewed information (level two). Four participants 
(n=44; 9.9%) accessed more detailed information than provided in the paper PIS.   
 
Twenty-six participants (n=44; 59.1%) accessed any one or more piece(s) of level 
one information.  The most accessed pieces of information were about expenses 
(22/44; 50%), what would happen if one took part (22/44; 50%) and the risks of 
taking part (22/44; 50%).  Slightly fewer accessed information about the benefits of 
taking part (21/44; 47.7%) and the purpose of the study (18/44; 40.9%).  Fewer than 
a quarter of participants looked at any information concerning confidentiality (10/44; 
22.7%), what would happen if they did not want to carry on with the study (14/44; 
31.8%), genetic testing (10/44; 22.7%) and further information/contact details (9/44; 
20.5%).  The least accessed area of information related to what would happen if one 
did not want to carry on with the study (7/44; 15.9%).  The remaining eight categories 
had access rates of between 25% (11/44) and 34% (15/44).  
 
Only nine participants accessed any one or more piece(s) of level two information.  
The most viewed FAQ (risks of taking part) was accessed by only 7 (n=44; 15.9%) 
participants at this level.  This reduced to 5 (n=44; 11.4%) for the expenses and 
benefits categories and to 4 (n=44; 9.1%) for the remaining FAQ’s.  No participants 
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accessed level two information about whether they had to take part or what would 
happen if they did not want to carry on with the study. 
 
Only 4 participants (n=44; 9.1%) accessed any one or more piece(s) of level three 
information, and the most accessed pieces of information were accessed by only 2 
participants.  No participants accessed level three information on whether they had to 
take part, what would happen if there were any problems, confidentiality or what 
would happen if they did not want to carry on with the study.  Only 1 participant 
(n=44; 2.3%) accessed level three information about why they had been chosen, 
what would happen during the study, the benefits of taking part and what their GP 
would be told about their participation.  Only 2 participants (n=44; 4.6%) accessed 
level three information for the purpose of the study, expenses, risks of taking part, 
results of the study, who organised and funded the study and who had reviewed the 
study.    
 
Only 4 participants (n=44; 9.1%) accessed any external information. Two 
participant’s accessed external information for the purpose of the study (2/44; 4.6%) 
and what would happen if one took part (2/44; 4.6%). 
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6.5 TIME SPENT READING INFORMATION 
 
A secondary aim of the Information Provision study was to determine how much time 
participants spent viewing each piece of information, with a view to determining if 
they had spent long enough on each piece to have read it.  
  
 The average time a participant spent viewing each piece of information was 
compared to the expected time it would take an average adult to read that piece of 
information, based on an average adult reading 200 words per minute191 (Table 16).  
No average viewing time could be recorded for the external information as it was 
accessed via an external link on the website.  
 
For all level one FAQ’s the average time participants spent viewing information was 
longer than the expected reading time so it is likely that where participants accessed 
this information they did read it.   
 
For level two FAQ’s the average time participants spent viewing information was 
usually much shorter than the expected reading time.  The only category where the 
average and expected times were equal was the purpose of the study category (38s 
and 38.4s respectively).  For all other categories it is likely that participants either 
skimmed through the information or clicked on the link just to see what was there.  
The increased reading time seen for the ‘Purpose of the study’ FAQ could have been 
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an artefact of it being the first FAQ offered by the IIS.  Participants may have read 
through all of the information for this first FAQ in order to decide whether they were 
interested in the types of information included in levels two and three. 
 
For level three FAQ information the average time participants spent viewing 
information exceeded the expected stay time in four categories (Why one had been 
chosen, expenses, risks, organising and funding) and took 75% of the expected time 
in five categories (purpose of the study, benefits, what their GP would be told, 
results, and who had reviewed the study).  There was only one category where the 
average time spent viewing the information was not within 25% of the expected time 
(what will happen if one takes part).  It is likely that although only small number of 
participants accessed level three information, those who did access it read it fully. 
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Table 16 – Average stay time measured in seconds for each level and expected time (in seconds) it would take the 
average adult to read each level of each question (based on average adult reading 200 words per minute) 
 Level one Level two level three Total time spent 
(seconds) 
Mean (95% CI); 
median   (IQR) 
Time spent 
(seconds) 
Mean  (95% 
CI);  
Median (IQR) 
Expected 
time 
(seconds) 
Time spent 
(seconds) 
Mean (95% 
CI);  
Median 
(IQR) 
Expected 
time 
(seconds) 
Time spent 
(seconds) 
Mean (95% CI); 
Median    (IQR) 
Expected 
time 
(seconds)  
 
Purpose of 
study 
24  
14  
(13; 35) 
(9; 34) 
8  38 
31 
(-4; 81) 
(21; 
56) 
38 116 
116 
(-1136; 1367)  
(17; 214) 
137 45 
28 
(17; 73)  
(13; 49) 
Have to take 
part 
13  
6  
(-6; 32)  
(4; 7) 
6 No 
responses 
27 No responses 156 13 
6 
(-6; 32)  
(4; 7) 
Why chosen 22 
17 
(15; 30)  
(14; 22) 
4 5 
n/a 
(0; 11) 12 147  
147 
(n/a) 
(n/a) 
73 43 
22 
(18; 69)  
(14; 68) 
Expenses 
 
21 
9 
(7; 36) 
(5; 19) 
2 <1 
0 
(0; 1) 
(n/a) 
3 73 
73 
(-379; 524)  
(37; 108) 
58 29 
10 
(4; 54)  
(5; 25) 
What will 
happen 
12  
12 
(8; 16) 
(6; 14) 
11 2  
0 
(0; 3)  
(n/a) 
59 99 
99 
(n/a)  
(n/a) 
228 20 
13 
(9; 31)  
(7; 23) 
Risks 13  
12 
(10; 17) 
(6; 19) 
3 2 
0 
(0 5; 4) 
(n/a) 
6 106 
106 
(99; 112)  
(105; 106) 
61 122 
122 
(39; 204)  
(115; 128) 
Benefits 
 
17  
14 
(11; 23) 
(7; 23) 
5 3 
0 
(0; 5)  
(n/a) 
23 46 
46 
(n/a)  
(n/a) 
62 99 
99 
(n/a)  
(n/a) 
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Problems 
 
15 
14  
(10; 21) 
(6; 24) 
2 <1 
0 
(0; 1) 
(n/a) 
6 n/a 
n/a 
51 16 
15 
(11; 22)  
(7; 24) 
Confidentiality 11 
7 
(5; 18) 
(6; 9) 
<1 1  
0 
(-1; 4) 
(n/a) 
59 No responses 
 
171 (570) 17 
8 
(3; 31)  
(7; 25) 
Don’t want to 
carry on  
9 
10 
(5; 14) 
(5; 13) 
4 No 
responses 
11 No responses 55 9 
10 
(5; 14)  
(5;13) 
GP 
 
15  
13 
(9; 20) 
(9; 17) 
4 <1 
0 
(0; 1)  
(n/a) 
5 29 
29 
(n/a)  
(n/a) 
38 19 
13 
(11; 26)  
(10; 24) 
Samples 
 
17  
10 
(9; 25) 
(7; 28) 
4 n/a n/a n/a n/a 17 
10 
(9; 25)  
(7; 28) 
Genetic tests 
 
3 
0 
(1; 5) 
(n/a) 
<1 n/a n/a n/a n/a 3 
0 
(1; 5)  
(n/a) 
Results 
 
11 
10 
(7; 15) 
(5; 15) 
4 1 
0 
(0; 2)  
(n/a) 
20 69 
59 
(-217; 354)  
(46; 91) 
72 27 
14 
(4; 51)  
(10; 22) 
Organising and 
funding 
7 
6 
(4; 10) 
(4; 13) 
5 1 
0 
(0; 1)  
(n/a) 
11 80 
80 
(-206; 365)  
(57; 102) 
60 24 
13 
(1; 48)  
(4; 16) 
Reviewed 
study 
8 
6 
(5; 11) 
(4; 10) 
3 9 
8 
(1; 17)  
(4; 13) 
11 22 
22 
(9; 35)  
(21; 23) 
26 42 
42 
(167; 67)  
(40; 44) 
Further info 
and contact 
28  
22 
(11; 45) 
(11; 41) 
31 n/a 
n/a 
n/a n/a 
n/a 
n/a 28 
22 
(11; 45)  
(11; 41) 
All FAQ 
 
137 
57 
(76; 200)  
(0; 195) 
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6.6 ADJUSTED ANALYSIS FOR INFORMATION ACCESSED 
 
Participants spent a total median of 57 seconds (IQR 0-195 seconds) accessing 
information in the IIS (mean 137 [CI 76 to 200] seconds).  Given this, it was 
hypothesised that participants may have sometimes clicked on information to see 
what was there without reading the information provided.  For this reason, 
proportions of participants accessing each level of information were recalculated, 
including only those participants who spent long enough on the piece of information 
to have read it according to average reading times.  To take into account variability in 
reading speed it was assumed that a participant had not read the information if they 
had the information open for less than 25% of the average reading time.  Table 17 
shows the proportion of participants who seemed to have spent long enough on each 
piece of information to have read it.  The proportion of participants that accessed any 
information type for each level remained the same for unadjusted and adjusted 
results.  Adjusted results were used as the principal analysis for the discussion 
chapter of this thesis, since they are more likely to accurately represent whether the 
information was read by potential participants. 
 
The information provided to participants can be broken down into four types of 
information – information about practical aspects of the study, that participating was 
voluntary, scientific aspects/design of the study, legal aspects of the study.  Based on 
the adjusted analysis, participants most often access information relating to study 
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aspects that could affect participants practically, including the risks and benefits of 
taking part, what would happen if they took part, what would happen if they had a 
problem whilst taking part, and any expenses they would received by participating.  
There were two types of information that very few participants were interested in 
knowing; that relating to the legal aspects of the study and that about the voluntary 
nature of participation.  Participants accessed specific sub-categories of information 
relating to scientific aspects/design in varying proportions. 
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Table 17 - Adjusted proportion of participants accessing and time spent on 
each level of information (with all those who accessed no information taken 
out) 
 
 Level one 
 
Level two Level three 
Accessed Did not 
access 
Accessed Did not 
access 
Accessed Not 
accessed 
Purpose of the study 17/44 
38.6% 
27/44 
61.4% 
3/44 
6.8% 
41/44 
93.2% 
1/44 
2.3% 
43/44 
97.7% 
Have to take part 
 
6/44 
13.6% 
38/44 
86.4% 
0/44 
0% 
44/44 
100% 
0/44 
0% 
44/44 
100% 
Why been chosen 18/44  
40.9% 
26/44 
59.1% 
4/44 
9.1% 
40/44 
90.9% 
1/44 
2.3% 
43/44 
97.7 
Expenses 
 
22/44 
50% 
22/44 
50% 
5/44 
11.4% 
39/44 
88.6% 
1/44 
2.3% 
43/44 
97.7% 
What will happen 13/44 
29.5% 
31/44 
70.5% 
0/44 
0% 
44/44 
100% 
0/44 
0% 
44/44 
100% 
Risks 
 
22/44  
50% 
22/44 
50% 
7/44 
15.9% 
37/44 
84.1% 
2/44 
4.6% 
42/44 
95.5% 
Benefits 
 
20/44 
45.5% 
24/44 
54.5% 
3/44 
6.8% 
41/44 
93.2% 
0/44 
0% 
44/44 
100% 
Problems 
 
16/44 
36.4% 
28/44 
63.6% 
1/44 
2.3% 
43/44 
97.7 
0/44 
0% 
44/44 
100% 
Confidentiality 
 
10/44 
22.7% 
34/44 
77.3% 
1/44 
2.3% 
43/44 
97.7 
0/44  
0% 
44/44 
100% 
Don’t want to carry 
on 
6/44 
13.6% 
38/44 
86.4% 
0/44 
0% 
44/44 
100% 
0/44 
0% 
44/44 
100% 
GP 
 
14/44  
31.8% 
30/44 
68.2% 
3/44 
6.8% 
41/44 
93.2% 
1/44 
2.3% 
43/44 
97.7 
Samples 
 
15/44 
34.1% 
29/44 
65.9% 
n/a n/a n/a n/a 
Genetic tests 
 
10/44  
22.7% 
34/44 
77.3% 
n/a n/a n/a n/a 
Results 
 
11/44  
25% 
33/44 
75% 
1/44 
2.3% 
43/44 
97.7% 
1/44  
2.3% 
43/44 
97.7% 
Organising and 
funding 
10/44  
22.7% 
34/44 
77.3% 
3/44 
6.8% 
41/44 
93.2% 
2/44 
4.6% 
42/44 
95.5% 
Reviewed study 11/44  
26% 
33/44 
75% 
2/44 
4.5% 
42/44 
95.5% 
2/44 
4.6% 
42/44 
95.5% 
Further info and 
contact 
4/44  
9.1% 
40/44 
9.1% 
n/a n/a n/a n/a 
Accessing any 
information type 
26/44 
59.1% 
18/44 
40.9 
8/44 
18.2% 
36/44 
81.8% 
4/44 
9.1% 
40/44 
90.9% 
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6.7 PREDICTORS OF INFORMATION ACCESSED  
 
Proportions of participants accessing each piece of information were conducted for 
each demographic group and between those that consented and did not consent to 
participate, to see if any clear patterns emerged.  These data showed a trend 
towards participants accessing more information if they consented to the parent 
study, which is true for every FAQ (Table 18) although this was not tested by formal 
statistical methods due to small numbers and the associated risks of over fitting194.  
These results must be interpreted with caution given the small numbers of 
participants in each group and may only be useful for hypothesis generation for 
future research.  No other trends were seen for demographic groups, which can be 
found in Appendix 9.7. 
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Table 18 – Proportions of participants accessing each level of information for each FAQ by participation (did consent 
or did not consent) 
 
 Accessed no levels Level one Level two Level three 
 Consent Did not 
consent 
Consent 
 
Did not 
consent 
Consent Did not 
consent 
Consent Did not 
consent 
Purpose of the 
study 
7/16 
(43.7%) 
19/28 
(67.9%) 
9/16  
(56.3%) 
9/28  
(32.1%) 
3/16  
(18.8%) 
1/28  
(3.6%) 
1/16  
(6.3%) 
1/28  
(3.6%) 
Have to take part 11/16 
(68.7) 
25/28 
(89.3%) 
5/16  
(31.3%) 
3/28  
(10.7%) 
0/16  
(0%) 
0/28  
(0%) 
0/16  
(0%) 
0/28  
(0%) 
Why been chosen 8/16 
(50.0%) 
18/2 
(64.3%) 
8/16  
(50.0%) 
10/28 
(35.7%) 
2/16  
(12.5%) 
2/28  
(7.1%) 
0/16 
(0%) 
1/28  
(3.6%) 
Expenses 7/16 
(43.7%) 
15/28 
(53.6%) 
9/16  
(56.3%) 
13/28 
(46.4%) 
3/16  
(18.8%) 
2/28  
(7.1%) 
1/16  
(6.3%) 
1/28  
(3.6%) 
What will happen 6/16 
(37.5%) 
16/28 
(57.1%) 
10/16 
(62.5%) 
12/28 
(42.9%) 
3/16  
(18.8%) 
1/28  
(3.6%) 
0/16  
(0%) 
1/28  
(3.6%) 
Risks 6/16 
(37.5%) 
16/28 
(57.1%) 
10/16 
(62.5%) 
12/28 
(42.9%) 
5/16  
(31%) 
2/28  
(7.1%) 
0/16  
(0%) 
2/28  
(7.1%) 
Benefits 7/16 
(43.7%) 
16/28 
(57.1%) 
9/16 
(56.3%) 
12/28 
(42.9%) 
4/16  
(25.0%) 
1/28  
(3.6%) 
1/16  
(6.3%) 
0/28  
(0%) 
Problems 9/16  
(56.3%) 
19/28 
(67.9%) 
7/16  
(43.8%) 
9/28  
(32.1%) 
0/16  
(0%) 
1/28  
(3.6%) 
0/16  
(0%) 
0/28  
(0%) 
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Confidentiality 12/16 
(75.0%) 
22/28 
(78.6%) 
4/16  
(25.0%) 
6/28  
(21.4%) 
0/16  
(0%) 
1/28  
(3.6%) 
0/16  
(0%) 
0/28  
(0%) 
Don’t want to 
carry on 
12/16 
(75.0%) 
25/28 
(89.3%) 
4/16  
(25.0%) 
3/28  
(10.7%) 
0/16  
(0%) 
0/28  
(0%) 
0/16  
(0%) 
0/28  
(0%) 
GP 9/16  
(56.3%) 
21/28 
(75%) 
7/16  
(43.8%) 
7/28  
(25.0%) 
3/16  
(18.8%) 
0/28  
(0%) 
1/16  
(6.3%) 
0/28  
(0%) 
Samples 8/16  
(50.0%) 
21/28 
(75%) 
8/16  
(50.0%) 
7/28  
(25.0%) 
n/a n/a n/a n/a 
Genetic tests 10/16 
(62.5%) 
24/28 
(85.7%) 
6/16  
(37.5%) 
4/28  
(14.3%) 
n/a n/a n/a n/a 
Results  9/16  
(56.3%) 
24/28 
(85.7%) 
7/16  
(43.8%) 
4/28  
(14.3%) 
2/16  
(12.5%) 
1/28  
(3.6%) 
1/16  
(6.3%) 
1/28  
(3.6%) 
Organising and 
funding 
9/16  
(56.3%) 
24/28 
(85.7%) 
7/16  
(43.8%) 
4/28  
(14.3%) 
3/16  
(18.8%) 
1/28  
(3.6%) 
1/16  
(6.3%) 
1/28  
(3.6%) 
Reviewed study 9/16  
(56.3%) 
24/28 
(85.7%) 
7/16  
(43.8%) 
4/28  
(14.3%) 
3/16  
(18.8%) 
1/28  
(3.6%) 
1/16  
(6.3%) 
1/28  
(3.6%) 
Further info and 
contact 
11/16 
(68.7%) 
24/28 
(85.7%) 
5/16  
(31%) 
4/28  
(14.3%) 
n/a n/a n/a n/a 
 
Total participants 
accessing any 
information 
5/16 
(31.0%) 
13/28 
(46.2%) 
11/16 
(68.8%) 
15/28 
(53.6%) 
6/16 
(37.5%) 
3/28 
(10.7%) 
2/16 
(12.5%) 
2/28 
(7.1%) 
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Further exploratory analyses were then conducted to look at whether the average 
number of pieces of information accessed varied by demographics or consent 
decision.  Table 19 shows the average number of pieces of information accessed per 
person split by age group, gender, ethnicity and participation decision.  A ‘piece’ of 
information was considered to be an element (i.e. a level of information) within a 
FAQ.  For example, a participant was deemed to have accessed one ‘piece’ of 
information if they looked at level one information for one FAQ and two ‘pieces’ of 
information if they looked at level one and level two information for one FAQ.  A 
participant was deemed to have accessed four ‘pieces’ of information if they had 
looked at levels one, two and three for one FAQ and level one for a separate FAQ. 
 
On average, participants looked at 6 pieces of information before deciding whether to 
participate in the parent study.  The average number of pieces of information 
accessed increased with age (44-55=5.6; 55-65=6.5; 65+=8.5).  For gender 
subgroups, there were no apparent differences in the total number of pieces of 
information accessed.  Black Caribbean participants accessed the most pieces of 
information (7.2 pieces) and South Asian participants accessed the fewest (4.0 
pieces).  Those who eventually consented to take part in the parent study read more 
pieces of information than those who refused (9.2 and 4.6 respectively).  Given the 
small numbers and exploratory nature of these analyses, these reported differences 
could be due to chance. 
 
  
198 
 
The exploratory analyses suggest that participants who accessed no information 
were likely to be: younger (45-55= 11/24 [45.8%]; 55-65= 5/14 [35.7%]; 65+= 2/6 
[33.3%]); White (White= 14/31 [45.2%]; South Asian= 0/2 [0%]; Black Caribbean= 2/9 
[22.2%]); and did not take part in the parent study (did not consent = 13/28 [46.4%]; 
consented= 5/16 [31.3%]) but this finding must be interpreted with caution given the 
small number of participants in groups, and used purely in hypothesis generation for 
future studies. 
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Table 19 – Demographics that predict the total number of levels accessed and 
total time spent 
 
 N Mean number of 
levels seen per 
person (95% CI) 
Number people 
accessed no 
levels 
 
Total IIS study 
population  
 
 
44 
 
 
7 
 
 
(4; 10) 
 
 
 
18/44 
  
 
(40.9%) 
 
Age 
 
45-55 24 6  (2; 10;) 11/24  (45.8%) 
55-65 14 7  (3; 12;) 5/14  (35.7%) 
65+ 6 9  (1; 18;) 2/6  (33.3%) 
 
Gender 
 
Male 24 7  (4; 10) 9/24 (37.5%) 
Female 20 7  (3; 11) 9/20  (45.0%) 
 
Ethnicity 
 
White  31 7  (4; 10) 14/31  (45.2%) 
Asian 2 5  (-33; 43) 0/2  (0%) 
Black 9 8  (2; 14) 2/9  (22.2%) 
 
Participation status for parent study 
 
Consented 16 10  (5; 15) 5/16  (31.3%) 
Did not consent 28 5  (2; 8) 13/28  (46.4%) 
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6.8 EFFECT OF IIS ON CONSENT RATE 
 
Feasibility of electronic information provision 
The highest consent rate was seen in the ‘No PIS’ group where 59.4% (63/106) of 
participants consented to the parent study (Table 20). 
 
When both IIS and PDF-PIS methods of electronic communication are compared with 
the paper PIS there is an increase in consent rate to 41.9% and 31.1% respectively 
(OR=1.25 [95% CL 0.98; 1.75]) (Table 21).   
 
When all methods of electronic communication are compared to paper PIS there is 
still a small increase in consent rate to 34.1% and 31.1% respectively (OR=1.25 [1; 
1.7]) (Table 21).   
 
IIS RCT 
The primary outcome of the IIS RCT was whether using an IIS affected the consent 
rate to the parent study in comparison with the use of the PDF-PIS.   
 
The consent rate for the parent study with the standard PIS was 31.1% (Table 20), 
so the effect size required to change practice was 27%, with a sample size of n=132 
(90% power) (Section 4.5.2).  The sample size was not met (IIS RCT sample size 
n=86).   
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Intention To Treat (ITT) analysis showed no statistically significant difference in 
consent rate for IIS when compared with a PDF-PIS; 36.4% and 47.6% respectively 
(OR=0.6 [95% CL 0.25; 1.4]) (Table 21).  The effect size seen in the study was 
considerably less than the effect size required to change practice, so even if the 
sample size had been met the study would still have been underpowered. 
 
Table 20 – Consent rate by study group   
 Number 
consenting / n 
Consent rate  
(95% CI) 
 
Electronic recruitment 
PDF 20/42 47.6% (31.9; 63.3) 
IIS 16/44 36.4% (21.6; 51.2) 
No PIS 63/106 59.4% (44.3; 74.5) 
All electronic  99/290 34.1% (28.6; 39.6) 
 
Postal recruitment 
Paper  271/870 31.1% (25.8; 36.4) 
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Table 21 – Comparison of consent rate between groups 
Comparison 
between 
groups* 
Number 
consenting / n 
Consent rate  OR (95% 
Confidence Limits) 
IIS vs. PDF 16/44 vs. 20/42 36.4% vs. 47.6%  0.6 (0.25; 1.4) 
PDF/IIS vs. Paper 36/86 vs. 271/870 41.9% vs. 31.1% 1.25 (0.98; 1.75) 
Electronic vs. 
Postal 
recruitment 
99/290 vs. 
271/870 
34.1% vs. 31.1% 1.25 (1.0; 1.7) 
Opened email 
(PDF/IIS/None) 
vs. Postal 
recruitment 
99/192 vs. 
271/870 
51.6% vs. 31.1% 1.5 (1.1; 2.1) 
 
*Logistic regression with variables gender and age 
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6.9  UNDERSTANDING AND SATISFACTION 
 
Participants were asked to complete questionnaires to determine what effect the 
method of information provision had on participant understanding and satisfaction.  
Figure 17 shows the number of understanding and satisfaction questionnaires that 
were sent and returned by each group of participants.   
 
Questionnaires were not sent to all study participants.  There were expected 
demographic differences between participants who did and did not provide an email 
address, and these differences mean responses from the two groups may have 
differed by a factor other than the format of information provision.  We were only 
interested in ensuring the adequacy of understanding by those who took part in the 
parent study, to help ensure valid consent was taken.  Given that electronic 
information provision is a new methodology, it was important that levels of 
understanding and satisfaction were not reduced because information was provided 
electronically.  This means that even though those with and without an email address 
were likely to differ demographically, we needed to collect levels of understanding 
from both groups so we could compare results.  
 
There were four distinct study groups that received understanding and satisfaction 
questionnaires: 
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1.  Those who did not provide an email address but participated in the parent 
study (n=870).  These participants are the ‘paper PIS’ group 
2. Those who did provide an email address and were randomised to PDF-PIS 
(n=42) regardless of consent status to parent study 
3. Those who did provide an email address and were randomised to IIS (n=44) 
regardless of consent status to parent study  
4. Those who provided an email address but were not randomised in the IIS RCT 
and, therefore, did not receive and study information, but who booked a 
consent appointment (n=63).  These participants are the ‘no PIS’ group 
 
Two groups of participants did not receive understanding and satisfaction 
questionnaires: 
1. Those who did not provide an email address and did not participate in the 
parent study (n=290) 
2. Those who did provide an email address but were not randomised in the IIS 
RCT and did not book a parent study appointment (n=600) 
 
Response rate to the understanding and satisfaction questionnaire for the ‘paper PIS’ 
and ‘no PIS’ groups were similar (61.3% and 57.1% respectively).  Response rate for 
participants receiving a PDF-PIS (n=42) was similar to the ‘paper PIS’ and ‘no PIS’ 
groups (57.1%) but the response rate for IIS randomised participants (n=44) was 
much higher (90.9%).   
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Figure 17 - Number of satisfaction and understanding questionnaires returned 
 
 
 
 
 
 
 
 
 
 
 
 
With email address n=290/1160 (25.0%) 
All parent study participants interested in phase II N=1160 
No email address N=870/1160 (75%) 
Did not consent 
to phase II 
N= 600/870 
(69.0%) 
Consented to phase II 
N= 271/870 (31.1%) 
Questionnaires 
delivered 
N= 266/269 
(98.9%) 
Questionnaire 
undeliverable 
N=5/269 (1.9%) 
Returned 
N= 108/269 
(40.1%) 
Reminder sent 
N=158/269 
(58.7%) 
Returned 
N= 
57/269(21.2%) 
Total Returned 
N= 165/269 (61.3%) 
Not in RCT but took part in parent study 
N= 63/290 (21.7%) 
Consented to phase II 
N= 63/290 (21.7%) 
Questionnaires 
delivered 
N= 63/63 
(100%) 
Questionnaire 
undeliverable 
N= 0/63 (0%) 
Returned 
N= 24/63 
(38.1%) 
Reminder sent 
N= 39/63 
(61.9%) 
Returned 
N= 12/63 
(19.0%) 
Total Returned 
N= 36/63 (57.1%) 
Took part in RCT 
N= 86/290 (29.7%) 
Randomised to PDF 
N= 42/86 (48.8%) 
Questionnaires 
delivered 
N=41/42 
(97.6%) 
Questionnaire 
undeliverable 
N= 1/42(2.4%) 
Returned 
N= 16/42 
(38.1%) 
Reminder sent 
N= 26/42 
(61.9%) 
Returned 
N= 8/42 
(19.0%) 
Total Returned 
N= 24/42 (57.1%) 
Completed 
online 
N= 0/42 
(0%) 
Randomised to IIS 
N= 44/86 (51.2%) 
Questionnaires 
delivered 
N= 8/44 (%) 
Questionnaire 
undeliverable 
N= 0/44 (%) 
Returned 
N= 1/44 
(2.3%) 
Reminder 
sent 
N= 7/44 
(15.9%) 
Returned 
N= 3/44 
(6.8%) 
Total Returned 
N= 40/44 (90.9%) 
Completed 
online 
N= 36/44 
(81.8%) 
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Understanding 
 Table 22 presents participants’ scores on the understanding questionnaire by 
study group.  The overall score on the understanding questionnaire is similar 
across groups, including those we know to have received no study information 
prior to agreeing to take part.   
 
Almost all participants across all groups correctly answered that they were 
being asked to take part in a piece of medical research rather than being asked 
to make a treatment decision.  The question with the most incorrect answers 
across all groups concerned why they had been chosen to participate.  The 
majority of participants believed they had been chosen to participate because 
they had high blood pressure when, in fact, the study was actually trying to 
recruit equal numbers of both normotensive and hypertensive participants.   The 
proportion of correct answers across the other thirteen questions varied and no 
consistent pattern emerged from the data.  For example, there were two groups 
of participants that accessed no information – those in the ‘no PIS’ group and 
those in the IIS group that accessed no levels of information. When asked what 
would happen to them if they took part, 83.8% in the ‘no PIS’ group but only 
35.3% in the IIS group answered the question correctly, even though 
participants in both groups had accessed no information.  The numbers in study 
groups were too small to test for statistically significant differences in the 
proportion answering correctly across individual questions. 
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The score on the understanding questionnaire was also presented by 
demographic group’s age, gender and ethnicity (Table 23).  The IIS participants 
were not split into different level groups for this analysis since numbers were 
already very small.  No pattern emerged for the average score on the 
understanding questionnaire-based on participant's age group, gender or 
ethnicity, and should be interpreted with caution due to the small numbers in 
individual groups. 
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Table 22 – Participant score on the understanding questionnaire split by study group 
 
 
 
 
 
No PIS IIS  
 
PDF-
PIS  
Paper 
PIS  
No 
levels 
Level 
one 
Level 
two 
Level 
three 
Overall 
Overall scores 
Mean score (95% CI) 11.1 
(10.3; 
11.8) 
n=37 
10.4   
(9.2; 
11.6) 
n=17 
11.7 
(10.6; 
12.7) 
n=15 
12.0  
(11.1; 
12.9) 
n=5 
9.8  
(5.8; 
13.8) 
n=4 
11.00  
(10.3; 
11.7) 
n=41 
11.2  
(10.0; 
10.9) 
n=26 
10.4  
(10.0; 
10.9) 
n=165 
 
Scores for each question 
Is this treatment or research?  35/37 
94.6% 
14/17 
82% 
15/15 
100% 
5/5  
100% 
4/4  
100% 
38/41  
92.3% 
24/26 
92% 
147/165 
89.1 
Purpose of the study - Is it to test for 
differences between methods of BP 
measurement and ethnic groups? 
 
28/37 
75.7% 
10/17 
58.8% 
12/15 
80% 
5/5  
100% 
4/4  
100% 
31/41 
75.6% 
18/26 
69.2% 
125/165 
75.8% 
Why have I been chosen? – Have you 
been chosen because you have high blood 
pressure? 
 
12/37  
32.4% 
9/17 
52.9% 
7/15 
46.7% 
2/5  
40% 
2/4  
50% 
20/41 
48.8% 
13/26 
50% 
59/165 
35.8% 
Do I have to take part? – Do you have to 31/37 16/17 15/15 5/5  3/4  39/41 23/26 132/165 
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take part in this study?  
 
83.8% 94.1% 100% 100% 75.0% 95.1% 88.5% 80.0% 
What will happen to me if I take part? – 
if you take part in this study will you be 
involved for 8 days? 
 
31/37 
83.8% 
6/17 
35.3% 
12/15 
80% 
4/5  
80.0% 
4/4 
100.0
% 
26/41 
63.4% 
20/26 
76.9% 
123/165 
74.6% 
What will happen to me if I take part? – 
Will you have to measure your BP yourself 
at home? 
 
37/37 
100% 
11/17 
64.7% 
12/15 
80.0% 
4/5  
80.0% 
3/4  
100% 
30/41 
73.2% 
23/26 
88.5% 
148/165 
89.7% 
GP involvement – Will your GP be told 
you are taking part? 
 
26/37 
70.3% 
9/17 
52.9% 
12/15 
80.0% 
4/5  
80.0% 
3/4  
100% 
28/41 
68.3% 
17/26 
65.4% 
122/165 
73.9% 
GP involvement – Will the research nurse 
offer you treatment? 
 
25/37 
67.6% 
11/17 
64.7% 
5/15 
33.3% 
2/5  
40.0% 
1/4  
25.0% 
19/41 
46.3% 
17/26 
65.4% 
107/165 
64.9% 
Confidentiality – Will we keep information 
about you confidential? 
 
36/37 
97.3% 
15/17 
88.2% 
15/15 
100% 
5/5  
100% 
2/4  
50% 
37/41 
90.2% 
25/26 
96.2% 
145/165 
87.9% 
Don’t want to carry on – If you decide to 
pull out, will it affect your care from your 
GP? 
 
36/37 
97.3% 
16/17 
94.1% 
15/15 
100% 
5/5  
100% 
4/4  
100% 
40/41 
97.6% 
24/26 
92.3% 
148/165 
89.7% 
Confidentiality – Will statisticians 
involved in the study be able to see your 
name, address and other personal details? 
27/37 
73.0% 
13/17 
76.5% 
14/15 
93.3% 
5/5  
100% 
3/4  
75.5 
33/41 
80.5% 
16/26 
61.5% 
86/165 
52.1% 
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GP - If you do not want your GP to know 
you are taking part will you still be able to 
take part? 
 
4/37 
10.8% 
3/17 
17.7% 
2/15 
13.3% 
5/5 
100% 
4/4  
100% 
5/41 
12.2% 
5/26 
19.2% 
24/165 
14.6% 
Organising and funding – Is this study 
being organised by professional 
researchers at the University of 
Birmingham? 
 
34/37 
91.9% 
16/17 
94.1% 
13/15 
86.7% 
5/5 
100% 
4/4  
100% 
38/41 
92.7% 
25/26 
96.2% 
149/165 
90.3% 
Results – When we publish the results of 
this study, will we identify you in any 
report? 
 
28/37 
75.7% 
15/17 
88.2% 
15/15 
100% 
5/5  
100% 
2/4  
50.0% 
37/41 
90.2% 
22/26 
84.6% 
113/165 
68.5% 
Reviewed the study – Has this study 
been looked at and approved by a REC? 
 
20/37 
54.1% 
13/17 
76.5% 
10/15 
66.7% 
4/5  
80% 
2/4  
50.0% 
29/41 
70.7% 
18/26 
69.2% 
94/165 
57.0% 
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Table 23 – The average score on the understanding questionnaire, split by method of information provision and 
demographics 
 All 
participants 
Mean score 
(n) 
IIS  
Mean Score 
(n) 
PDF-PIS  
Mean Score 
(n) 
Paper PIS  
Mean Score 
(n) 
All participants 
 
10.8 (265) 11.00 (40) 11.15 (24) 10.8 (201) 
Age 45-55 
 
10.66 (75) 10.9 (21) 10.8 (12) 10.5 (42) 
55-65 
 
11.0 (73) 10.8 (14) 10.6 (8) 11.1 (51) 
65+ 
 
10.8 (77) 11.8 (6) 12.5 (6) 10.5 (65) 
Gender Male 
 
10.5 (114) 10.8 (24) 10.9 (14) 10.4 (76) 
Female 
 
11.0 (114) 11.2 (17) 11.5 (12) 10.9 (85) 
Ethnicity WB 
 
11.3 (130) 11.0 (29) 11.8 (19) 11.4 (82) 
SA 
 
9.9 (28) 13 (1) 8.3 (3) 10.0 (24) 
BC 
 
10.1 (67) 10.9 (9) 9 (3) 10.0 (55) 
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Satisfaction 
Participant satisfaction was assessed to determine if providing information 
electronically affected whether participants were happy with the method of 
information provision (Table 24).  Questionnaires were delivered to the same 
groups and at the same time as the understanding questionnaires. 
 
Overall, 32/265 (12.1%) participants stated that they would have liked more 
information about the study.  Participants were less likely to want more 
information about the parent study if they received study information 
electronically - only 1/40 (2.5%) of those in the IIS and 2/24 (8.3%) in the PDF-
PIS group wanted to know more information about the study compared with 
28/137 (20.4%) in the paper PIS group.  One person (1/36; 2.8%) who received 
no PIS before booking a parent appointment stated that they would have liked 
more information about the study. 
 
One person randomised to IIS but who accessed no information stated that they 
would have liked more information about the study.  It is possible that this 
participant was unable to get the information they required because they were 
unable to use the website, which is a concern of providing electronic 
information.  This participant did, however, complete the understanding and 
satisfaction questionnaire online.  In order to do this s/he had to navigate 
through the website successfully to access the questionnaire pages.  If they 
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were able to do this, it is likely they did have an understanding of how to use the 
Internet, and they were not unable to access information because they could 
not use the website.  This may be an example of participants not using the 
information provided to make a decision but still requesting more information 
when asked. 
 
9.1% (24/265) of all participants stated that they did not need as much 
information about the study as they were given, which increases to 22.5% 
(9/40) when only IIS participants are considered (PDF= 3/24 [12.5%]), no PIS= 
2/36 [5.6%], paper PIS= 28/137 [20.4%]). 
 
Overall, 20.4% (54/265) participants stated that they would prefer to have 
information provided electronically if they took part in research again.  This 
figure rises to between 45% and 50% when considering only responses from 
participants who received electronic information (IIS= 18/40 [45%]; PDS-
PIS=12/24 [50%]) and falls to 10.2% when considering responses from 
participants who received paper information (Paper PIS= 14/137).  Comparable 
results were seen for those stating that they would prefer to have information 
provided on paper if they took part in research again. 
 
12/40 (30%) participants who returned the questionnaire stated they did not 
click on any of the (+) signs.  Results, however, showed that 40.9% (18/44) of 
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those that accessed the IIS did not click on any of the + signs.  A high 
proportion of participants stated that they found the information under the (+) 
signs useful, but it only influenced the decision to take part of 13/40 (32.5%).  
Sixteen participants (n=40; 40%) stated that the information under the (+) signs 
did not influence their decision to participate, and eleven (11/40; 27.5%) did not 
respond to the question.  Of those that stated they did access information under 
the (+) signs, most participants either skimmed through the information (12/40; 
30%) or picked out only the bits that were important to them (14/40; 35%).  A 
high proportion of participants stated that they would have been happy without 
reading any information under the (+) signs (17/40; 42.5%) but 11/40 (27.5%) 
would not have agreed to take part in the study without being able to read the 
information under the (+) signs. 
 
Almost all participants stated that they read all of the information sheet they 
were given about the parent study, including most of those that we know to 
have received no information sheet at all (No PIS= 34/36 [94.4%]; PDF-
PIS=18/24 [75.0%]; Paper PIS=129/137 [94.2%]).  Fewer participants stated 
that they only read some of the information they were given (No PIS=4/36 
[11.1%]; IIS=14/40 [30.0%] PDF-PIS=8/24 [33.3%]; Paper PIS=30/137 [21.9%]) 
or skimmed through the information sheet (No PIS=4/36 [11.1%]; IIS=12/40 
[30.0%]; PDF-PIS=4/24 [16.7%]; Paper PIS=18/137 [13.1%]) and less than 5% 
(excluding the IIS group ) stated that they did not read any of the information 
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sheet (No PIS=1/36 [2.8%]; IIS=12/40 [30.0%] PDF-PIS=0/24 [0%]; Paper 
PIS=6/137 [4.4%]).  Despite almost all participants stating that they had read 
the entire information sheet, proportions for the remaining questions do not tally.  
For example, for the Paper PIS group, 94.2% said they read the entire 
information sheet, 21.9% said they read some of it, 13.1% said they skimmed 
through it and 4.4% said they did not read any of it, which equals 133.6%, so 
participants often answered ‘yes’ to more than one discrete question. 
 
When asked questions about the importance of the PIS to their decision-
making, the majority stated that it was important to read and helped them to 
decide whether to participate (No PIS=24/36 [66.7%] IIS=11/40 [27.5%]; PDF-
PIS=19/24 [79.2%]; Paper PIS=114/137 [83.2%]), around half found the 
information sheet interesting but it did not influence their decision to participate 
(No PIS=17/36 [47.2%]; IIS=17/40 [42.5%]; PDF-PIS=10/24 [41.7%]; Paper 
PIS=67/137 [48.9%]) and around half said they would not have agreed to take 
part without being able to read the information sheet (No PIS=17/36 [47.2%]; 
IIS=11/40 [27.5%]; PDF-PIS=9/24 [37.5%]; Paper PIS=73/137 [53.3%]).  This is 
interesting because 17/36 (47.2%) of those in the ‘No PIS’ group, all of whom 
took part in the parent study, stated that they would not have agreed to take 
part in the study without being able to read the information in the information 
sheet, but we know that they did not receive one. 
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The trend of participants agreeing with conflicting statements or agreeing with 
statements known to be untrue (based on the information we know they actually 
accessed) was apparent throughout the results of this questionnaire. 
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Table 24 – Participants’ satisfaction with the method of information provision, split by method of information 
provision 
 
 
 
 
No PIS IIS  
 
PDF-
PIS  
Paper 
PIS  
No 
levels 
Level 
one 
Level 
two 
Level 
three 
Overal
l 
I would have liked more information about 
the study  
1/36  
3% 
1/17 
6% 
0/14 
0% 
0/5 
0% 
0/4 
0% 
1/40  
3% 
2/24  
8% 
28/137 
20% 
I did not need as much information about 
the study as I was given 
2/36  
6% 
3/17 
12% 
3/14 
21% 
2/5 
40% 
1/4 
25% 
9/40 
23% 
3/24 
13% 
10/137 
7% 
I would prefer to have information provided 
electronically if I took part in research again 
10/36 
28% 
5/17 
29% 
5/14 
36% 
4/5 
80% 
4/4 
100% 
18/40 
45% 
12/24 
50% 
14/137 
10% 
I would prefer to have information provided 
on paper if I took part in research again 
16/36 
44.4% 
5/17 
29.4% 
0/14 
0% 
0/5 
0% 
0/4 
0% 
5/40 
13% 
8/24 
33% 
116/137  
85% 
 
I did not click on any of the (+) signs  4/17 
12% 
7/14 
50% 
1/5 
20% 
1/4 
25% 
12/40  
30% 
 
I found the information under the (+) signs 
useful and it influenced my decision to take 
part in this study 
4/17 
24% 
6/14 
43% 
1/5 
20% 
2/4 
50% 
13/40  
33% 
I found the information under the (+) signs 
interesting but it didn’t influence my decision 
to participate in the Blood Pressure 
Monitoring study 
2/17 
12% 
3/14 
21% 
0/5 
0% 
0/4 
25% 
16/40  
40% 
I clicked on the (+) signs to see what was 
there but did not read the information 
6/17 
35% 
4/14 
29% 
2/5  
40% 
1/4 
25% 
5/40  
13% 
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I clicked on the (+) signs and skimmed 
through the information.  I did not read it 
fully 
2/17 
12% 
6/14 
43% 
3/5 
60% 
2/4 
50% 
12/40  
30% 
I clicked on the (+) signs and skimmed 
through the information.  I picked out and 
read only parts which were important to me 
5/17 
29% 
8/14 
57% 
1/5 
20% 
1/4 
25% 
14/40  
35% 
I would have been happy with just the first 
piece of information from each section.  I did 
not need to read any of the information 
under the (+) signs to make a decision about 
whether I wanted to take part in the Blood 
Pressure Monitoring study 
10/17 
59% 
5/14 
36% 
1/5 
20% 
1/4  
25% 
17/40  
43% 
I would not have agreed to take part in the 
Blood pressure Monitoring study without 
being able to read the information under the 
(+) signs 
1/17 
6% 
5/14  
36% 
3/5 
60% 
2/4 
50% 
11/40  
28% 
 
I read all of the information sheet I was 
given about the Blood Pressure Monitoring 
study 
34/36  
94% 
 18/24  
75% 
129/137  
94% 
I read some of the information in the 
information sheet I was given about the 
study 
4/36  
11% 
8/24  
33% 
30/137  
22% 
I skimmed through the information in the 
information sheet I was given about the 
study and read only the bits that were 
important to me 
4/36  
11% 
4/24  
17% 
18/137  
13% 
I did not read any of the information in the 1/36  0/24  6/137  
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information sheet I was given about the 
study 
3% 0% 4% 
I read some of the information in the 
information sheet but it did not help me to 
decide whether or not I wanted to take part 
in the study 
2/36  
6% 
1/24  
4% 
18/137  
13% 
The information sheet was important to read 
and helped me to decide whether or not I 
wanted to take part in the study 
24/36  
67% 
19/24  
79% 
114/137  
83% 
I found the information in the information 
sheet interesting but it did not influence my 
decision to take part 
17/36  
47% 
10/24  
42% 
67/137  
49% 
I would not have agreed to take part in the 
study without being able to read the 
information in the information sheet 
17/36  
47% 
9/24  
38% 
73/137  
53% 
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6.10 ESTIMATION OF COSTS 
 
The cost analysis performed suggested that it was more expensive per 
participant to send electronic invitations than it was to send postal ones (Table 
25).   
 
It is estimated that it would cost £1173 in researcher’s time (Table 26) to 
develop the content for the IIS, in addition to the time spent writing the 
‘standard’ level two information. 
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Table 25 – Estimate of cost for electronic and postal invitations 
Postal invitations 
Type of cost Reason for cost Estimate of total 
cost for item 
Printing  Invitation letter £0.05 
 PIS £0.05 
Stationery A4 envelope £0.10 
 2
nd
 Class stamp, large letter £0.69 
Administrator time Printing and sorting invitation letters and 
PIS  
- 15 seconds per letter 
£0.039 
 Filling envelopes 
- 15 seconds per envelope 
£0.039 
 
Total cost per person 
 
 
£1.07 
 
 
Electronic invitations 
 
All participants 
Administrators time  Compiling email and sending, assuming 
mailing list rather than per person  
- 15 seconds 
£0.039 
 
Total cost to send email to each participant 
 
£0.039 
 
Costs to call participants - in 28.6% that answered 
Phone call 10 minutes £0.50 
Administrators time On the phone talking to participants 
- 10 minutes 
£1.56 
 Calling participants when they did not 
answer  
- 1 minute x 10 phone calls 
£1.56 
 
Total cost to call each participant that answered 
 
 
£3.62 
 
Costs to call participants - in 16.9% that did not answer 
Administrators time  Calling participants when they did not 
answer  
- 1 minute x 10 phone calls 
£1.56 
Total cost to call each participant that did not answer £1.56 
 
 
Total average cost per invited participant  
 
 
£1.34 
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Table 26 – Estimate of cost to develop the content for the IIS 
 Research 
associate 
(Grade 6) 
Research 
fellow 
(Grade 7) 
Principal 
investigator 
(Grade 9) 
Total cost 
of IIS 
Number of hours 67 7 4 
Approx wage per 
hour 
£14 £17 £29 
Total cost £938 £119 £116 £1173 
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Key results 
Consent rate: 
Electronic communication did not affect consent rate, although the study 
was not powered to detect this. 
Encouraging participants to open emails improved recruitment rate. 
Highest consent rate seen in the group that accessed no PIS. 
 
Information accessed: 
High proportion accessed little or no study information. 
The paper PIS matched the reading patterns of only 11.4%: 9.1% read 
more and 79.5% less than the information in the paper PIS. 
 
Understanding and satisfaction: 
Understanding consistent across groups, including those accessing no 
information. 
Participants generally happy with the level of information received. 
Participants were unable to accurately recall what information they had 
accessed. 
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6.12 LIMITATIONS OF THE INFORMATION PROVISION STUDY 
 
The consent rate for electronic recruitment was shown to be higher than that for 
postal recruitment but not to statistical significance.  Participants were also not 
randomised to the postal recruitment group because it was not feasible using 
the selected parent study.  A further RCT would be needed to ascertain whether 
the improvement in consent rate was due to electronic recruitment or whether 
participants that provided an email addresses differed in some other way that 
made them more likely to participate.   
 
Where participants were prompted to open their emails with a telephone call, 
the consent rate was shown to be higher in the electronic group.  It is not known 
whether this was due to the electronic method of communication itself or 
whether calling participants influenced participation rates. 
 
The highest consent rate was seen in the group that accessed no PIS.  It is not 
known what proportion of those who received postal information read it and 
whether there was a similar correlation in the postal group.  We know from the 
results of the questionnaire that what participants say they did does not reflect 
actual practice, so asking potential participant whether they read the information 
provided may not yield an accurate result. 
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The older average age of parent study participants may have been a limitation 
to this research.  The study required participants to be competent Internet 
users, and ONS data101 showed that Internet use declines with increasing age.  
The majority of the study population did not provide an email address and so we 
assumed they were not able to access information electronically.  We cannot be 
certain that this is the case though, since some participants may have chosen to 
not provide their email address, or they may have been able to access a study 
website with the help of a relative, for example, if they had been provided with 
the website details.   
 
An exploratory retrospective analysis of costs was undertaken for the 
Information Provision study, but the costs and resource use could not be 
accurately calculated as they were not collected during the study.  In future 
studies, a full cost-effectiveness analysis needs to be conducted comparing 
postal and electronic communication. 
 
The sample size was lower than anticipated, with only 86 participants 
randomised in the IIS RCT by the end of recruitment.  This was due to the 
proportion of parent study participants accessing the study website being much 
lower than expected, and an unexpectedly high number of people participating 
in the parent study without accessing any study information. 
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6.13 A STREAMLINED PIS 
 
The results of the observational study were used to produce a streamlined PIS 
for the parent study because we wanted to see what an information sheet would 
look like that contained only that information which the majority participants 
(who accessed information) used to make a decision to participate. The 
resulting PIS can be found at the end of this section. The section justifies the 
length of this streamlined PIS, the information included and how it is structured.   
 
Length 
The median time spent reading the IIS was 57 seconds (IQR 0 to 195 seconds).  
The median and mean times differed due to a high proportion of potential 
participants reading no information and a few people spending a long time 
reading information.  In order to account for the skew in the data caused by the 
few people that spent a long time reading, the median rather than the mean was 
used.  For a streamlined PIS to be read in 57 seconds, it should be around 190 
words long (assuming the average person reads 200 words per minute).   
 
Information to be included 
 There are two reasons for including information in a PIS: 1) to ensure potential 
participants are sufficiently informed;  2) to ensure participants are provided with 
the information that meets international guidelines, which protects the 
researcher from the claim that adequate information was not provided.  
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Information participants want to know 
Included here was the information most commonly accessed by participants 
randomised to IIS - the level one information for expenses, risks and benefits, 
purpose of the study, what would happen if they took part, what would happen if 
they had any problems, if their GP would be told of the results and what would 
happen to any samples they gave.  Based on the access patterns, we can 
hypothesise that these were the sections of most interest to potential 
participants and should, therefore, be included in a PIS. 
 
Around 20% of participants accessed more than the minimal level of 
information.  Providing a streamlined PIS to these participants may not provide 
them with the information they need to make an informed decision.  In order to 
meet the informational needs of this minority, greater access to information is 
needed.  A streamlined PIS should include information about how more 
information can be found.  This could include contact with researchers, or the 
opportunity to request a lengthier paper PIS or access more information on an 
IIS placed on the study website. 
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Information participants ought to know 
There are some pieces of information that are specified by the ICH and the 
statutory instrument that reflects the EU directive (Section 2.2).  The guidelines 
do not include the detail in which these pieces of information should be 
provided, so a brief and accurate summary may be all that is required to satisfy 
these regulations.  The ICH states that4:   
“Both the informed consent discussion and the written informed 
consent form and any other written information to be provided to 
subjects should include explanations of the following:  
a) That the trial involves research. 
b) The purpose of the trial. 
c) The trial treatment(s) and the probability for random assignment 
to each treatment. 
d) The trial procedures to be followed, including all invasive 
procedures. 
e) The subject’s responsibilities. 
f) Those aspects of the trial that are experimental. 
g) The reasonably foreseeable risks or inconveniences to the 
subject and, when applicable, to an embryo, fetus, or nursing 
infant. 
h) The reasonably expected benefits.  When there is no intended 
clinical benefit to the subject, the subject should be made aware 
of this. 
i) The alternative procedure(s) or course(s) of treatment that may 
be available to the subject, and their important potential benefits 
and risks. 
j) The compensation and/or treatment available to the subject in 
the event of trial-related injury. 
k) The anticipated prorated payment, if any, to the subject for 
participating in the trial. 
l) The anticipated expenses, if any, to the subject for participating 
in the trial. 
m) That the subject’s participation in the trial is voluntary and that 
the subject may refuse to participate or withdraw from the trial, 
at any time, without penalty or loss of benefits to which the 
subject is otherwise entitled. 
n) That the monitor(s), the auditor(s), the IRB/IEC, and the 
regulatory authority(ies) will be granted direct access to the 
                                            
4
 Section 4.8.10 of the ICH Topic E6(R1) Guideline for Good Clinical Practice 
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subject’s original medical records for verification of clinical trial 
procedures and/or data, without violating the confidentiality of 
the subject, to the extent permitted by the applicable laws and 
regulations and that, by signing a written informed consent 
form, the subject or the subject’s legally acceptable 
representative is authorizing such access. 
o) That records identifying the subject will be kept confidential and, 
to the extent permitted by the applicable laws and/or 
regulations, will not be made publicly available.  If the results of 
the trial are published, the subject’s identity will remain 
confidential. 
p) That the subject or the subject’s legally acceptable 
representative will be informed in a timely manner if information 
becomes available that may be relevant to the subject’s 
willingness to continue participation in the trial. 
q) The person(s) to contact for further information regarding the 
trial and the rights of trial subjects, and whom to contact in the 
event of trial-related injury. 
r) The foreseeable circumstances and/or reasons under which the 
subject’s participation in the trial may be terminated. 
s) The expected duration of the subject’s participation in the trial. 
t) The approximate number of subjects involved in the trial. 
 
Nine of these areas reflect the information that the majority of our potential 
participants accessed: risks and benefits (g, h), expenses (l), purpose of the 
study (b), what would happen if they took part (d, e, r, s), what would happen if 
they had any problems (q). 
 
Four sections of the guidelines are not applicable to this piece of low risk 
interventional research and were therefore excluded:  those aspects of the trial 
that are experimental (f), the trial treatment(s) and the probability for random 
assignment to each treatment (c), the alternative procedure(s) or course(s) of 
treatment that may be available to the subject, and their important potential 
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benefits and risks (i), the anticipated prorated payment, if any, to the subject for 
participating in the trial (k) 
 
This left seven pieces of information required by ICH guidelines that were 
incorporated into the streamlined PIS using simple sentences as follows: 
 
a) That the trial involves research: “You are being invited to take part in a 
research study about x.” 
 
j) The compensation available: “If something does go wrong and you are 
harmed during the research and this is due to someone’s negligence then you 
may have grounds for a legal action for compensation against The University of 
Birmingham.” 
 
m) That participation is voluntary: “It is up to you to decide whether or not to 
take part and your decision will not affect your healthcare.  If you decide to take 
part you are able to withdraw your consent to participate at any time and this 
will not affect your healthcare.” 
 
n) Who will have access to their confidential information: “Personal data 
(names and addresses) will be only accessible by authorised persons such as 
researchers and regulatory authorities.” 
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o) That participant’s information will be kept confidential: “your taking part 
in this study will be kept confidential and will not be made publically available.  If 
the results of the trial are published, your identity will remain confidential.” 
 
u) The approximate number of subjects involved in the trial:  “The study will 
involve x participants.” 
 
p) Informing participants of changes to the study: “You will be informed in a 
timely manner if information becomes available that may be relevant to your 
willingness to continue in the study.” 
 
Structure 
As our results demonstrate, most participants read very little of the information 
available to them.  When considering what the PIS might look like, the 
information participants are likely to want to know, and, therefore, is likely to 
influence their decision-making, was included first.  The PIS begins by informing 
participants that they are being invited to participate in research.  Participants 
are then made aware that reading the information provided is important and that 
they should ask the researchers if they have any questions.  The rationale here 
is to encourage participants to read all of the PIS and to inform them that more 
information is available if they want it.  Following this is the information that we 
hypothesised that participants want to know.   
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Finally, the information required by international guidelines was added.  This 
information may not be decisive to participant’s decision-making since it was not 
accessed in the Information Provision study.  Accordingly, the rationale for 
placing it last was that putting it first may deter potential participants from 
reading on.  
 
The resulting streamlined PIS (Appendix 9.8) was thereby generated for the 
parent study: 
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 Introduction 
◦ Aim of study 
◦ Advice to read 
info 
 Information 
participants wanted 
◦ Expenses 
◦ Risks and 
benefits 
◦ Purpose 
◦ What will 
 ICH required 
◦ Compensatio
n 
◦ Voluntariness 
◦ Confidentialit
y 
◦ Number 
participants 
 Where to access 
more information 
◦ Study website 
◦ Researchers 
◦ Detailed 
paper PIS 
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6.14 FUTURE OF THE STREAMLINED PIS 
 
In order to seek feedback on the study results and resulting streamlined PIS, a 
meeting was arranged with the NRES expert panel on the 13th June 2012.  This 
meeting discussed the results of this PhD, the panels opinions on the use of a 
streamlined PIS for low risk interventional research, and their advice on how to take 
the research further.  The account of this interaction taken from the official, published 
minutes of the meeting can be found in Appendix 9.9.   
 
The NRES expert panel exists to “help with the strategy, quality assurance and 
service development of RECs and improve the research environment in the UK”203.  
The panel is made up of the NRES Ethics Advisor, Dr. Hugh Davies, 12 other 
members with expertise in different areas of research and a secretary, Clive Collet.  
As quoted from the NRES website204, members of the panel present and areas of 
expertise at the time of the meeting included: 
 The chair, Professor Andrew George, who has extensive experience of clinical 
research and holds a number of key positions, for example being a member of 
the Clinical Trials Expert Advisory Group for the MHRA. 
 Caroline Harrison, who is a Barrister and lecturer with a special interest in 
legal aspects of medical research. 
 Professor Nalin Thakker, who is a Professor and Clinician in the field of 
Dentistry, has been a vice-chair of a REC for 10 years and advises NRES on 
issues of human tissues for research. 
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 Professor John Saunders, who is a Consultant Physician in Abergavenny, 
chairman of the Committee for Ethical Issues in Medicine at the Royal College 
of Physicians, and has been a member of RECs for 20 years. 
 Dr. Richard Tiner, who is a GP and President-Elect of the Faculty of 
Pharmaceutical Medicine and has a strong interest in clinical research. 
 Dr. Arthur Tucker, who is a clinical embryologist and Senior Lecturer in Clinical 
Pharmacology, with a special interest in research regulation and who is 
currently the chair of a REC. 
 Dr. Frank Wells, who has held many key positions including Medical Director 
of the Association of the British Pharmaceutical Industry (ABPI). 
 Dr. Simon Woods, who is a Senior Lecturer at PEALS, Newcastle University 
and is involved in teaching and public engagement of ethical and social 
implications of the life sciences and  who has a special interest in the ethical 
and social implications of research. 
 
Dr. Hugh Davies, the NRES ethics advisor, is leading a group to revise NRES 
guidance for writing a PIS.  One of this group’s principles is to take into account 
results of recent empirical research regarding information provision, such as that 
undertaken for this PhD, with an aim to improving the guidance provided.   
 
There were a few key discussion points relating to this thesis that came from the 
meeting, which are presented below and picked up for further discussion in the next 
chapter.   
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The use of summary PIS 
Providing a summary of the PIS is something panel members in their REC roles 
frequently advise researchers to do, especially as a coversheet for complex studies.  
We commented that it would be useful for summary PISs to be advised throughout all 
REC’s for all studies.  The panel also compared the streamlined PIS to a recruitment 
document such as a poster or invitation letter, provided in addition to an existing 
lengthier PIS. 
 
Distinguishing between what participants want and ought to know 
There was a discussion of whether what potential participants want to know may be 
different from what they ought to know.  The streamlined PIS was designed to take 
this into account, since it included both the information that participants had 
accessed and the information that ICH guidelines require.  The ICH and related 
statutory instrument only list the topics required and not the level of detail and this 
proved something of a sticking point. The panel seemed to think that on balance, 
there was some information that participants must be given, even if they appeared 
not to want it, though there was not sufficient time to pin down the precise content for 
each at this meeting. One suggestion offered by Dr Calvert was that REC’s could 
provide researchers with a list of important things that participants ought to know.  
Patient groups, researchers and the NRES expert panel were considered as other 
‘experts’ that may make decisions on the level of detail to be included. 
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The PIS is a legal document 
The NRES panel agreed that the PIS as a legal document, provided to potential 
participants protect researchers.  They were concerned that scaling down the PIS 
information would diminish the legal protection it affords to researchers.   
 
The PIS is a reference document 
The panel reiterated that people have to have something to refer back to, and in 
research, this is the PIS. They made a comparison to reading the Patient Information 
Leaflet (PIL) in drug packets where people do not read the information until they have 
a side effect, for example, and then refer back to the PIL for advice.  In the 
Information Provision study no one logged back onto the study website at a later date 
to refer to the information, but this was a low intervention study with no expected 
adverse effects. 
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Consent interviews 
If the PIS is not read by potential participants, the consent interview was considered 
as an alternative platform on which to inform participants.  There was a discussion of 
how the process of informing potential participants could be implemented if 
information provision was to fall more heavily on the verbal consent interviews.  
Suggestions were for consent interview scripts to be written and approved by REC’s 
with researchers testing understanding of the information, rather than just providing 
the information. But again, this seemed to be preferred as an adjunct to rather than 
replacement for the traditional PIS.   
 
The guidelines for information provision suggest that participants should be given 
sufficient time to consider the information, which is generally taken by researchers to 
mean 24 hours17-19.  If consent interviews are used to impart information then 
participants may not be given sufficient time to make a considered decision.  This 
concern was discussed by the panel and they were happy this should not prevent 
participants from taking part if they do not wish to consider verbal information for 
longer.  There was not sufficient time for the panel to consider what sufficient time for 
consideration would mean if all the weight fell on the consent interview.  If 
participants are presented with the information for the first time at the consent 
interview and not given any time to consider the information, it has implications for 
guidelines that says participants should have ‘sufficient’ time to consider the 
information. 
 
 239 
 
Taking the research further 
There was concern that electronic PIS would not suit all studies, especially those 
involving the elderly, who are the least likely to have access to a study website. 
 
The panel were confident that similar research to the Information Provision study 
would be given favourable opinion by a REC, provided there were certain safeguards 
in place, for example, providing the standard lengthy PIS at some point during the 
study so that participants do have the PIS for future reference purposes.   
 
Summary 
In summary, the panel were interested in the work and broadly supportive of taking it 
further.  They may be happy for PIS to be streamlined for low risk studies such as the 
parent study used in this PhD but were keen for this streamlined PIS to be used in 
addition to a full PIS, although the panel were not unanimous about this.   
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7 DISCUSSION – THE FUTURE OF INFORMATION 
PROVISION IN RESEARCH  
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The discussion to this thesis is split into three.  The first section considers whether 
using electronic PIS would be feasible in research and looks at the practicalities of 
providing information electronically.  The second section considers the ethical 
concerns of information provision in light of the results of the studies conducted for 
this PhD.  The final section explores the future of information provision in research 
and considers ways this research could be taken further. 
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7.1 THE FEASIBILITY OF ELECTRONIC INFORMATION PROVISION 
 
Internet access 
When considering the feasibility of electronic methods of communication, future use 
depends on the proportion of potential participants willing and able to use the 
Internet.  One aim of the Information Provision study was to determine the proportion 
of potential participants that had Internet access and were willing to access study 
information online.  If participants provided an email address it was assumed they 
had Internet access and were willing to access study information electronically.   
 
The proportion of participants that provided an email address in this study was lower 
(290/1160; 25%) and the average age higher (mean age 57 years) than the general 
population (80% of households in the UK have an Internet connection101-103; average 
age 40205).  When the participants who provided an email address were broken down 
into age groups (Table 14), younger participants were more likely to provide an email 
address (45-55=174/508 [34.3%]; 55-65=69/303 [22.8%]; 65+=47/350 [13.4%]).  
Since it is known that younger people are much more likely to use the Internet for 
everyday tasks102;206-210, it can be anticipated that a much higher proportion would 
provide an email address as a method of communication if invited to participate in 
research.  Antoniou et al6 used the IIS successfully in a study with younger 
participants (20-50 years) and previous research has also shown that the frequency 
of Internet use and the types of Internet activity engaged in may also increase as 
number of years of Internet use increases210.   As today’s younger generation 
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become tomorrow’s older generation, the proportion of research participants willing to 
access study information electronically is likely to increase211.     
 
The participants of this study had a higher deprivation level (median IMD score 37.8) 
than the general population (average IMD score 19.0212).   The level of deprivation of 
participants also adversely affects whether they have Internet access208, since having 
access to the Internet requires both an Internet connection (or access to a free 
Internet connection) and a device to connect to it with.  Mobile phones and 
Smartphones, which are likened to a hand-held computers, provide a more cost-
effective method to access the Internet213.  As their popularity has increased over 
recent years, the link between deprivation and Internet access has lessened214.  It 
may be that in time, access to the Internet does become as common and accessible 
as the telephone, and even the more deprived areas will have Internet access213.   
 
The Information Provision study showed that White participants were the most likely 
(172/639; 27.0%) and South Asian the least likely (43/218; 19.7%) to provide an 
email address, and previous research has shown that Internet users are 
predominantly White210.  Whilst not a demographic collected in the Information 
Provision study, previous research has also found level of education to be strongly 
correlated with Internet use208;210;211.  
 
Electronic communication is commonly used in other aspects of life215;216 and there 
are already a large proportion of the population that use the Internet to do everyday 
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tasks, such as banking, that would previously have been done either in person or 
over the telephone215.  It is expected that people of the future will generally conduct 
relationships electronically as the Internet becomes more accessible.  The most 
prevalent and convenient communications methods need to be reflected in research 
if we are to continue to encourage people to participate in research.  According to 
2012 ONS data102, 80% of households currently have Internet access and this has 
been rising steadily for the past 8 years.  Figure 18 shows that based on a linear 
forecast of this rise, it is expected that all households will have Internet access by 
2018.  As more households are able to access the Internet, research using the 
Internet is likely to become more generalisable to the UK population. 
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Figure 18 – Household Internet access with linear future predictions, adapted 
from ONS data102 
 
 
 
Although only 25% of participants in the Information Provision study provided an 
email address, around half of those who did provide an email address said they 
would prefer to have information provided electronically if they took part in research 
again.  This suggests that electronic information provision methodology could be 
readily developed in populations where the proportion of participants willing to use 
the Internet for communication is likely to be higher, for example in studies that 
recruit mostly younger people in less deprived areas. 
 
y = 0.0156x + 0.1611 
R² = 0.198 
Proportion of households
with Internet Access
Linear (Proportion of
households with Internet
Access)
Year 
Percent 
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Problems contacting potential participants electronically 
Two problems were encountered during the study that meant additional work was 
needed to maximise recruitment to the Information Provision study.  These problems 
were: 1) incorrect email addresses provided and 2) ensuring emails were delivered to 
the inbox rather than the ‘spam’ box and read by the recipient.  
 
Inaccurate email addresses were provided by 37 (N=290, 12.8%) potential 
participants and these then had to be rectified with a telephone call, which increased 
the number of potential participants eligible for the study (23/37; 62.1% addresses 
were rectified). This added costs to the study that would need to be taken into 
account in studies using electronic recruitment.   
 
The second problem encountered with contacting potential participants electronically 
was ensuring that the invitation emails were not filtered into ‘spam’ boxes. The initial 
response rate to the email was much lower than the response rate to the paper 
invitation, which suggested that emails were either not being received or not being 
read. Although a read receipt was requested, these are not automatically issued 
when an email is opened and recipients were free to choose not to send one, and not 
all email servers allow read receipts to be sent.  Emails could only be identified as 
having been opened if a read receipt was returned, the participant had logged into 
the study website using their unique username, or they had booked a consent 
appointment. To ensure that potential participants were aware that they had been 
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sent an invitation by email, we telephoned them if they had not responded within 
three days of the email being sent.  
 
Around half of the potential participants (146/290; 50.3%) did not respond to the 
email within three days and attempts were made to contact all by telephone.  If they 
could not be contacted or did not respond to the email within seven days of it being 
sent they were sent a postal invitation.  In the parent study, potential participants 
were given two weeks to respond to the letter of invitation before a reminder was 
sent out.  The shorter time frame for the Information Provision study was a condition 
of embedding into the parent study, as this time frame permitted a postal invitation to 
be issued in timely fashion so that recruitment was not adversely affected, even 
though it was not unreasonable for participants to have taken longer than three days 
to reply.  Contacting participants via telephone increased the number of participants 
available to participate in the IIS RCT component of the Information Provision study.  
It is difficult to know, however, whether making the phone call itself increased the 
chance that they would take part, or whether participants would have accessed their 
emails eventually if given two weeks to respond and a further reminder.  Further 
research is required to determine how comparatively reliable electronic 
communication methods are and how reliability can be improved.  
 
Methods that are already used to maximise recruitment from postal invitations may 
be adapted to assist with electronic recruitment in the future.  One such is to send out 
invitation letters from their GP surgery or hospital clinic, which encourages more 
 248 
 
reliable responses and negates the need to further contact217;218. This also ensures 
data protection as if the surgeries/clinics send out the letters the researchers are not 
given access to personal information without consent219.  Once GP surgeries and 
hospitals routinely use email to communicate with patients, not only will accurate 
email addresses be routinely collected by them, but hospital/GP email addresses are 
likely to be on patients’ email ‘safe’ list so emails are not filtered into junk boxes. At 
this point, the practice of sending invitations from GPs surgeries and clinics will be 
readily adaptable to electronic research recruitment. This would combine all of the 
advantages of electronic communication with that of invitations sent from 
collaborators known to the potential participant.  
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Effect on consent rate 
One of the aims of the study was to determine if using an IIS could improve consent 
rates to research when compared to a PDF-PIS.  We found that it did not improve 
consent rates and actually decreased consent rates slightly, although not statistically 
significantly (PDF=20/44 [47.6%; IIS=16/44 [36.4%]; OR 0.6 [95% CL 0.25; 1.4]).  
The IIS RCT did not meet its target sample size and it emerged that the effect size 
used in sample size calculations was overly optimistic.  The method used to 
determine the effect size179  (set out and justified in Section 4.5) were hampered by 
the fact that no previous effect size was available.  Future studies, however, could 
calculate a sample size using the 13.2% effect size seen in the Information Provision 
study.  Given that the study was not powered to detect the effect size seen, no 
confident conclusions can be drawn from this study about the effect of using an IIS 
on consent rate. 
 
When exploratory analyses were conducted between electronic and postal 
communication groups as a whole, electronic communication appeared to increase 
consent rate, although not statistically significantly (electronic=99/290 [34.1%]; 
postal=271/870 [31.1%]; p=0.3).  Participants in this study were also not randomised 
to electronic or postal information provision and those with email addresses may be 
more likely to participate in research because of systematic differences to those 
without an email address. This finding could, however, be used a hypothesis for a 
future equivalence study to determine the effect of electronic recruitment on consent 
rate.   
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Effect on understanding 
As was discussed in Section 2.3, it is difficult to determine research participants’ 
understanding of information provided at the time of recruitment since there are no 
standardised methods to measure understanding, and such methods tend to 
measure recall rather than understanding58.  The understanding questionnaire was 
based on the best current tool for assessing understanding, the Quality of Informed 
Consent Tool1.  It is likely, therefore, that this study also measured recall rather than 
understanding, and this remains a limitation to comments on understanding in this 
research.  
 
The level of understanding was shown to be consistent across all study groups and 
there was no difference seen in understanding between participants that received 
electronic and those that received paper information.  Interestingly, though, the level 
of understanding was similar in all groups including those that chose to access no 
information.  There are several potential reasons for this.   
 
First, some of the information participants were asked about was also contained in 
the invitation letter; for instance, that they were being invited to participate in a 
research study.  To have booked an appointment, the participants must have read at 
least some of the invitation letter even if they did not read the PIS, and this was the 
source of their knowledge. Accordingly, it is also possible that designing the invitation 
letter along the lines of the suggested streamlined PIS might be an effective means 
 251 
 
of ensuring that the basic study information is communicated to participants 
effectively. The ethics of proceeding to recruitment on the basis of limited 
information, and what the minimum information required might be, are discussed in 
the next sections.  
 
Second, the understanding questionnaire included generic questions about research, 
in addition to questions specific to the study in hand.  It is possible that participants 
who understood that they were being asked to participate in health research were 
therefore able to make valid assumptions based on their existing knowledge of 
healthcare and research; for example, they may assume their medical information is 
kept confidential because health care practitioners normally protect confidentiality220.  
If so, it is arguable that it is not necessary to provide information to research 
participants that reflect existing norms.  In the case of confidentiality, for example, 
participants need only be informed when information will not be kept confidential.  
The most incorrectly answered question on the questionnaire related to why they had 
been chosen to participate: the participants assumed it was because they had high 
blood pressure.  This was not the case and may be the reason why the parent study 
initially recruited more hypertensive than normotensive participants5.  This again 
suggests that it is information that is contrary to what invitees might reasonably 
expect that needs to be emphasised in the invitation letter, because participants may 
make assumptions in place of reading the PIS.   
                                            
5
 The difficulties in recruiting normotensive participants were discussed during investigator meetings 
for the parent study. 
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Third, it is possible that the questionnaire was too simple and participants were able 
to take an educated guess at the answers by deduction or they selected the right 
answer by chance, since the questionnaire provided multiple choice answers.  The 
questions reflected the information that statutory instruments require all research 
participants to be given.  This suggests that even if the questions were too simple 
and generic to research rather than specific to the study, participants already had an 
adequate understanding of what being asked to participate in research means.  If so, 
this is a further reason to suppose that generic information need not be included in a 
PIS, since our results suggest that reading the PIS did not improve understanding in 
the areas tested.  The Information Provision study, however, used a low risk 
interventional study as the parent study and it may be that more information is 
needed for high risk studies22. 
  
Effect on satisfaction 
Level of information provided 
Participants provided with an IIS were generally happy with the level of information 
they received, whether they received a small or large amount.  This goes some way 
to showing that even though participants may have only accessed a small amount of 
information, it was enough to satisfy their own informational requirements.  It also 
suggests that different potential participants do need different amounts and types of 
information about a study before they consent to participate. 
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The advantage of using an IIS is that participants can choose the type and level of 
detail of information they access.  More information can be included in the IIS than is 
possible with a paper PIS, and it is easier for the user to pick out the specific pieces 
of information that interest them.  If participants are able to access information more 
easily, it may be possible that they are more likely to read the information they are 
actually interested in.  They may be deterred from accessing any information if they 
have to skim through a lengthy PIS to find the information they require for their 
decision making.  
 
The detailed information provided in the IIS can be chosen by clinicians/researchers 
on the basis of their expert assessment of the existing evidence.  This decreases the 
risk that participants who do want more information will research the topic 
themselves221;222 and, in the process, access unreliable information223;224. 
 
With a paper PIS participants are able to skim through all of the information and then 
pick out what is important.  With an IIS they have to click on a specific topic of 
information to read and may miss information that is important to their own decision-
making because they chose not to click on that topic of information.  If a lengthy PIS 
was provided, however, they may have picked out additional information by skim 
reading the whole document that they would not have accessed (in the IIS) based on 
title alone.  It is not known whether participants who received the paper PIS did skim 
the information provided, and they may have not read it at all.    It would be useful to 
explore the information-seeking behaviours of potential research participants to 
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determine exactly what they do when they receive a paper PIS.  Research in this 
area may be difficult to conduct, however, since we know from this study and that of 
Antoniou et al6 that what participants say they do when asked may not reflect what 
they actually do.  Since it is generally held that hypothetical opinions may not reflect 
real opinions170-172, asking potential participants to indicate what information they 
would access may also not reflect what they actually do.  It may not, therefore, be 
sufficient to ask potential participants what they read, or what they want to read, and 
future research may achieve better results from observational techniques.   
 
Method of communication 
The majority of those who provided an email address said they would like to receive 
information electronically if they took part again.  This may be because they found 
electronic communication more convenient than postal communication.  In this case, 
electronic communication may have improved their research experience.  They may 
also prefer electronic communication for other reasons; for example, a participant 
may find it less convenient to access information electronically if they have to go to 
the library to access it, for example, but they may prefer electronic communication 
because of a desire to reduce paper waste.  Here the participant may prefer to 
receive information without it actually improving their research experience (since it 
was more inconvenient).  
 
Equally, however, those who received postal information tended to prefer to receive 
paper information in the future. There may be no conflict between these two 
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preferences, provided researchers ask potential participants to give their email 
addresses as routinely as they ask them to give other contact details.  It might then 
be safely assumed that participants who do provide an email address may prefer 
electronic communication. Invitation letters and PDF copies of PIS can easily be sent 
electronically, and the majority of participants were satisfied with the way in which 
they received information. This suggests that there are no disadvantages to receiving 
identical information electronically, but there may be advantages, such as not having 
to reply by post, which entails going to a post box.  This is a particular advantage for 
questionnaire-based research since a link to an online questionnaire can be included 
in the email.  Giving participants the option of electronic communication may be a 
relatively easy way to improve their level of satisfaction. 
 
Consideration of cost 
Electronic communication 
In terms of cost, communicating electronically appears cheaper than by post since it 
avoids printing, stationery and postage costs, and there is no need to stuff 
envelopes, mail merge and print letters or send mail, all of which absorb staff 
time112;118;128;129;135;136.  As found in this study, however, having an email delivered 
quickly is no guarantee that it will be read, or responded to, quickly.  This study 
incurred additional costs because of the telephone calls required to prompt 
participants to open and respond to the email invitation.  A further driver of cost was 
the development of the IIS, which will be considered separately in the next section 
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The cost analysis performed on the Information Provision study suggested that it was 
more expensive per participant to send electronic invitations than it was to send 
postal ones (Table 25) primarily because of the additional costs involved in calling 
participants.  Such costs may decrease if email becomes the main mode of written 
communication because potential participants would be more likely to access their 
emails regularly, and email addresses would be routinely collected as a 
communication method.  Participants were only given three days to respond to the 
invitation email before being contacted by telephone, but they were given two weeks 
to respond to the postal invitation letter before being sent a reminder.  Three days is 
a short a timeframe and our participants may not have accessed their emails 
frequently enough to respond this quickly, or may have accessed the email but not 
intended to respond immediately.  If participants had been given longer to respond to 
the email, fewer telephone contacts may have been necessary, and, therefore the 
corresponding costs may have been lower.   
 
Development of the content of the IIS 
It was estimated that it would cost £1173 in researcher’s time (Table 26) to develop 
the content for the IIS, in addition to the time spent writing the ‘standard’ level two 
information.  There would also be costs associated with writing the website to host 
the study information.  These costs would diminish with frequency of use since, once 
written, the system could be readily used for other studies with little or no additional 
cost. 
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It may be difficult for researchers to justify the additional cost to develop an IIS for 
small studies since, based on the costs outlined above, it would cost £11.70 per 
participant for a study with 100 participants.  As the study size increases, however, 
the cost per participant will decrease, i.e. it would only cost 23p per participant for a 
study with 5,000 participants.  The cost of developing the IIS may also be justified if 
there are other reasons for using it, for example, participants are more satisfied if 
they can easily tailor the information to their individual requirements.  The next 
section will explore why an IIS, despite the associated development costs, may be 
justified for use in future research. 
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Key points 
Internet access 
It is likely that email communication will become routine for most people. 
Current communications methods should be used in research – this will 
require a well developed methodology to be established in advance.  
 
Difficulties communicating electronically 
It is not clear whether emails have been received by participants. 
If GP surgeries, for example, use email to communicate with patients, it may 
provide a reliable way to contact potential research participants electronically. 
 
Consent rate 
The effect size reported in the IIS RCT could be useful in similar future 
research. 
Results suggest there may be no difference in consent rate between postal 
and electronic communication. 
 
Understanding 
Communication method and amount of information did not affect 
understanding.  This may be because participants:  
 Gathered information from the invitation letter. 
 Applied common sense to respond to questions. 
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 Correctly guessed answers because the questions allowed educated 
guesses based on deduction or shear guesses because of the multiple 
choice answer format. 
 
Satisfaction 
Making detailed information available to participants who want it allows 
accurate information to be provided, rather than further information be sourced 
by participants.  
Future research on the informational requirements of research participants 
should rely on observational methods. 
Providing a choice of communication method may improve satisfaction. 
 
Consideration of cost 
Additional costs of electronic communication may decrease as emails become 
the main source of written communication.  
The IIS was expensive to develop in terms of additional researcher’s time, but 
the cost may be justified if there are other reasons for using it. 
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7.2  INFLUENCES ON THE PARTICIPATION DECISION 
 
Previous studies have shown that when asked directly, potential research 
participants will often say they want more information regardless of how much they 
have already received6;26;225-230.  In this study the IIS allowed the amount of 
information actively accessed by potential participants to be recorded when they 
were deciding whether to participate in a low risk interventional study. The integration 
of the technology in this study enabled us to show that when given the option to 
access more information than was provided in the paper PIS, the majority chose to 
read very little of the information available.  Even more surprisingly, perhaps, are the 
59% that booked a study appointment despite accessing no study PIS at all because 
they chose not to click the link to access it, and the 40.9% that were randomised to 
IIS but still chose not to access any information. These results reflect those of 
Antoniou et al6 who, for a questionnaire study, found that 88% of potential 
participants agreed to participate without reading the level of information pegged at 
the level of the standard PIS and between 28% and 30% chose not to access any 
information.  These two studies are, as far as we know, the first to record the amount 
of information actively accessed by potential study participants.   
 
It can reasonably be assumed that in the Information Provision study, participation 
decisions were based on something other than the information provided in the PIS, 
since the information was often not read.  This section seeks to explore how 
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participant’s decisions might have been made, if not based on the information 
provided.   
 
Using common knowledge 
Previously in this chapter, it was hypothesised that participants may have a ‘common 
knowledge’ about research and research practices that does not need to be repeated 
in a PIS.   One way to reduce the length of future PISs without compromising 
participant understanding may be to only include information contrary to the norm. 
Extra care may need to be taken when a study deviates from the norm, to ensure 
that participants really do understand what they are consenting to.  It may also be 
useful to have a central point of information that states what the norms of research 
are, so potential participants are able to check their knowledge. 
 
Preferred communication  
In order to measure the effect of the PIS on consent, this study took the decision to 
book a consent interview, rather than actual consent at interview, as the outcome 
against which to measure the consent rate.  The aim of the Information Provision 
study was to determine the effect of written (rather than verbal) information on 
participation decision.  Using the decision to book a consent interview as the 
measure of consent discounted the impact of information provided during the consent 
interview on actual consent rates.  
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Kreiger et al231 found that participants may be more likely to participate in research if 
they are able to establish a rapport between themselves and researchers and results 
from Townsend et al119 suggest that electronic communication may be an effective 
way to establish that rapport, since 76% (29/38) of participants used email as the 
main form of communication with researchers.  Townsend et al119 also used a found 
there to be a high level of communication between researchers and potential 
participants concerning aspects of recruitment and consent before the consent 
decision was made.  Taken together with results from Townsend and Kreiger, the 
results reported in the Information Provision study may suggest that participants did 
not access information in the PIS because they preferred to communicate directly 
with researchers.  Participants may have contacted researchers to discuss the study 
and only after this discussion decided to book a consent interview.  If participants do 
use information communicated verbal and/or via email to make participation 
decisions, inviting participants to communicate with researchers prior to booking a 
consent interview, for example, may be one way to inform study participants.  Study 
invitations usually include a contact number for researchers22, so it may be that 
proactive communication from the researchers is key to providing verbal information 
before the consent interview.  This would be another way of tailoring information to 
individual requirements, but would be labour intensive and, therefore, costly.   
 
Most evidence of preference for method of information delivery is limited to patients 
rather than potential research participants66;67;232-234.  As outlined in Section 2.2, in 
the routine clinical setting, the decision of how much information to provide to 
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patients is left with the treating physician2;37, whilst information provision in research 
has to meet requirements of statutory instruments for GCP22;26;35;42-45.  Guidelines for 
information provision are different for patients in routine care and research 
participants, but the reasons for providing the information remain the same – 
information allows patients and potential participants to make an informed and 
voluntary decision regarding participation.  Since the reasons for information 
provision are the same, it may be that research concerning information provision 
preferences will apply to both patients and potential research participants alike.  Prior 
evidence suggests that verbal communication is well received by patients and that 
discussion with research staff can improve understanding of study information66;234.  
Recent studies have also shown a mix of verbal and written communication to be 
preferred67;232;233, and so the consent interview may be important in providing verbal 
information to potential participants and satisfying informational requirements.  If this 
is the case, in addition to written information, verbal communication needs to be 
offered to potential participants, in order to inform them about the study.  If potential 
participants do prefer a mix of written and verbal communication, the results of the 
Information Provision study suggest that they may only want basic written 
information, with further information provided verbally. 
 
In addition to individual potential participants wanting different levels of written 
information, then, they may also want that information communicated in different 
ways.  In order to further tailor information provision to individual participants, they 
could be provided with access to both verbal and written communication.  An IIS that 
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incorporates a streamlined PIS could be provided to potential participants first, to 
attempt to tailor information to the individual and reduce the number of potential 
participants likely to want the information delivered verbally.  In addition to written 
information, an offer of contacting researchers may satisfy participants who want a 
mix of communication types, or who prefer only verbal information provision.  
Challenges with providing verbal information include ensuring the consistency of 
verbal information and ensuring information is provided sufficiently to provide legal 
protection to researchers.  These issues are considered in later sections. 
 
Length of PIS 
Smith et al233 randomised patients to a summarised participant information leaflet 
(PIL) and verbal information about a treatment, compared to verbal information 
alone.  90% of participants across both groups preferred to receive both written and 
verbal communication and providing a summarised PIL improved recall of risks.  
Since it is difficult to distinguish between a measure of recall and that of 
understanding (Section 2.3), it may be that providing a summarised PIL also 
improved understanding in Smith et al’s study.    The information in their summarised 
PIL contained the same information as provided verbally and comprised a summary 
of practical details of the treatment such as the diagnosis, proposed treatment, 
possible risks, postoperative care and rehabilitation.  This equates to the types of 
practical information that participants in the Information Provision study wanted to 
know.  If study information summarised only the practical information that potential 
participants wanted to know, as in the study by Smith et al, participants may use that 
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summary to aid their decision making66.  This summary information could be provided 
as a streamlined PIS rather than a standard (often lengthy) PIS, with the same 
information provided verbally at the consent interview.  An IIS could also be provided 
as a back-up for those who do need to access more information to satisfy their 
informational requirements. 
 
Participants may not have wanted to know the information 
The lines of discussion so far have focussed on other ways participants may have 
accessed information, either by using their common sense to make assumptions or 
by extracting the information from verbal discussion with researchers.  It may be, of 
course, that participants did not access very much information because they did not 
want or need to know the information to make a participation decision.  If this is the 
case, then there must be other factors influencing their decision-making.  Three 
possibilities to consider are: altruism, trust and external influences unrelated to the 
study. 
 
Participants often take part in medical research for altruistic reasons235-237 and it is 
healthy patients, such as the ones in this study, who are more likely to suggest that 
they are altruistically motivated238.  It is not surprising that healthy patients are the 
most likely to be motivated altruistically, since participation is unlikely to be of benefit 
in terms of their health.  There may, however, be limits to their willingness to help 
others, and the extent of risks and inconveniences of participating may be a 
consideration when making a participation decision.  In addition to this, they may also 
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consider the extent to which the research is likely to help the wider community.  If 
participants were taking part purely for altruistic reasons, this may help to explain why 
certain topics were accessed more often.  Information accessed most frequently 
concerned expenses, what would happen if they took part, the risks of taking part 
and the purpose of the study.  These topics of information may have helped 
participants weigh up the costs and inconveniences of taking part against the 
benefits of the study to the wider community, to decide if they did want to make an 
altruistic participation decision. 
 
Another influence on the potential participant’s participation decision may be that of 
trust in the person inviting them.  The invitation for the first phase of the parent study 
(the questionnaire-based phase) was from a University researcher.  The invitation, 
however, came via the potential participants’ GP surgery rather than directly from the 
University.  This may have meant that the potential participant believed their GP, 
rather than a University researcher, was inviting them to take part.  This is common 
practice in primary care research, both for data protection purposes and as a way to 
improve recruitment.  There are data protection issues surrounding accessing 
patient’s names and addresses unless they have consented for researchers see that 
information219, and so one common way around this is to send the invitation directly 
from the GP surgery and ask potential participants to return their contact details to 
researchers, as happened in the parent study239.   
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Patients can often trust doctor’s opinions explicitly240-244, and sending an invitation as 
if from a patients GP plays on that trust, in order to improve recruitment rates.  
Kraetschmer et al240 found a strong correlation between the level of trust a patient 
had in their doctor and their desired level of participation in decision-making.  The 
higher the level of trust the patient had in their doctor, the less likely they were to 
want to be involved in decision-making (between 81.1% and 97.3% [depending on 
the type of decision] with very high levels of trust wanted their doctor to make the 
treatment decision).  As the level of trust in their doctor decreased, patients were 
more likely to want to share the decision-making role or make the decision for 
themselves (between 14.8% and 26.4% with low levels of trust wanted their doctor to 
make the treatment decision).  In addition to the results found by Kraetshmer et al, 
the Information Provision study also found potential participants accessed very little 
information.  This relation of trust to the level of information accessed was consistent 
with views expressed at the NRES expert panel meeting, where one member quoted 
(Appendix 9.9):  
“He felt that patients in this country particularly are still very trusting of 
their healthcare professionals........this culture of trust was still very 
important factor in a patient’s decision to take part or not in research as 
they will tend to trust an invitation coming from their doctor or other 
healthcare professional.”  
 
Manson and O’Neill’s15 thoughts are useful when defining trust in the doctor-patient 
relationship.  Since patients have a limit to their capabilities in terms of their medical 
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knowledge, they rely on their doctor’s knowledge and expertise to provide information 
on their medical condition and appropriate treatments.  Having trust in another 
means relying on what they say.  One may also make a judgment of trustworthiness 
of a person based on previous episodes of trust.  If a patient has previously been 
able to rely on what their doctor has told them they are more likely to trust that they 
can rely on what they say in the future.  Over time, this builds a relationship of trust 
between doctors and their patients, and patients come to the conclusion that their 
doctor is trustworthy.  If participants of the parent study believed that the invitation 
was from their GP, they may have believed their GP would not invite them to 
participate in something that was not safe or of no benefit to them; evidence of their 
trust in their doctor.  If the potential participant believed the study to be safe and 
appropriate for them to participate in, they may have neglected to read the 
information provided.   
 
In clinical trials, the first study discussion about participation is often between a 
doctor and patient in clinic39-41.  In this situation, the doctor could meet all of the 
consent criteria by telling the participant about the study and ensuring they 
understood the information, but the participant could still disregard everything they 
have been told and continue to base their decision on trust in their doctor’s 
judgement and the belief that the doctor would protect their best interests by, for 
example, not exposing them to unnecessary harm.  Patients often do not want to 
make an independent decision regarding their treatment, and actually want to share 
the decision-making with their doctor242.  Salkeld et al243 found, however, that even 
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when patients expressed that they preferred a less active role in decision-making, the 
information provided by their doctor still had an impact on their decision-making.  
This means that if information provision preferences are consistent between patients 
and potential research participants, any study information provided may still influence 
decision-making for potential participants, even for those that usually prefer the 
doctor to make decisions for them. 
 
There may be other factors, completely unrelated to any medical situation, which 
influence a decision to take part in the research245;246.  Cohen245, describes four 
thought experiments where patients used something other than the information in 
hand on which to base their decision.  He refers to these cases as ‘Gettier’ type 
cases. One example245 is of a patient who had understood all of the information 
about a treatment and decided against it.  She then had a dream that resulted in a 
belief that the doctor was her ‘god sent saviour’ and later agreed to the treatment on 
the basis of that dream.  If this situation is applied to research settings, the 
participants would have been given all of the information, understood that information 
and been capable of making a participation decision, but based their decision on 
something entirely unrelated.  Or, the participant could have chosen not to even read 
any of the information provided because they had already made the decision to 
participate based on the external influence alone. 
 
The question Cohen raises is whether providing information and giving free consent 
are dependant or independent.  The current informed consent model suggests 
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dependency, since the term ‘informed’ would not be used if information did not play a 
causal role in the consent decision.  In practice, this dependence would be 
impossible to ensure, since ulterior motives for consent could never be ruled out.  
The current consent model uses autonomous deliberation of the information provided 
as the grounds for free consent to be given12-14.  If the provision of information and 
giving free consent were to be acknowledged as independent from each other, there 
would need to be a revised consent model that took this into account.  This revised 
consent model would still allow potential participants the option of autonomous 
deliberation when making a consent decision, i.e. the potential participant is able to 
use the information provided to make a consent decision.  It would, however, also 
respect an idea of free choice of whether the potential participant acts autonomously 
or not, i.e. it would allow potential participants to choose to make a participation 
decision based on something other than study information. 
 
 271 
 
Key points 
Participants may use their common knowledge to assume things about 
research.  If this is the case, care must be taken to ensure participants are 
informed when a research protocol deviates from normal expectation. 
 
Participants may prefer a mix of verbal and written communication.  Potential 
participants may prefer a summarised PIS with additional verbal information. 
 
Participants may not have been interested in study information at all and 
based their decision on an influence other than the information provided.  An 
altruistic desire to participate, trust in their GP, or another influence completely 
unrelated to the research may explain why little information was accessed.  
The current consent model may need to be revised in order for these 
influences to conform to meet consent requirements.  
 272 
 
7.3 CONSENT WHEN PARTICIPANTS CHOOSE TO READ LITTLE INFORMATION 
 
For consent to be valid it has to fulfil three criteria: 1) the participant is given specific 
detailed information about the study; 2) the participant is capable of understanding 
the information provided and using it to make a decision regarding participation; 3) 
the decision is made voluntarily2;3;15;16.  In the previous section it was suggested that 
when potential participants read little or no study information, they base their 
participation decision on common knowledge, preferred other forms of 
communication, were deterred by the length of the PIS or based their decision on an 
influence other than the information provided, such as an altruistic desire to take part, 
trust in their doctor, or an alternative external influence unrelated to the study.  In all 
of these suggestions, criterion one for consent was met since all participants were 
given access to detailed study information (the IIS), even though they often chose not 
to read it. Criterion three was also met since, although the decision may have been 
based on something other than the information in hand, all decisions were voluntary.    
The uncertainty lies in whether criterion two was met by participants.  All study 
participants were deemed competent by their GP to understand the information 
provided and use it to make a decision regarding participation, but they often did not 
use the information provided to make the decision.  The criterion states that 
participants should have the capacity to use the information to make the decision.  
The problem, however, is that the formulation infers the information provided should 
be used to make the decision.  This is a different issue to that of capacity, since a 
participant can have the capacity to use the information to make a decision without 
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basing their decision on that information, and a participant can have the capacity to 
understand the information but still choose not to read it.  This section considers 
whether valid consent can be given if a participant chooses not to access all of the 
information provided. 
 
It was suggested in the previous section that participants may not read study 
information because they used their common sense to assume things about the 
research based on information provided in the invitation letter.  In a sense, 
participants were using information about the study to make a decision, although this 
was assumed rather than given knowledge.  It is reasonable for participants to make 
assumptions about research, assuming these beliefs match the facts, i.e. they 
believe their information is going to be kept confidential, and it is.  A problem arises 
when their beliefs do not match facts about the study, i.e. their information is not 
going to be kept confidential but they assume it will be.  In this situation, the 
participant may have decided not to participate if they had known that their medical 
information was not going to be kept confidential, but they would not know this to be 
the case unless they read or were told that information.  It is in this situation that their 
consent may not be valid; not because they lack capacity, but because they lack the 
relevant information.  In order for their consent to be valid, then, their 
misunderstanding would need to be corrected.  One way to do this would be to make 
it explicit to potential participants when protocols deviate from the norm, although 
doing this assumes that everyone has the same norm.  Since participants may not 
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read the PIS, this information would need to be imparted in some other way, for 
example, verbally during the consent interview.  
 
Participants may not have read the PIS because they obtained the information they 
needed from research staff instead.  If so, the participants used the verbal 
information to make a participation decision.  There may be a concern that where 
verbal information was given at consent interviews, participants were not given 
sufficient time consider the information before giving their consent and may have only 
been given the information they wanted rather than ought to know, or vice versa.  
The NRES expert panel confirmed that there is no requirement to give participants 24 
hours to consider their decision, though this is often the period of time allocated in 
custom and practice17-19.  The validity of the consent would only be affected if 
participants were not given sufficient time to consider the information.  Fulfilling this 
requirement would mean allowing each participant the time they personally needed 
to consider the information before being asked to make a participation decision.  This 
may vary considerably between participants, and for some participants may mean 
they have to come back for a further consent interview at a later date.  The 
implications of this would need to be considered, since it may have resource and cost 
implications and may not be feasible for participants to be offered an additional 
consent interview in all studies. 
 
The final hypothesis as to why potential participants accessed little of the information 
provided was that an influence unrelated to the study affected the decision to 
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participate.  As outlined in the previous section, these types of participation decisions 
do not fit with the current consent model that does not allow a potential participant 
the free choice to make a participation decision based on an influence other than the 
study information.  Providing potential participants with an IIS would provide them 
with a free choice to choose what information they access.  There are difficulties in 
allowing potential participants the free choice of what information to access, since 
even if they chose not to access any study information, there still may be parts of the 
PIS that if read, may have been important to their decision making.  They would not 
know this, however, if they made the decision not to use the information provided to 
inform their decision-making.  There are also adverse legal implications to allowing 
potential participants to enter into research without adequate understanding of the 
information provided5.  As the consent model currently stands, participants that chose 
to access no study information because they made their decision on a completely 
external influence, would not have given their valid consent to participate.   
 
In this study and that by Antoniou et al6, we were in the unique position of knowing 
what information potential participants had accessed.  In the Information Provision 
study 59% of participants booked a study appointment despite accessing no study 
PIS at all because they chose not to click the link to access it, and 40.9% of those 
randomised to the IIS still chose not to access any information.  Antoniou et al found 
that between 28% and 30% of participants chose to take part without accessing any 
information.  These findings should be a concern to other studies, since one of the 
consent criteria is that the participant must be given specific information about the 
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study.  The way in which the information is provided to potential participants should, 
therefore, be a consideration in, and for, future research. 
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Key points 
When research protocol deviates from the norm, participants may use 
incorrect beliefs (using common knowledge) to assume things about research.  
When research deviates from the norm, this should be made explicit to 
potential participants - if they do not read the PIS, this needs to be imparted 
verbally. 
 
Participants may base their decision on information provided at the consent 
interview.  It is not necessary to give potential participants 24 hours to 
consider information provided at the consent interview, but they must be given 
the sufficient time they personally need to consider the information. 
  
If participants use a reason unrelated to the study to make a decision, their 
consent would not be taken in accordance with the current consent model. 
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7.4  AUTONOMY, PATERNALISM AND CONSENT 
 
As outlined in Section 2.1, the requirement for consent prior to research participation 
comes from a respect for autonomy.  When the research community use ‘respect for 
autonomy’ in terms of consent it is generally understood to mean that potential 
participants make a choice based on their own values, for their own reasons and 
should have that choice respected12-14. Providing potential participants with study 
information allows them to decide if participating in the research is consistent with 
their values, interests and preferences and contributes to autonomous decision-
making2;3;14;21-23;247.  Buchanan248 describes paternalism as “interference with a 
person’s liberty of action, where the alleged justification of the interference is that it is 
for the good of the person whose liberty of action is thus restricted” (p.371).  There 
are at least two ways in which paternalism can manifest itself in information provision.  
The first is where the doctor-researcher acts in the patient’s best’s interests to make 
a decision on their behalf.  This takes the decision away from the participant, who is 
no longer able to exercise their autonomy to make the decision.  The second is 
where the doctor-researcher withholds information.  This does not interfere with the 
potential participant’s freedom to make a decision.  It does interfere with their 
autonomy, however, since they are not provided with all of the information pertinent 
to their decision making.   
 
When researchers decide what information to provide this can be described as 
paternalistic since researchers are deciding what potential participants need to know 
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in order to be able to make a decision. Researchers may be described as acting 
paternalistically by making the decision about how much information potential 
participants need to know, since it takes the decision of how much information is 
required away from the potential participant.  They may also be described as acting 
paternalistically if they do not include every aspect of the research in the PIS, since 
this would mean they were withholding information from the potential participant.  
Someone has to decide what information to provide, because the alternative would 
be to provide potential participants with every piece of information relating to the 
study, which may itself hinder decision-making.  Researchers act in the potential 
participants best interests to provide the information they think will have an effect on 
decision-making.  Deciding what information to provide may be paternalistic, but it is 
a justified paternalism since someone has to make a decision of what and how much 
to provide.  It may be, however, that researchers alone are not best placed to make 
the decision of how much information to provide. 
 
It is reasonable to expect that individual potential participants may want different 
levels of study information and that for some this may mean they autonomously 
choose not to receive any study information at all, trusting perhaps in their doctors 
judgement, whilst others want much greater information provision6;25;225;249.  
Helgesson et al250 discuss that the current formulation of consent assumes that if 
participants ask for more information they should get as much detail as they need 
until they are satisfied with what they have been given.  Participants may not be 
given all of the information that researchers decided to leave out, but the paternalism 
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here is weak, since allowing participants to ask further questions concerning the 
research allows them to gather any further information they require for their own 
decision-making.  Weak paternalism is often justified because it has a positive effect 
on the person, in this case, improving the information provision process for the 
potential participant.  
 
What Helgesson et al250 do not consider the current consent model to do, however, is 
to cater for those who wish to access less information, a topic they believe had been 
ignored in the literature.  The results of the Information Provision study showed that a 
large proportion of participants accessed little or no information before deciding to 
participate.  If we accept that different people will want to know different information, 
and for some this may mean not knowing anything, then a different model of consent 
would be required.  A problem with allowing participants to choose to access no or 
little study information is that a potential participant cannot possibly know how much 
or what types of information would be important to their own decision-making until 
they had read that information.  A participant may make an autonomous decision to 
access no information before making a consent decision, but when a researcher 
paternalistically insists she reads it, she may decide she does not want to participate 
on the basis of the information she reads.  In this case, insisting that the potential 
participant reads the information neither affected her freedom to make a consent 
decision, nor did it mislead her by omitting information, but it gave her the information 
she required to make a consent decision.  It follows then, that some acts of weak 
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paternalism can be beneficial to decision making, without restricting the potential 
participants freedom to make an autonomous decision. 
 
Allowing potential participants to access no information about a study would also 
bring about a tension for researchers, since in order to comply with statutory 
instruments for GCP there is a certain amount of information that must be provided to 
potential participants; although guidance is silent concerning what to do if a potential 
participant does not want that information7;42-45;50.  Researchers may also consider 
informing participants to be part of their moral duty, regardless of the law251. 
 
Previous research has suggested that research participants often get better care, 
which may be due to additional tests being carried out and care being monitored in 
order to adhere to strict research protocols192;252-254.  A recent Cochrane review by 
Vist255 et al, however, suggests that the outcomes of research participants are often 
similar, rather than superior, to those of patients receiving similar treatments outside 
of the trial.  It may not be an ethical problem if participants choose not to access any 
study information, if their care is unaffected by participating in research, or if the 
study benefits them in some other way, for example, a new treatment in a clinical trial 
proves to be of benefit.  The concern, however, is that there will always be some 
known and unknown risks that mean participating in research of new therapies may 
lead to harm.  Although potential participants cannot be told about unknown risks 
because they are unknown, they could be told about the potential for unknown risks.  
The knowledge that they are putting themselves at unknown risk may be sufficient to 
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prevent some participants from giving their consent.  Information about risk, including 
the potential for unknown risks, then, is likely to be one topic of information that if 
made mandatory, may affect a potential participant’s participation decision, even if 
they had previously decided they did not need to access any study information.  This 
means that in addition to providing mandatory information to meet statutory 
requirements, there is some information that potential participant’s ought to know 
because it is likely to affect their participation decision. 
 
A final problem with accessing no/little information lies in the different types of 
participants doing this.  One can imagine a participant who understands they are 
being asked to take part in research and wants to take part regardless, so makes a 
decision to access very little information (for one of the motivations outlined in the 
previous sections).  This participant is choosing to access little information for a 
reason based on their own beliefs.  They may, for example, trust researchers to act 
ethically and may only want to know what they would have to do in order to 
participate, to ensure that taking part would not inconvenience them 
substantially256;257.  Imagine a second type of participant, one who does not read the 
information because they do not understand what is being asked of them.  An 
example would be a participant who believed the decision being sought related to 
treatment rather than research and confused the invitation to participate in a clinical 
trial with a recommendation to take a certain treatment.  It is this latter participant 
who is of concern, because they may, after actually reading the PIS, realise the true 
nature of what is being asked and be unwilling to participate.  Mill258 uses the 
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example of a person attempting to cross a dangerous bridge, to argue that it is not 
paternalistic to stop a person from making a decision when they do not have all of the 
necessary information before them.  Preventing him from crossing whilst bringing to 
his attention the danger of doing so would not infringe his autonomy, since he can 
use that information to decide whether he still wishes to cross the bridge.  Although 
he can be prevented from crossing whilst the information is given, he cannot be 
detained if he still decides to cross.  If the dangerous bridge analogy is applied to the 
research setting, it would not be deemed paternalistic or an infringement on 
autonomy to verbally force study information on potential participants who chose not 
to read the PIS.  It would, however, be paternalistic to prevent someone from 
entering a study if they chose not to listen to and demonstrate understanding of that 
information.  
 
It seems then, that there is a requirement for some mandatory information to be 
provided to potential participants in order for them to be able to make an autonomous 
participation decision.   
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Key points 
There are at least two ways in which paternalism can manifest itself in 
information provision - the researcher makes a decision on behalf of a 
potential participant, or withholds information pertinent to their decision 
making. 
 
Weak acts of paternalism may be beneficial in research. A participant may 
make an autonomous decision to access no information before making a 
consent decision, but when a researcher paternalistically insists she reads it, 
she may decide she does not want to participate on the basis of the 
information she reads.  
 
In order to comply with statutory instruments for GCP, potential participants 
must be provided with a certain amount of information. 
 
Bringing important information to the attention of potential participants does 
not impact on their autonomy since they can still use that information to decide 
whether they want to take part.  Preventing them from participating in the 
study because they chose not to listen and demonstrate understanding of that 
information would be paternalistic.  
 
There is a requirement for some mandatory information to be provided to 
potential participants in order for them to make a participation decision. 
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7.5 MANDATORY INFORMATION 
 
There is a risk that when researchers (and RECs) exercise their judgement on how 
much and what information to include in a PIS, some participants will not have 
enough information to make an autonomous decision and some will consider it too 
much information.  The problem with standardised information is that it is impossible 
to know which piece of information is decisive, and therefore significant, for any given 
individual.  Just as it is reasonable to expect that different people will want different 
amounts of information25, it is reasonable to expect that different people will give 
differing significance to the same piece of information in their decision-making.  
Previous research has also shown that researchers and potential participants have 
different opinions on what information is important to potential participants70;259;260.  
What we can do, is to conduct research, such as that done for this PhD, that enables 
us to produce a best guess of what the average potential participant regards as 
important when producing standard information sheets. 
 
The consensus from the NRES expert panel was that PIS’s are not only to provide 
information for consent purposes but also legal documents that protect researchers.  
General Medical Council (GMC) guidance2 concerning consent to research also 
states that potential participants should be given the fullest possible information, and 
this is echoed in common law261.  Providing a lengthy PIS, then, provides legal 
protection for researchers since it allows full information to be provided.  The NRES 
expert panel agreed that there may be a need to simplify PISs for low risk research 
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such as the parent study in this thesis, but felt that there are inevitably essential 
items that must be included in the PIS, in accordance with international 
statements7;35.  In addition, the PISs provide a reference of information for 
participants if they encounter problems during the study.  If lengthy PISs must to be 
provided to participants for legal reasons, then assuming researcher’s responsibilities 
are to inform participants rather than simply provide information, the problem of how 
to inform participants still remains since our results suggest that the majority of 
research participants may not read the PIS. 
  
On reviewing the suggested streamlined PIS for the parent study, the NRES expert 
panel draw a distinction between what participants want to know and what they ought 
to know.  The first consideration to determining what potential participants ought to 
know, is who should decide on the list of key information to be provided; patient 
advocates, researchers, experts such as the NRES expert panel, by following 
statutory guidelines for medical research, or a combination of these?   
 
This and research by Antoniou et al6 has shown that when asked, patients will often 
say they want to know more information even if they will not actually use it to make a 
decision, so providing patient groups with a PIS and asking them if they want to know 
more information is unlikely to provide results that reflect what they would do in 
practice.  If a patient group were to be provided with a full PIS and then asked what 
they thought people needed to be told, however, they may decide differently.  In 
designing the content for level one of the IIS for this PhD, participants were provided 
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with a PIS and asked to identify what they thought was the most important 
information to know in each section.  Participants were able to identify what 
information they thought to be the most important, and this proved to be useful in 
determining what information to include in level one.  Research has shown that the 
information patients want to know is likely to differ from what experts think they want 
to know70, and so using user groups may be one way to ensure the information that 
patients want to know is provided.  
 
Experienced researchers also seem well placed to form a judgement, since it is their 
obligation to gain valid consent and they often understand the study and its 
ramifications. Their experience in what participants ought to know is likely to come 
from the information they have included in PIS in the past.  This may be 
advantageous if they have had contact with potential participants, since it may give 
them an idea of the types of information that those participants wanted to know.  It 
may also be a disadvantage, however, since researchers currently design PIS that 
are often considered to be lengthy and complex22. 
 
The streamlined PIS demonstrated that something more streamlined that still 
followed GCP guidelines could be produced.  Providing information that met GCP 
guidelines would provide a defensive argument for researchers, since they would 
have told potential participants all of the information they need to know to meet legal 
guidelines.  Experts within the area of research ethics, such as those on the NRES 
expert panel, could make the decision about what participants ought to know about 
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research in order to meet statutory requirements and provide this information in 
NRES guidelines for writing PIS22.  The strength of the panel lies in the mix of 
backgrounds of individuals whose experiences cover a range of areas within 
research ethics204.  Members of the panel are key stakeholders within the NHS, 
Clinical Trials units, REC’s, and the pharmaceutical industry.  As mentioned 
previously, there is likely to be a mismatch between what researchers and potential 
participants think, and so they may not be best placed to decide what potential 
participants want to know.  Given their diverse and experienced backgrounds, 
however, the panel are likely to have expert opinions on the information that 
participants ought to know to participate.  The NRES expert panel may be able to 
suggest (and provide guidance on) how information could be presented to potential 
participants in order to meet statutory requirements.  RECs should then use this 
guidance to determine if there is any additional information they consider wise for 
potential participants to know before they consent.   
 
NRES PIS guidance is currently being updated (led by Hugh Davies), and one 
update could be to provide a list of mandatory information that potential participants 
must be told about research, devised by experts within research ethics, such as the 
NRES expert panel.  The guidance already covers information they recommend to be 
included in a PIS, but in order to produce a streamlined PIS, mandatory information 
specifications would need to be much more succinct.  A paragraph of information 
could be included in the PIS guidance document, for example, that covers all the 
basic aspects of research, such as that used in the streamlined PIS example 
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provided in Section 6.12.  This paragraph of information could be adapted to each 
study.  It could also be expanded, for example in an attached lengthier PIS, but used 
to help ensure that basic mandatory information is provided to potential participants 
who otherwise would choose not to access any information about the research.  In 
addition to this mandatory information required to meet statutory guidelines patient 
advocates, and evidence from empirical research such as this PhD and the study by 
Antoniou et al6, could be used to add information that potential participants are likely 
to want to know, to the information that potential participants ought to know, to 
produce a streamlined PIS for each research study.   This is the process used to 
produce the streamlined PIS in Section 6.12, and it allows both the information that 
potential participants want (according to the information they are likely to access) and 
ought (according to the statutory instruments) to know to be presented in a succinct 
and accessible way. 
 
These recommendations for future information provision and the resulting 
streamlined PIS are only appropriate for the low risk interventional study used in the 
Information Provision study.  The focus may be different in low risk studies using a 
different disease area or participant group, and in higher risk studies.  Further 
research should be conducted to determine if these recommendations can be 
translated to other types of research, and this research would need to be conducted 
before general guidance could be produced for the mandatory information to include 
in a PIS.  Guidance on producing a streamlined PIS could be developed now and 
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used in addition to a lengthier PIS, but in the future it may be advantageous to 
provide just the reduced PIS.  
 
The NRES expert panel suggested that the aim of lengthy PIS documents is not only 
to inform potential participants, but also to act as legal protection for researchers.  In 
order to deal with this, the panel suggested that a streamlined PIS could be included 
at the beginning of the PIS as a summary of the information provided.  If this 
streamlined PIS provided both the information that potential participants ought to 
know and the information that they want to know, it may be sufficient to inform a 
consent decision for the majority of potential participants.  The streamlined PIS may 
also be more likely to be read by potential participants if they were previously 
deterred by the length of the document.  If the information in the streamlined PIS was 
not sufficient, they could access the attached, lengthier PIS, for more information.  
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Key points 
The PIS provides information for consent purposes and legal protection for 
researchers. 
 
Mandatory information for research could take into account what potential 
participants both want and ought to know, with experts such as the NRES 
expert panel developing guidance for the basic information participants ought 
to know, and the information that potential participants want to know 
developed using research evidence with input from patient advocates. 
 
A streamlined PIS providing mandatory information used in conjunction with 
an IIS or attached lengthier PIS could improve information provision in 
research. 
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7.6 PROVIDING VERBAL INFORMATION 
 
The streamlined PIS developed for this PhD thesis was an attempt to provide 
mandatory information for participants whilst meeting the needs of those who need 
more information than this by including at the end of the streamlined PIS ways the 
participants could access more information.  Even if a streamlined PIS does 
encourage potential participants to read the basic information, the results of the 
Information Provision study suggest that there will be some participants that still 
choose not to read it.  If there is mandatory information for potential participants to 
know before taking part, then other ways to impart this information also need to be 
considered. 
 
Previous research has shown that extended discussion with research staff is likely to 
improve understanding73;91-94.  In research, potential participants are not only 
provided with information in a PIS but also have a consent interview with a member 
of the research team.  This interview gives the opportunity for researchers to check 
that potential participants understand the information they have been given, and to 
ask if there is more the potential participant wants to know.  If there is mandatory 
information that potential participants should know before making a participation 
decision, providing it orally at this interview and checking understanding allows 
researchers to ensure the information has been given.  Simply providing the 
information as a PIS is not sufficient, since the Information Provision study suggested 
that a significant proportion of potential participants may not be reading it. 
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Ensuring participants understand the information is difficult since there is a difference 
between participants being able to recall the information provided and understanding 
it sufficiently to use it to make a decision, and measuring actual understanding is not 
easy (Section 2.3).  Ensuring participants have understood the information at the 
consent interview means more than simply reading the PIS to participants and a 
standard method to encourage understanding needs to be developed.  In order to do 
this, the person gaining consent must check the level of understanding throughout 
the consent interview.  If mandatory information was provided verbally, it is 
advocated that the interview scripts of consent interviews be reviewed by REC’s, in a 
similar way to PIS.  This would standardise the verbal information to ensure that 
mandatory information was both imparted and provided in an easily accessible way.  
Developing scripts through input with patient representatives may improve the 
accessibility of the information provided.  
 
In addition to the review process, the information provided at the consent interview 
could be further standardised by providing additional training to consent receivers to 
ensure that consent is given in accordance with the study protocol.  This additional 
training may have logistical issues and cost implications for research studies, 
however, particularly if there are a number of sites. 
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Key points 
Since potential participants often do not read the PIS, mandatory information 
should be reinforced verbally. 
 
Interview scripts of consent interviews should be reviewed by REC’s and 
additional training provided to consent takers, to standardise verbal 
information provision and ensure consent is taken in accordance with the 
study protocol. 
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7.7 IS AN IIS A SOLUTION TO INFORMING THE MINORITY? 
 
Researchers have a legal and moral obligation to ensure that valid consent is 
obtained from participants, and this means ensuring that participants understand 
what they have consented to.  Given that this PhD has shown the majority of 
participants did not to want to know very much information about the parent study, a 
streamlined PIS with information that participants both want and ought to know, such 
as the one presented in Section 6.12, may be one way to provide the majority of 
participants with enough information to make a participation decision and give their 
valid consent.  If further research showed that these streamlined PISs were also not 
read, then the previous section has suggested that the consent interview may be an 
alternative way to impart key knowledge and check understanding.  These 
recommendations would likely satisfy the majority of participants that did not want to 
know very much information.   
 
The results reported above suggested that there was a minority of participants for 
whom this minimal level of information would not be sufficient to meet their 
informational requirements, even in low risk research such as the parent study in this 
thesis. These are the participants who accessed the higher levels of information and 
more than is included in the traditional paper PIS.  In addition to this, the NRES 
expert panel suggested that lengthy PIS provide legal protection for researchers by 
providing full information and allow participants to refer back to information at a later 
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date.  An IIS may meet both of these concerns since it allows a substantial amount of 
detailed information to be easily accessed by participants.  
 
If an IIS was provided to inform potential participants in future studies, it could be 
designed to display the level one information rather than requiring users to select the 
information they wish to access from a list of FAQs.   This would produce an 
electronic version of the streamlined PIS, but as a hybrid of the IIS since users would 
have the option to access more information on each topic if required. 
 
Providing an IIS will not be feasible in all studies because not all potential participants 
will have access to the Internet.  If an IIS could not be used, then lengthy paper PIS 
could be provided to participants for reference purposes.  As suggested previously, a 
streamlined PIS could then be included as a cover page to this lengthier PIS as a 
summary of the information included.  This would provide potential participants with a 
summary of information sufficient to inform the majority, whilst providing access to 
lengthier information to satisfy those participants who require more information.  
Given that that there are likely to be a range of informational needs across all study 
participants, however, providing only a streamlined and current standard length PIS 
is not likely to satisfy those that want to know detailed information on only some 
study aspects.  The IIS allows participants to easily choose the topics of information 
where they require more detail, rather than a lengthy paper PIS that requires 
participants to sift through detailed information for all topics.  The IIS provides a 
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tailored approach to information provision in general that may satisfy the individual 
specific needs of participants.   
 
As a final thought, the results of this study and the discussion above provided an 
ethical issue for future electronic research that is conducted remotely with no face-to-
face contact between potential participants and researchers262.  As these types of e-
trials become more popular, the results of the IIS study show there to be a certainty 
that many participants read little, if any, of the information provided to them and, 
therefore, would not be informed to give their valid consent in the way that UK GCP 
Guidelines currently require22.  Further research is needed in this area, to ensure that 
e-trial participants do give their consent in such a way that meets requirements. 
 
 
Key points 
A minority of potential participants are likely to want more than the mandatory 
information.  Their needs may be met by providing an IIS, since this allows a 
substantial amount of detailed information to be easily accessed by 
participants.  Where an IIS is not feasible, a lengthy paper PIS could be 
provided in addition to mandatory information. 
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7.8  FUTURE OF INFORMATION PROVISION IN RESEARCH 
 
This thesis has shown that electronic communication does have a place in the future 
of research and could be a mainstream form of communication if the right safeguards 
are in place.  This final section of the chapter provides suggestions for future 
provision of information in research.   
 
Other communication technologies 
There are many other technologies available now that could be used to communicate 
electronically with research participants.  These include text messaging263-266, mobile 
phone software called applications (apps) 213;214;267-274 and interactive buttons on the 
TV275-277, which could all be used to invite potential participants to research studies or 
communicate with them throughout studies.  Mobile phone apps are the most likely of 
these to be suitable for research and mobile phone technologies are already 
becoming widely used in the healthcare and research setting213;214;267-274.  Mobile 
phone apps have great scope for inclusion in research and could have multiple uses.  
Participants could, for example, download study software (an app) that alerted them 
when it was time to complete a study questionnaire, the questionnaire is completed 
using the app and sent straight to the researchers. In fact, all aspects of e-trials could 
be incorporated into a mobile phone app that the participant keeps with them all the 
time and so communication is not limited to when the participant is sat at the 
computer screen278.  
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The Internet and electronic recruitment at the moment is best suited to questionnaire-
based studies because of the functionalities that can be added to online 
questionnaires, for example, automatic collating of information112;128;129.  In the future 
there may be scope for e-trials to use electronic consent forms when electronic 
signatures become more widely used and accepted124-126, and consent interviews 
could be conducted remotely via Skype type video conferencing279;280. This could 
minimise disruption to potential participants who could do the meetings from their 
office or home and so may improve recruitment to trials.  There may, however, be 
some confidentiality issues if the conversation could be overheard.  The future use of 
the Internet in research could reduce costs and improve the effectiveness of them 
greatly112;118;128;129;135;136, but requires further advancement of the technology.   
 
Future of the IIS 
This research has shown that the IIS may have a place in research, either as a first 
line method to provide information to potential research participants, or as a way for 
participants who want more than a minimum amount of information to access more 
information about a study.  Now a web-based template has been written for the IIS, it 
would be easily adaptable to other studies.  It could be set up in a user friendly 
manner that allows researchers to use it to input the information for their study.  
Instead of having to deal with code, administration pages could be set up that allow 
researchers to easily add their own information and logos.  
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Further to this, a central website could be set up where researchers can add their 
study specific information and participants can access it by logging in with a 
username and/or password unique to that study.  If the website was managed 
centrally it would also include admin pages that mean researchers would not have to 
learn code to use web-based information sheets.  These could be used in addition to 
short paper PIS and the minority of participants that wanted to know more 
information could access the IIS online.  There are a lot of steps involved in hosting a 
website112, and so a central user friendly website may promote online information 
and the use of an IIS because researchers would not have to work out the logistics of 
posting information online.   
 
Other populations 
The other point to consider in the future of the IIS is conducting similar studies to the 
one done for this PhD in other populations.  It could be used with younger people to 
see if results were similar and to see if it was more acceptable with that cohort.  It 
could be tested in a higher risk study to see if potential participant’s informational 
requirements are different for studies of different risk.  It may be that participants 
want to know more information when the risk is higher.  There may be ethical 
implications of trying to conduct this research in higher risk trials if researchers knew 
that participants had not accessed any study information before agreeing to 
participate, since the risks of taking part are considered to be greater.  In high risk 
research, particularly early phase cancer trials, there is often more of an emphasis on 
discussion of trials with patients than in low risk primary care research281;282.  This 
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may mean that high risk research is actually a safe environment in which to place 
further work because the verbal information may be more comprehensive than in low 
risk studies.  The NRES expert panel noted that a lengthy PIS is required as a legal 
‘living document’ that protects researchers and allows participants to refer back to 
information at a later date.  The panel were happy for the work to be continued in a 
higher risk setting, providing that the standard lengthy PIS was provided at the time 
consent was received. 
 
A discussion with the NRES expert panel about taking the research forward into 
riskier clinical trials was led by Professor Heather Draper.  Prior to the meeting she, 
Dr Melanie Calvert and Dr Sarah Damery circulated a report to the panel that 
identified how clinical trials may entail greater risk for participants: 
 
“The intervention itself may be riskier in terms of known or potential side-
effects (such as in clinical trials of pharmacological interventions) 
 
Different levels or types of risks for participants may be associated with 
different phase clinical trials (from those designed to determine treatment 
safety, through trials to assess treatment efficacy or the broader 
effectiveness of an intervention) 
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The trial may be conducted in a clinical area where the risks are greater 
due to the condition of interest itself being more serious, regardless of the 
study arm to which a participant may be allocated 
 
The trial design may be complex (e.g. adaptive or cross-over designs), 
and/or comprise a multi-factorial intervention, so there may be a risk that 
participants will not understand the complexities of participation 
 
The research may take place over a long period of time and there may be 
a risk that the participants may not remember what they have been told 
about it 
 
There may be little time for a considered decision to be made (e.g. for trials 
being undertaken in an emergency medicine setting)” 
 
Future work would be required in all of these different higher risk areas, in order to 
determine what information potential participants want when taking part in studies 
considered higher risk than that conducted for this PhD. 
 
 If a study in the higher risk population was not feasible, it could be conducted for a 
‘sham’ study instead283.  Healthy participants could be invited to take part in a high 
risk study, such as phase I clinical trial, and asked to read the information available 
before they consented to take part.  They could then be asked online whether or not 
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they would still like to take part in this study, and the information they accessed 
would have been recorded.  They would not actually be taking part in a study, but 
they would think they were and so their information seeking behaviours are likely to 
be consistent with what they would do it asked to participate in a real high risk study.  
This would also raise ethical issues though, for example, deception of participants283. 
 
There is much research required before we can be sure that participants are properly 
informed about research and it is an area currently neglected by researchers.  This 
PhD has advanced our knowledge and provides an evidence base for future 
research. 
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8 CONCLUSION  
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The overall aim of this thesis was to gather further evidence on the topics and level of 
detail of information potential research participants access when deciding whether to 
participate in a piece of low risk interventional research, and to determine the 
feasibility of electronic information provision.  In relation to this aim, four important 
research questions have been addressed: 1. What does the current evidence 
suggest potential participants want to know when they are deciding whether to 
participate in research? 2.  Is electronic information provision in research feasible? 3. 
What information did potential participants access when they made a decision about 
whether to participate in a piece of low risk interventional research?  4.  What are the 
implications for the future of information provision given answers to research 
questions 2 and 3?   
 
The first chapter of this thesis considered the background information required to put 
these research questions into context.  Consent is a pre-requisite for participation in 
research, and participants understanding the study they are giving their consent to 
participate in is required for valid consent to be given8-11.  Information provision in 
research is tightly controlled by regulatory codes and overseen by ethics committees 
and institutional review boards22;26;35, but although international GCP guidance states 
that participants should be ‘adequately’ informed of a study before making a consent 
decision, it does not detail what ‘adequately’ informed means.   
 
There is a concern that current PIS are not readable and consequently participants’ 
understanding of the study is not sufficient55-63.  Previous research has shown that 
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study understanding can be improved by providing less detailed information88;89, re-
arranging the information in a PIS to be more user friendly79;81;86;87 and allowing 
participants to have extended discussions with researchers73;91-94.  A problem with 
ensuring that participants have achieved a suitable level of understanding is that 
understanding is difficult to measure; recall is often measured, but being able to 
recall the information is different to being able to understand it23;58.  Measurement 
strategies for understanding are tailored towards individual trials and no standardised 
method to measure understanding exists1.  A final problem with ensuring the 
understanding of participants is that participants think themselves to be well informed 
but when tested are considered by researchers to have low levels of understanding. 
This may be because the information researchers think participants need may differ 
from what participants think they need60;67-69.  
 
A systematic review (Chapter 3) was the first study conducted for this PhD.  In 
answering the first research question, the systematic review found limited evidence 
to suggest what information potential participants want to know at the time they are 
deciding whether to participate in research.  This may be because the research is 
difficult to conduct accurately, since results from the Information Provision study and 
that by Antoniou et al6 suggest that asking participants what information they used to 
make a decision is unlikely to produce accurate results. 
 
In answering the second and third research questions, the Information Provision 
study gathered evidence on the feasibility of electronic information provision and the 
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information that potential participants access when making a decision of whether to 
participate in a piece of low risk interventional research.  The Information Provision 
study used an IIS that allowed participants to choose both the types of information 
and level of detail they accessed and also recorded the information accessed by 
each participant. The study also compared electronic recruitment and information 
provision to paper versions and assessed participants understanding of the study 
and satisfaction with the information provided.  The study found that electronic 
communication did not affect consent rate, and the highest consent rate was actually 
seen in the group that accessed no study information.  The study was underpowered 
to detect this, however.   
 
The study information that had been favourably reviewed by the REC was found to 
satisfy only 11.4% of participants, undersupply 9.1% and oversupply 79.5% of 
participants.  Understanding was consistent across groups, including those 
accessing no information, and participants were generally happy with the level of 
information they received, regardless of the mode of information delivery.  The final 
important result was that participants were unable to accurately recall what 
information they had accessed. 
 
Problems were encountered when trying to contact participants electronically; 
incorrect email addresses were provided and email invitations were often not opened 
and participants had to be contacted by telephone to prompt them to open their 
emails.  Participants receiving electronic information, however, were often more 
 308 
 
satisfied with the information provided than those receiving paper information and 
those that provided an email address were likely to prefer electronic communication 
in future research.  99% of young people101 use the Internet but the mean age of the 
Information Provision study population was higher than the general population, at 57 
years.  This presents difficulties in recruiting and providing information purely 
electronically since only 40% of the population over the age of 65 currently use the 
Internet101.  As the younger generation of today become the research participants of 
tomorrow, it is likely that electronic communication and information provision will 
become more feasible.  Given that recruitment rate and understanding were not 
compromised and satisfaction may have been improved by electronic information 
provision, this study, together with the results of that by Antoniou et al, suggest that 
electronic communication and information provision may be feasible and further 
research is warranted, particularly in higher risk studies.   
 
The observational component of the Information Provision study found that little 
information was accessed by participants - 59% booked a study a study appointment 
despite accessing no study PIS at all because they chose not to click the link to 
access it, and 40.9% of those randomised to IIS also chose not to access any 
information.  Understanding, however, remained consistent across all study groups, 
including those accessing no study information.   
 
In answering the fourth and final research question, the final part of this PhD aimed 
to discuss the implications for the future of information provision given the results of 
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the studies conducted.  A streamlined PIS was produced for the parent study that 
combined the information that most participants using the IIS wanted to know before 
participating with the information required by the ICH7.  This streamlined PIS and the 
results of the PhD were presented to the NRES expert panel to gather their opinions 
on the work and seek advice on how to take the research further.  The panel were 
interested in the work conducted for this PhD and broadly supportive of taking it 
further.    
 
Participants did not base their consent decision on the information in the PIS, since 
results showed that they did not access the information.  If they did not use this 
information, they may have based their decision on common knowledge about 
research in general, they preferred verbal communication from researchers67;119;231-
233, or they did not want to know they information because they based their decision 
on an influence such as an altruistic desire to take part235-237, their trust in their health 
care professional240-244, or an influence completely unrelated to the study245;246. 
 
In order for participants to be informed about a study, researchers (and RECs) have 
to decide what information to impart to potential participants, and this may be 
considered paternalistic, although only of a weak form if potential participants are 
able to gather further information about the research by asking questions.  This 
information may be required for the potential participant to make an autonomous an 
informed decision, and so this type of weak paternalism may be beneficial to the 
potential participant.  In addition to this, in order to comply with statutory instruments 
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for GCP, potential participants must be provided with certain information.  Although 
there is mandatory information that must be provided to potential participants of all 
studies, this could be relayed to potential participants in the form of a streamlined PIS 
and/or verbally at the consent interview. 
  
The final consideration was how to ensure that participants do understand the 
mandatory information. This is likely to be a challenge given that the results of the 
information study suggest that potential participants may not read information 
provided in a PIS.  One way to do this may be to develop the verbal consent 
interview for studies.  Mandatory information could be provided verbally at the 
consent interview to ensure participants have been given it, and the person gaining 
consent could check their understanding as the information is imparted.  In this case, 
the content of these consent interviews may need to be reviewed by REC’s just as 
the PIS is currently, in order to standardise the information imparted. Placing the 
burden of information giving on the consent interview may necessitate additional staff 
training, and further research would be required into ways to check the 
understanding of potential participants. 
 
In the Information Provision study there was a minority of participants whose 
informational requirements may not have been met by a streamlined PIS plus verbal 
information at a consent interview.  The traditional PIS also functions as a reference 
document for participants and provides legal protection for researchers.  For both 
these reasons, it may not be desirable to make a complete move to a streamlined 
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PIS reinforced by a verbal consent interview. In research where electronic 
communication is feasible, access to an IIS would allow participants to access further 
information.  A hybrid version of the IIS could also be developed that displayed 
information from the streamlined PIS with the option to access more information for 
each topic.  Where access to an IIS is not appropriate, the streamlined PIS could be 
included as a cover summary sheet to the traditional, lengthier PIS. 
 
In order to improve information provision in low risk interventional research, a few 
suggestions are made in conclusion of this PhD.  A streamlined PIS may be a useful 
adjunct to the traditional PIS and improve understanding.  Given that the results of 
the information study suggest that the majority of potential research participants may 
not read the traditional PIS, any information important enough to be included in a 
streamlined PIS should be reinforced verbally at the consent interview.  Given that 
this study showed that a high proportion of potential participants do not read the 
written information provided, providing information verbally at the consent interview 
may be central to ensuring valid consent in future research. 
 
8.1 CONSIDERATIONS FOR FUTURE RESEARCH 
 
The results and discussion in this thesis are important to the future of research, and 
identify concern with the current informed consent process.  Much more research 
needs to be conducted in this area, and in this final part, I outline considerations for 
future research. 
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The rise of the Internet in medical research107-119 means a move towards online PIS 
and a consideration of ways for participants to give consent that fit with the remote 
nature of e-Trials.  Given that the results of this thesis have shown that a verbal 
consent interview may be central to ensuring valid consent is given, it is important 
that this is considered in future research.  It may, for example, be possible to conduct 
virtual ‘face-to-face’ consent interviews to ensure that researchers engage 
participants and assess understanding.   The consent process in e-Trials should, 
therefore, be a consideration for future research to ensure that participants are 
adequately informed. 
 
If IIS, or more structured consent interviews are to be used in future research, these 
may come with higher costs.  There may also be other technologies that could be 
used to communicate with research participants, including text messaging263-266,and 
mobile phone software applications (apps)213;214;267-274. Research is needed to identify 
the value of other methods of information provision, and full economic evaluations of 
each process are required. 
 
This thesis considers information provision in only one group of patients, in a low risk 
interventional study.  All interventions come with different levels of risk, and 
participants may want more information when considering participation in a study 
perceived to be of higher risk.  The research methodology developed in this thesis 
needs to be replicated in higher risk interventional studies to determine patterns of 
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information access across a range of study types.  Information requirements may 
differ between different sub groups of the population, both in terms of demographic 
groups and disease areas.  Further research should also, therefore, be conducted 
with different sub groups of participants.   
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9.2 INFORMATION INCLUDED IN THE IIS 
 
 
Welcome to the Blood Pressure Monitoring Study information website 
You are being invited to take part in a research study about the different ways of 
measuring blood pressure.  Before you decide if you are willing to get involved, it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with your friends and relatives if you wish.  Ask us if there is anything that is not clear 
or if you would like more information.   
 
How to use this website 
This study information website is an interactive website.  This is a new way of 
providing information about a research study to patients.  To the left of this page you 
will see a list of frequently asked questions (FAQ’s) about medical research.  You 
should click on as many of these as you want to before deciding whether or not you 
want to take part.   
 
When you click on a FAQ you will be given a short response.  If you want to know 
more, please click on the + button under that text.   
 
Some pieces of information are coloured blue and underlined – these are called 
hyperlinks.  If you click on one of these hyperlinks, it will take you to an external 
website which will give you even more information.  An example of a hyperlink might 
look like this –  
 
Blood pressure is likely to be lower when measured at home. 
 
If you click on the hyperlink ‘Blood pressure’ it would take you to an external website 
which would tell you more about blood pressure. 
Please click on as many of the links as you like, and spend as long reading the 
information as you like before you decide whether or not you would like to take part in 
this blood pressure monitoring study. 
 
When you have finished 
To the right of each page you will see a box which says ‘Finished?’.  When you have 
finished reading all of the information you wish to read and have decided whether or 
not you want to take part in the study, please click this button. 
[stats – Flesch Reading Ease score= 73.2; Flesch-Kincaid Grade Level Score 7.6] 
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What is the purpose of the study? 
 
Level one 
Blood pressure is likely to be lower when it is measured at home.  This study is to 
see if blood pressure measurements are lower in all ethnic groups when taken at 
home. 
 
[stats – Flesch Reading Ease score= 74.2; Flesch-Kincaid Grade Level Score 6.8] 
 
Level two 
Blood pressure can be measured in a number of different ways.  The most common 
method is to have it measured at your GP practice by your doctor or nurse.  
However, it is also possible to measure it yourself at home, or to wear a cuff for a day 
with a small machine which will measure it for you.   
 
Research has shown that blood pressures measured at home are likely to be lower 
than those measured at the GP practice.  However, no studies have been done to 
look at whether the differences between blood pressure measured at home and at 
the GP surgery are the same for different ethnic groups (for example White British, 
Asian, White Irish, African-Caribbean): this is what we will be looking at in this study. 
   
[stats – Flesch Reading Ease score= 61.8; Flesch-Kincaid Grade Level Score 10.9] 
 
Level three 
 
Blood pressure  <external link to ‘What is blood pressure’ 
http://www.bhf.org.uk/keeping_your_heart_healthy/preventing_heart_disease/blood_pressure.aspx > is 
measured by a blood pressure machine.  There are two main types of blood pressure 
machines which you could be asked to use at home: 
 
 An electronic blood pressure machine.  This is similar to the one you may 
have seen at your GP surgery.  If you were asked to measure your blood 
pressure in this way at home, you would be trained to use the machine.  You 
would then be given a machine to take away and use at home and asked to 
keep a record of your blood pressure readings. 
 A 24-hour blood pressure monitor. If you were asked to use this, you would 
have to wear a cuff for a day with a small machine attached.  This machine 
automatically measures your blood pressure at set intervals over 24 hours.  
The blood pressure readings are stored on the machine and would give your 
GP a range of blood pressure readings over an entire day.   
If you would like to know more about home blood pressure monitors, please click 
here. <http://www.bhf.org.uk/plugins/PublicationsSearchResults/DownloadFile.aspx?docid=dd61a3e7-e0a9-
4082-9f87-b4cda0e5bad2&version=-1&title=IS42+Blood+Pressure+Monitors&resource=IS42> 
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Research has shown that blood pressure may be lower when it is taken at home.  
Blood pressure can increase when you are worried or stressed, and some people get 
worried about going to see their GP or nurse.  This means that for some people 
blood pressure may be higher at their GP surgery because they are worried.  These 
people may have normal blood pressure when they are not at their GP surgery.  This 
appearance of raised blood pressure only when people go to see their doctor is 
known as ‘white coat hypertension’. 
<http://www.bpassoc.org.uk/BloodPressureandyou/Medicaltests/Whitecoateffect > If you would like to 
know more about why blood pressure may be lower at home, please click here. <Link 
to external paper  – Ambulatory Blood Pressure Monitoring and Blood Pressure Self-Management in the 
Diagnosis and Management of Hypertension.  Appel LJ, Stason WB >  
 
People in some ethnic groups tend to develop high blood pressure more often than 
people in other ethnic groups.  We do not fully understand yet why this is the case.  
High blood pressure is more common in African-Caribbean and South Asian people 
living in the UK.  Research has shown that blood pressure measurements are likely 
to be lower when taken at home.  However, no research has been done to see if 
blood pressure is lower at home for members of different ethnic groups. (For example 
White British, Asian, White Irish, and African Caribbean).  This study is trying to find 
out two things: 
 
 Blood pressure may be lower when measured at home.  We want to see if 
blood pressure is lower at home than at the GP surgery for all of the ethnic 
groups being tested.  
 Blood pressure measurements may be lower when measured at home.  We 
want to see if home blood pressure measurements even are lower when taken 
at home for some ethnic groups than for others. 
 
[stats – Flesch Reading Ease score= 70.8; Flesch-Kincaid Grade Level Score 7.5] 
 
 
Why Have I been Chosen? 
 
Level one  
You expressed an interest in taking part when you returned our questionnaire. 
 
[stats – Flesch Reading Ease score= 60.7; Flesch-Kincaid Grade Level Score 7.7] 
 
Level two  
The study will involve 800 people from four different ethnic groups (White British, 
Asian, White Irish, African-Caribbean).  You kindly expressed your interest in taking 
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part when you returned our initial questionnaire, and we have chosen you on the 
basis of this.   
 
[stats – Flesch Reading Ease score= 43.6; Flesch-Kincaid Grade Level Score 12.2] 
 
Level three 
We recently sent a survey to about 8000 people who go to a GP practice in the area.  
Your GP practice was asked to take part because it has patients from one or more of 
the ethnic groups we are studying.  The ethnic groups we are studying are White 
British, Asian, White Irish and African-Caribbean.   You were invited to take part 
because you fall into one of these groups.   
 
All patients from the GP practices taking part in this study were randomly selected 
(like tossing a coin) to be sent a survey through the post.  You were one of the 8000 
patients chosen to receive a survey.  The survey invited all patients to take part in 
this blood pressure study.  You filled in the survey and kindly said you were 
interested in taking part in this study.  Of those patients who were interested in taking 
part, the first 800 patients to respond were invited to take part.  We invited a mixture 
of people to take part.  We invited:  
 
 100 White patients with high blood pressure. 
 100 Black patients with high blood pressure. 
 100 Asian patients with high blood pressure . 
 100 Irish patients with high blood pressure. 
 100 White patients who do not have high blood pressure. 
 100 Black patients who do not have high blood pressure. 
 100 Asian patients who do not have high blood pressure . 
 100 Irish patients who do not have high blood pressure. 
[stats – Flesch Reading Ease score= 67.7; Flesch-Kincaid Grade Level Score 7.9] 
 
 
Do I have to take part? 
 
Level 1 
It is up to you to decide whether or not to take part and your decision will not affect 
your healthcare.   
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[stats – Flesch Reading Ease score= 76.6; Flesch-Kincaid Grade Level Score 7.7] 
 
Level 2 
It is up to you to decide whether or not to take part.  If you decide that you would like 
to get involved then we will ask you to sign a consent form.  We will need to let your 
GP know that you are involved, and will also ask for your permission to access your 
medical records at your GP’s practice.  Once the study has started you are still free 
to withdraw at any time without giving a reason: this will not affect the care that you 
receive from your GP.  
 
[stats – Flesch Reading Ease score= 77.7; Flesch-Kincaid Grade Level Score 8.0] 
 
Level 3 
You may have been asked to sign a consent form <Link to PDF of consent form used in study> 
before for other medical things such as surgery or treatment.  The process is similar 
to this.  Before you sign the consent form we need to make sure you understand the 
study.  We do this by giving you an information sheet about the study (this is what 
you are reading now).  We then give you time to talk to a research nurse to make 
sure you understand the study.   Once you and the research nurse are happy that 
you understand the study, you will be asked to sign a consent form.  This gives your 
official consent to say that you want to take part in the study.  Signing the consent 
form does not mean that you cannot pull out of the study later on.  You can decide 
you no longer want to take part in the study at any point after you have signed it.  
If you do decide to take part in this study, we would like to let your GP know that you 
are involved.  If you are found to have high blood pressure we will tell your GP so 
that they can treat you appropriately.  The research team cannot treat patients found 
to have high blood pressure and we would feel uncomfortable thinking you needed 
treatment that we could not provide.  Therefore, if you do not want us to tell your GP 
that you are involved then you will not be able to take part in this study.  For more 
information about the risks of high blood pressure and why treating high blood 
pressure is important, please click here < http://www.nhs.uk/Conditions/Blood-pressure-
(high)/Pages/Introduction.aspx >  
We need to look at your medical records to look for important things in your past 
medical history.  We may look to see if you already have high blood pressure or to 
see if you are taking any medication.  Only those giving medical care can look at your 
medical records without asking you.  Not all of the researchers that need to look at 
your medical records for this study give you medical care.  This is why we need to 
ask your permission for us to look at your medical records. 
If you agree to take part in this blood pressure monitoring study and then decide it is 
not for you then you do not have to continue.  We would appreciate you letting us 
know straight away if you decide to pull out.  We will ask you to return the equipment 
to us.  You will be asked at this time whether your data can be kept or not.  You do 
not have to agree to this.  We will also ask you why you no longer want to take part in 
the study.  This is so we can see if you were unhappy with the study and then try to 
improve the study for other patients.  You do not have tell us why you no longer want 
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to take part.  If you do pull out of the study once it has started this will not affect the 
care that you receive from your GP or any other health care provider. 
 
[stats – Flesch Reading Ease score= 77.9; Flesch-Kincaid Grade Level Score 7.2] 
 
 
What will happen to me if I take part? 
Level one 
You will make three visits to your GP surgery over 8 days.  During that time you will 
be asked to have a 24 hour blood pressure monitor and take your own blood 
pressure for a week. 
 
[stats – Flesch Reading Ease score= 85.1; Flesch-Kincaid Grade Level Score 5.7] 
 
Level two 
You will be involved in the study for a period of eight days.  This will involve three 
visits to our research nurse / facilitator, as follows: 
 
Visit 1 (day 1) – You will initially come in to have your blood pressure measured by 
the nurse and to answer a questionnaire.  You will then be taught to measure your 
own blood pressure at home: you will need to do this both in the morning and the 
evening for the next seven days and we will lend you equipment to do this.  The 
equipment will store the readings that are taken, but you will also need to write them 
down.   
 
Visit 2 (day 7) – You will return the home monitoring equipment and have your blood 
pressure taken by the nurse again.  You will then be fitted with a cuff which will 
measure your blood pressure automatically over the next 24 hours: this should not 
interfere with your daily activities.  
 
Visit 3 (day 8) - You will come back to return the cuff, have your blood pressure taken 
by the nurse for the last time and complete a final questionnaire. 
   
Each visit to the nurse should not take more than 30 minutes.   
 
[stats – Flesch Reading Ease score= 69.9; Flesch-Kincaid Grade Level Score 9.2] 
 
Level 3 
This study will take place at your normal GP surgery within normal surgery hours.  
We will try to make these visits as convenient for you as possible.   
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Visit 1 (day1).   
On the first visit you will have your blood pressure measured by the nurse.  You will 
also be taught to take your blood pressure at home.  We want to see if the blood 
pressure readings you take at home are different to those taken by the nurse.  This is 
why we need to take a blood pressure reading at your GP practice as well as ask you 
to take them yourself at home.  
 
During this visit we will also ask you to complete a questionnaire <Link to PDF copy of the 
questionnaire used in this study>.  This questionnaire will ask about your health, things about 
you, and then about your feelings to having your blood pressure measured at the GP 
practice. 
 
The nurse will then teach you how to measure your own blood pressure at home.  
You will be lent an electronic blood pressure machine that you can use to measure 
your blood pressure at home.  You will also be given a written set of instructions in 
case you need reminding how to use the machine.  You will also be given a 
telephone number that you can call the research team on if you have any problems. 
You will be asked to take two blood pressure readings each day for 7 days.  Once in 
the morning between 6am-12pm and once in the evening between 6pm and 12am.  
The blood pressure machine will record the readings that are taken.  We also need 
you to write down the readings in case they are lost or deleted from the blood 
pressure monitor.  You will also be asked to write down all of the readings on a home 
monitoring blood pressure record sheet. <Link to PDF copy of the sheet used in the questionnaire> 
You will be asked to return the blood pressure monitor at your next visit.   
 
A picture of the type of blood pressure monitor you are likely to be given can be seen 
below. 
<picture of electronic blood pressure monitor> 
 
Visit 2 (day 7) 
We will compare the blood pressure readings that are taken by the nurse with the 
blood pressure readings that you take at home.  When doctors take blood pressure 
readings they measure it at three different visits.  Only if your blood pressure is found 
to be high at all three visits will they diagnose you with high blood pressure.  We want 
to make the readings taken at the surgery as close to ‘normal’ as possible.  You 
would normally have your blood pressure taken three times by your doctor.  
Therefore we want to measure your blood pressure at the surgery three times.  The 
nurse will measure your blood pressure again during this visit. 
 
You will also complete a second questionnaire <Link to PDF copy of the second questionnaire> 
that will ask you about your feelings towards measuring your blood pressure at home 
using an electronic blood pressure machine.  
 
You will then be fitted with a 24-hour blood pressure monitoring machine < 
http://www.bpassoc.org.uk/BloodPressureandyou/Medicaltests/24-hourtest>.  You will be given an 
information sheet about this 24-hour monitor.  <link to PDF copy of 24-hour BP monitor 
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information sheet used in the study>.    This 24-hour monitor will collect blood pressure 
measurements over a 24-hour period.  The recordings will provide a detailed picture 
of your blood pressure.  It will record your blood pressure every half hour between 
7am and 11pm.  It will then record your blood pressure every hour between 11pm 
and 7am.  Wearing the 24-hour monitor should not stop you from doing most of your 
normal activities.  A cuff will be fitted to your arm like the cuff on the electronic blood 
pressure machine.  This will blow up tight on your arm to make a reading. You should 
be able to sleep during the night as normal.  Depending on how deep a sleeper you 
are you may be woken up each time a blood pressure reading is taken.  After 24 
hours you may remove the cuff and switch the monitor off.  We ask you to return the 
monitor at the next visit. 
 
Visit 3 (day 8) 
This will be the last visit to the GP practice for this blood pressure study.  You will be 
asked to return the 24-hour blood pressure monitor and cuff at this visit.  You will 
then have your blood pressure taken by the nurse for the third and last time.   
 
You will also complete a final questionnaire <Link to PDF copy of the final questionnaire used in 
the study> which will ask you about your feelings towards measuring your blood 
pressure at home using a 24-hour blood pressure machine.  
 
If you have any problems with taking recordings, using any of the equipment of any 
other questions you can contact the research team.  They can be contacted on 0800 
234 6 432. 
 
If you would like to know more about how blood pressure is measured and how high 
blood pressure (hypertension) is diagnosed, please click here. < 
http://www.nhs.uk/Conditions/Blood-pressure-(high)/Pages/Diagnosis.aspx> 
. 
[stats – Flesch Reading Ease score= 72.6; Flesch-Kincaid Grade Level Score 7.3] 
 
 
Expenses and payments 
Level one 
Travel expenses will be refunded. 
 
[stats – Flesch Reading Ease score= 33.5; Flesch-Kincaid Grade Level Score 9.5] 
 
Level 2 
Any traveling expenses you incur will be refunded for this study.  
 
[stats – Flesch Reading Ease score= 41.8; Flesch-Kincaid Grade Level Score 10.1] 
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Level 3 
We will refund travel expenses for traveling to and from the GP practice if you provide 
a receipt for your journey.   
 
We ask you to travel to the surgery in the way that you normally would.  For example, 
if you would normally get a taxi or bus to the surgery then you can claim the cost of 
the taxi or bus journey back from us.  However, if you would normally travel by car 
then we ask you do this.  Please do not get a taxi to the surgery if you would not 
normally do so. 
 
We refund traveling expenses because they are costs involved for patients to take 
part in research.  We do not provide expenses to cover missed days of work or any 
other expenses.  We also do not pay you for your time to take part in this study.  We 
do not pay participants because they might then only take part because they want 
the money and not because they actually want to take part. This wouldn’t be ethical 
because it would be bribing people to take part.  Therefore we do not pay participants 
to take part in this study. 
 
[stats – Flesch Reading Ease score= 71.9; Flesch-Kincaid Grade Level Score 7.5] 
 
 
What are the possible benefits of taking part? 
Level one 
Your GP will be given the blood pressure measurements and offer you treatment if 
you need it. 
 
[stats – Flesch Reading Ease score= 70.1; Flesch-Kincaid Grade Level Score 7.6] 
 
Level two 
The information that we get from this study will hopefully help to treat future patients 
with high blood pressure more effectively.  In addition, your taking part will give us 
some really accurate information about your blood pressure: this will be passed on to 
your GP.  Should the results suggest that you need treatment for high blood pressure 
(or a change in treatment if you are already taking it) then your GP will let you know. 
 
[stats – Flesch Reading Ease score= 60.7; Flesch-Kincaid Grade Level Score 10.9] 
 
Level three 
The results of this study may help us to treat other patient’s blood pressure better.  
We hope to get a better understanding of how much lower blood pressure is when 
measured at home.  We also hope to find out if blood pressure is lower when 
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measured at home for different ethnic groups.  We hope that the results of this study 
will help us to treat the right patients for high blood pressure.  For example, we hope 
that fewer patients who only have high blood pressure when they visit their doctor will 
be treated.  
 
This study may help you personally, as it will tell us if your blood pressure really is 
high or not.  These readings will be passed onto your GP straight away.  This will 
provide them with a detailed picture of your blood pressure.  Your GP can then 
recommend the best management for your blood pressure.  This may mean that your 
doctor: 
 
 Gives you treatment for high blood pressure. 
 Increases your treatment if you are already taking it. 
 Takes you off treatment if you are already taking it.  
 Lowers your treatment if you are already taking it.  
If you want to know more about high blood pressure (hypertension) please click here.   
<http://www.nhs.uk/Conditions/Blood-pressure-(high)/Pages/Introduction.aspx> 
 
[stats – Flesch Reading Ease score= 76; Flesch-Kincaid Grade Level Score 6.1] 
 
 
What are the risks of taking part? 
Level one 
Some people find it uncomfortable to have their blood pressure measured. 
 
[stats – Flesch Reading Ease score= 57.2; Flesch-Kincaid Grade Level Score 8.0] 
 
Level two 
The study does not involve any long term risks to you.  Some people may find having 
their blood pressure measured uncomfortable.   
 
[stats – Flesch Reading Ease score= 67.2; Flesch-Kincaid Grade Level Score 6.4] 
 
Level three 
To measure your blood pressure < http://www.nhs.uk/Conditions/Blood-pressure-
(high)/Pages/Diagnosis.aspx> a cuff is put around your arm.   This cuff inflates to allow the 
machine to take a measurement.   The cuff will feel slightly uncomfortable as blood 
can’t get through to your lower arm, but this is normal.  There is a small chance that 
the blood pressure cuff can cause slight bruising to your arm although this is very 
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unlikely.  If you find it too uncomfortable you can remove the cuff quickly by pulling 
open the Velcro fastening.   
 
On the day that you are wearing the 24-hour monitor < 
http://www.bpassoc.org.uk/BloodPressureandyou/Medicaltests/24-hourtest> you may be distracted 
when measurements are being taken.  You also need to keep your arm still when 
measurements are being taken.  We advise you not to drive or operate electrical 
tools when you are wearing the cuff.  This is because you may become distracted or 
move your arm around.  The blood pressure monitor will take readings every half an 
hour during the day and every hour during the night.  You may drive/operate 
electrical tools between measurements.  You can return to normal activities as soon 
as you have removed the cuff.  Do not worry about this.  If this is inconvenient to you 
we can try our best to work around your needs. 
 
[stats – Flesch Reading Ease score= 69.9; Flesch-Kincaid Grade Level Score 7.1] 
 
 
What if there is a problem? 
Level one 
Any problem you have will be addressed. 
 
[stats – Flesch Reading Ease score= 78.8; Flesch-Kincaid Grade Level Score 3.9] 
 
Level two 
If you have a concern about any aspect of this study, you can contact the 
researchers on  
 
[stats – Flesch Reading Ease score= 36.4; Flesch-Kincaid Grade Level Score 14.4] 
 
Level three 
If you are worried about any part of this study you should speak to the researchers.  
They will do their best to answer your questions.  Any complaint you have about the 
study will be dealt with as quickly as possible.  If you are still unhappy after talking to 
the researchers, you can complain formally.  You can do this by speaking to Ms 
Sarah Bathers.  She can be contacted at: 
 
Primary Care Clinical Trials Unit Manager,  
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Ms Bathers is responsible for the safety of patients involved in research at the 
University of Birmingham.  She will also address the problem personally if possible, 
otherwise she will advise you on what you can do. 
 
If something does go wrong and you are harmed during the research and this is due 
to someone‘s negligence then you may have grounds for a legal action for 
compensation against The University of Birmingham.  You may have to pay your 
legal costs. 
 
[stats – Flesch Reading Ease score= 66.4; Flesch-Kincaid Grade Level Score 7.6] 
 
 
Will my taking part in this study be kept confidential? 
Level one 
Yes.  
 
[stats – Flesch Reading Ease score= 100.0; Flesch-Kincaid Grade Level Score 0] 
 
Level two 
We will follow ethical and legal practice and all information about you will be handled 
in confidence. If you agree to take part then you will be given a copy of this 
information sheet, and a signed consent form for you to keep.  
 
The study data will be collected by questionnaire, measurement (eg blood pressure, 
weight) and from your medical records (eg past medical history, current medications).  
Under the Data Protection Act of 1988, all personal data (names and addresses for 
example) will be stored securely at the University of Birmingham overseen by Dr 
Richard McManus.  Personal data (names and addresses) will be kept separately 
from study results.  Anonymised data from the study will be used in the main analysis 
and may be used in future work, for example comparing blood pressure levels in 
different parts of the country.   
 
Personal data (names and addresses) will be only accessible by authorised persons 
such as researchers, sponsors, regulatory authorities and for R&D audit (for 
monitoring of the quality of the research) and will be retained for approximately three 
years (as long as needed to inform participants of the results of the study).  It will 
then be disposed of securely. 
 
[stats – Flesch Reading Ease score= 39.0; Flesch-Kincaid Grade Level Score 13.9] 
 
Level three 
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We will follow legal practice and keep data in line with the Data Protection Act of 
1988. <http://www.opsi.gov.uk/acts/acts1998/ukpga_19980029_en_1>  
Anonymised data is data that does not include any personal details such as name 
and address.  You cannot be identified from anonymised data.   
 
Personal data is details such as your name, address and anything else that can be 
used to identify you. 
 
To anonymise the data in this study we will give you a unique ID number that can be 
used to identify you.  This means that personal data can be kept separate to your 
results.  Only your ID number needs to be given out to people who do not need your 
personal details.  For example when the data is being analysed, your personal data 
will not be given to people such as statisticians.  They will be able to identify you by 
ID number only.   
This anonymised data may also be used in future work, for example to compare 
blood pressures in different parts of the country.  Passing on anonymised data from 
the study might mean passing on details such as: 
 
 Age. 
 Sex. 
 Ethnicity. 
 If you have high blood pressure or not. 
 Results of blood pressure measurements from the study.   
This allows relevant data to be used for future studies without the need to collect that 
data again.  Collecting the same data again would be time consuming, costly, and a 
burden to patients. 
 
If you would like to know more about how anonymised data is used in research, 
please click here < 
http://www.ncrm.ac.uk/research/outputs/publications/WorkingPapers/2006/0706_anonymising_research_data.pdf 
> 
 
Your personal data will be password protected to stop people accessing it who are 
not authorized to do so.  Before you agree to take part in the study only the 
healthcare team such as your nurse and doctor at your GP surgery will have access 
to your personal data.  If you agree to take part in this study then members of the 
research team will also have access to it.  This information is required by the 
research team so that they can  
 
 Arrange follow up visits. 
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 Send reminder letters. 
  Send you information about the results of the study.   
All staff at the University of Birmingham have confidentiality clauses in their contracts.  
This means they have agreed to keep all information about you and any other 
patients confidential. 
 
Personal data will be kept for three years after the study has finished so that we can 
write to patients to let them know the results of the study.  After this time the data will 
be destroyed.  This means that anything stored on a computer will be deleted in such 
a way that it cannot be restored.  Any paper documents will be cross-shredded. 
We need to keep anonymised data for many years after the study has finished incase 
the study is called for a Research and Development (R&D) audit. 
<http://www.nres.npsa.nhs.uk/rec-community/quality-assurance/accreditation/?locale=en> All research in 
the UK has to meet approvals and follow strict guidelines which protect patients and 
staff.  R&D audits are done on around 10% of all studies taking place in the UK.  
They make sure that these guidelines and approvals are being stuck to.  If a study is 
called for R&D audit then all of the data and documents for the study must be 
available.  This is why we need to keep your anonymised data for many years after 
the end of the study.  No identifiable data will be passed onto any other bodies or 
third parties. 
 
 [stats – Flesch Reading Ease score= 64.2; Flesch-Kincaid Grade Level Score 7.9] 
 
 
What will happen if I don’t want to carry on with the study? 
Level one 
You do not have to carry on and it will not affect your care. 
 
[stats – Flesch Reading Ease score= 84.9; Flesch-Kincaid Grade Level Score 3.6] 
 
Level two 
You are free to withdraw from the study at any time without affecting your treatment 
by your GP.  If you withdraw from the study, we will need to use the data collected up 
to your withdrawal.  
 
[stats – Flesch Reading Ease score= 71.0; Flesch-Kincaid Grade Level Score 7.8] 
 
Level three 
You are free to withdraw from the study.  If you pull out of the study this will not affect 
any treatment from your GP or anyone else involved in your care.  We will ask you 
why you would like to withdraw from the study, but you do not have to tell us.  We will 
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ask you so that we can see if you were unhappy with the study and then try to 
improve the study for other patients.  We will let your GP know about your decision 
so that they are not waiting for blood pressure results. 
 
We would like to use the data collected up until the time you pulled out.  The 
researchers involved in this study have a professional duty to care for you.  With your 
permission we would like to give your GP any blood pressure information we have in 
case this affects your care.  We will also ask whether you are willing to let us 
continue to use the data and information from your records that may help our 
research.  You do not have to agree to this.   
 
[stats – Flesch Reading Ease score= 78.1; Flesch-Kincaid Grade Level Score 6.8] 
 
 
Involvement of your General Practitioner/Family doctor (GP) 
Level one 
We would like to let your GP know that you are taking part. 
 
[stats – Flesch Reading Ease score= 92.2; Flesch-Kincaid Grade Level Score 2.2] 
 
Level two 
We will ask your permission to inform your GP regarding the results from the study. 
 
[stats – Flesch Reading Ease score= 67.5; Flesch-Kincaid Grade Level Score 6.5] 
 
Level three 
If you do decide to take part in this study we would like to let your GP know that you 
are involved.  This is because we would like to give your GP your blood pressure 
results.  If you are found to have high blood pressure, your GP may like to start 
treatment or change your current treatment.  The research team cannot treat patients 
found to have high blood pressure.  If you do not agree for us to tell your GP then 
you will not be able to take part in the study because we would not be able to provide 
the appropriate follow up for you. 
 
For more information about the risks of high blood pressure and why treating high 
blood pressure is important, please click here. <http://www.nhs.uk/Conditions/Blood-pressure-
(high)/Pages/Introduction.aspx>  
 
[stats – Flesch Reading Ease score= 79.4; Flesch-Kincaid Grade Level Score 7.3] 
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What will happen to any samples I give? 
This study does not involve the taking of blood or other samples. 
 
[stats – Flesch Reading Ease score= 74.8; Flesch-Kincaid Grade Level Score 5.8] 
 
 
Will any genetic tests be done? 
No. 
 
[stats – Flesch Reading Ease score= 100.0; Flesch-Kincaid Grade Level Score 0] 
 
 
Who is organising and funding the research? 
Level one 
The research is being done at the University of Birmingham and funded by the 
Department of Health.  
 
[stats – Flesch Reading Ease score= 55.2; Flesch-Kincaid Grade Level Score 9.7] 
 
Level two 
The research is organised by the University of Birmingham.  It is funded by the 
Research for Patient Benefit Programme which is part of the National Institute for 
Health Research and is funded by the Department of Health.   
 
[stats – Flesch Reading Ease score= 50.8; Flesch-Kincaid Grade Level Score 10.7] 
 
Level three 
The study is run from the University Of Birmingham.  The study has been designed 
by staff at the University, who are part of a larger research community there.   
The research is funded by the Research for Patient Benefit Programme (RfPB). < 
http://www.nihr-ccf.org.uk/site/programmes/rfpb/default.cfm> The RfPB aims to improve how health 
care is delivered for patients, the public and the NHS.  It does this by funding 
research to improve health services and social care.   
 
The RfPB is part of the National Institute for Health Research (NIHR), < 
http://www.nihr.ac.uk/Pages/default.aspx> which is funded by the Department of Health. < 
http://www.dh.gov.uk/en/index.htm> They fund NHS and social care research that helps to 
improve public health and social services.  The main aim of the NIHR is to improve 
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the quality, relevance and focus of research in the NHS and social care.  It does this 
by giving out funds after open competition and peer review.  The NIHR funds a range 
of programmes, which cover a wide range of health priorities.   
 
The funding we have pays for the following: 
 
 Wages for staff in the research team. 
 Admin costs such as sending letters and making telephone calls. 
 Equipment needed for the study such as blood pressure monitors. 
 Costs to publish results. 
 
[stats – Flesch Reading Ease score= 68.4; Flesch-Kincaid Grade Level Score 7.0] 
 
 
What will happen to the results of the research study? 
Level one 
We hope to publish the results in professional magazines and present them at 
meetings. 
 
[stats – Flesch Reading Ease score= 53.6; Flesch-Kincaid Grade Level Score 9.2] 
 
Level two 
We are hoping to publish the results of this study in one or more medical journals and 
to present them at one or more conferences.  We will also write to you with the main 
findings of the study after it has finished unless you do not want us to.  We will not 
identify you in any report/publication unless you have specifically given your consent 
for this.   
 
[stats – Flesch Reading Ease score= 60.4; Flesch-Kincaid Grade Level Score 10.3] 
 
Level three 
It is important for us to publish our results so that other researchers can see them.  
The results can then hopefully be used to improve health care.  Publishing helps to 
stop the same piece of research being repeated, which wastes patient’s time and 
funder’s money.  It also allows other researchers to see what has already been done 
so that they can build on the work.  It would be unethical not to publish our results for 
these reasons.  We will publish the results of this study in one or more medical 
journals and present them at one or more conferences.   
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The results will also be produced as an internal report.  This means that other staff at 
the University can see what research is currently being done.  The results of this 
study will also be put on a website so that everyone who is interested can see them.  
They will be distributed through patient groups for example the Blood Pressure 
Association. <http://www.bpassoc.org.uk/Home>.  This will allow patients to see what research 
is being done. None of your personal details will be included in any reports. 
 
If you agree to take part in this study will ask you if you would like to be told the 
results.  If you tell us that you would like to see the results you will be sent a 
summary of the results.   You will also be given the opportunity to receive full details 
such as published papers if you wish.  
 
[stats – Flesch Reading Ease score= 68.3; Flesch-Kincaid Grade Level Score 7.6] 
 
 
Who has reviewed this study? 
Level one 
This study has been reviewed by an ethics committee. 
 
[stats – Flesch Reading Ease score= 66.1; Flesch-Kincaid Grade Level Score 6.2] 
 
Level two 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by the Black Country Research Ethics Committee.  
 
[stats – Flesch Reading Ease score= 45.0; Flesch-Kincaid Grade Level Score 11.6] 
 
Level three 
The National Research Ethics Service (NRES) <http://www.nres.npsa.nhs.uk/> helps to 
protect the rights and safety of people involved in research.  They also help to make 
sure that only research that might help patients or improve science is done.  NRES is 
made up of RECs.  They look at applications and decide whether they think the 
research is ethical.  They balance the need for the piece of research to go ahead 
against the safety and care of the people involved.  RECs are separate from 
investigators and those funding and hosting the research. 
 
[stats – Flesch Reading Ease score= 62.3; Flesch-Kincaid Grade Level Score 8.3] 
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The need for a Study 
What is the problem to be addressed? 
 Cardiovascular outcomes for people from some minority ethnic groups are worse than those of the 
White British group. This increase in cardiovascular risk is due to an interplay of complex factors that 
includes genotype, phenotype, environment and inequalities in access to health care. Measurement of 
risk factors including blood pressure (BP) is assumed to be equivalent between populations but no 
evidence exists to underpin this assumption which is vital in both the diagnosis and management of 
hypertension. Should these assumptions be erroneous, subsequent inadequate care maybe partly to 
blame for the observed outcomes. This has importance locally where significant proportions of 
patients are drawn from diverse and disadvantaged minority populations. This research will investigate 
blood pressure monitoring activity, preferences and results from different methods in four different 
ethic groups.   
 
 
Research Questions 
This study has four main research questions: 
1. How often and in what ways does monitoring of blood pressure occur (including professional 
monitoring, community monitoring and self monitoring) and how does it differ between White and 
*minority ethnic populations? 
2. Are the thresholds for diagnosis and management of hypertension comparable for White and 
minority ethnic  populations using different measurement modalities: office blood pressure, ambulatory 
blood pressure monitoring (ABPM) and self monitoring? 
3. What preferences for blood pressure measurement do people from White and minority ethnic  
populations have? 
* This includes  South Asian (i.e. of Indian, Pakistani or Bangladeshi origin), Black African-Caribbean, 
and Irish. 
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4.  What information are research participants interested in knowing when they are deciding whether 
or not to participate in research and does an interactive information sheet influence participation 
rates? 
 
Why is a study needed now?   
Cardiovascular Outcomes in Ethnic Minority Populations 
Cardiovascular outcomes for people of South Asian, Caribbean and Irish origin are worse than those 
of the White British group.(2,8) For example, South Asians have a 40-50% higher mortality from 
coronary heart disease (CHD) than the population average (9,10) with evidence that the poorest 
groups of Pakistani and Bangladeshi origin have the highest rates.(2,11,12) The mortality of migrant 
Caribbeans from CHD is lower than the national average but stroke deaths are higher (in women by 
57%, men 24%) with hypertension (HT) being the major associated risk.(2) What data there are 
suggest little improvement in mortality of UK-born Caribbeans.(13) Similarly, the Irish living in Britain 
experience higher mortality from both CHD (in women by 20%, men 24%) and strokes (in women by 
23%, men by 38%). Little is known about CHD and stroke mortality among UK-born Irish but reported 
cardiovascular mortality for men with Irish names living in Scotland was found to be increased by 
51%.(14) 
 
This increase in cardiovascular risk in ethnic minority groups is due to an interplay of complex factors 
including genetic, cultural (smoking habits, diet, barriers to health care) and deprivation.(13,15) HT 
remains a significant and treatable risk factor in all groups. For example, in a Bangladeshi population 
with type 2 diabetes the authors identified a prevalence rate 23.2% for systolic HT.(16) There is also 
evidence HT may go undetected and under treated in ethnic minority groups. Cappuccio et al found a 
2-3 fold increase in HT in South Asians and Caribbeans; only 49% of hypertensives had adequate 
control; 18% were undiagnosed before the survey and 17% were not receiving medication.(17) 
 
Cardiovascular Process Measures in UK Primary Care 
Data from the Quality and Outcomes Framework suggests that practices providing care to minority 
ethnic populations achieve lower quality scores.(3) Few studies of BP monitoring undertaken over the 
last 20 years have included people from South Asian, Caribbean or Irish populations with the result 
that very little is known about comparative measurements including self monitoring. For instance, it is 
not clear whether the white coat effect seen in white populations is similar, greater or less amongst 
these ethnic minorities. Nor is it known whether observed differences between office and home 
measurements in Whites are similar or different in Asian, Caribbean or Irish populations. 
Diagnosis and management  of blood pressure 
The diagnosis and management of blood pressure are informed by guidelines largely based on 
research from White populations.(18,19) These guidelines recommend diagnostic and treatment 
thresholds for hypertension on the basis of office BP readings with the option of 24 hour ambulatory 
monitoring (ABPM) but make no distinction between ethnic groups. 
 
Blood Pressure Monitoring 
Increased availability of various automated devices has encouraged individuals to monitor their BP at 
home. The use of ABPM has also led to a realisation that multiple readings may improve accuracy of 
diagnosis. In general, both ABPM and home monitoring may help to improve treatment,(20,21) identify 
resistant HT,(22) diagnose white coat HT (1,23,24) and predict cardiovascular outcomes.(25,26,27) 
ABPM is the only method that can identify poor night time dipping which is a poor prognostic 
indicator.(28) The definitive diagnosis of white-coat HT by means of ABPM may ultimately reduce 
health care costs.(27) 
 
Conclusions 
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The proposed study will look at accuracy and acceptability of home, ABPM and clinic readings in 
minority ethnic populations in relation to the White British group. The local setting is ideal for the 
proposed study as  70% of the population in the Heart of Birmingham PCT are from black minority 
ethnic groups and the Birmingham and Black Country locality has a high prevalence of people 
describing themselves as Irish. This work has the potential for significant impact on local policy-making 
and improvement in service delivery both in terms of increased access to services in a deprived local 
population and also of improvements in service stemming from new knowledge. 
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Has a systematic review been carried out and what were the findings? 
No systematic review of blood pressure monitoring in different ethnic groups has been carried out. 
Few studies have directly compared both methods of home monitoring with clinic readings (29,30) and 
ethnic minorities have not been included as a separate group. It is recommended that thresholds for 
treatment be adjusted down by 10/5 mmHg when home readings are used but these standards have 
not been specifically set in ethnic minority groups. Some patients may find it difficult to comply with 
ABPM which requires them to keep the arm still while the cuff is inflating and to avoid physical exertion 
during monitoring.(31) In addition, measurement of night time readings may interrupt sleep. The 
impact of these practicalities on use of home monitoring has not been addressed in different ethnic 
groups where language barriers and cultural differences may be relevant. 
 
How will the results of this trial be used? 
Over 12% of the adult population are currently receiving treatment for hypertension however despite 
this many people still have inadequate blood pressure control. One reason for this may be that current 
monitoring regimes are inappropriate for sections of the population both in the diagnosis and further 
management of hypertension. In Birmingham, ethnic minority populations form the majority of 
constituents in many wards and yet monitoring regimes are tailored to the White population with little 
research evidence that this is appropriate. This is important because each 5mmHg reduction in usual 
systolic blood pressure is associated with reductions in stroke and coronary heart disease risk of 
around 20% and 10% respectively. 
 
Information about norms for ambulatory and self monitoring in minority ethnic groups is vital to allow 
optimum care to be provided both in the diagnosis of hypertension and in further management by 
intensifying care for those with high risk and removing unnecessary treatment (and therefore side 
effects) where appropriate. The White Irish population are in particular often ignored in research 
despite high levels of cardiovascular disease. Self monitoring has the potential to achieve reductions 
of blood pressure whilst encouraging increased use of non pharmacological interventions and the 
work will identity which method of monitoring is most acceptable to patients, which may vary among 
ethnic groups. 
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Risks to the safety of participants involved in the trial 
Potential Risks 
We anticipate that the potential risks of this study are low and similar to those attributable to usual 
care. Particular issues are where a patient finds an excessively high or low reading in the home 
monitoring arm and the possibility of increased anxiety due to the study. The patient guideline will 
advise contact with the supervising physician or nurse in the case of excessively high or low readings. 
Training of participants will cover repeated measurements in the case of unusually high or low 
readings and a help line will be available should subjects require advice over and above that available 
in the guideline. 
 
Potential Benefits 
Potential benefits for an inidividual taking part include better information about their usual blood 
pressure and the possibility that either new hypertension or poor blood pressure control will be 
recognised during the study.  Furthermore, from a societal view point, information about norms for 
ambulatory and self monitoring in minority ethnic groups is vital to allow optimum care to be provided 
both in the diagnosis of hypertension and in further management by intensifying care for those with 
high risk and removing unnecessary treatment (and therefore side effects) where appropriate. 
 
 
The Study 
Study design 
Part 1 
A cross sectional survey of 8000 people including representative samples of four ethnic groups (as 
given in part 2 below) chosen to cover both normotensive and hypertensive blood pressure ranges will 
elucidate current blood pressure monitoring patterns (self, third party (pharmacy etc), health 
professional), confirm ethnic group and identify participants for the validation study.   
 
Part 2 
This is a validation study comparing the ability of the different modes of BP measurement to diagnose 
hypertension and to detect thresholds for up or down titration of medication. Typically three office 
measurements are required to make a diagnosis of hypertension and a threshold of 140/90 mmHg 
(standard office measurement) is used by NICE guidelines in both diagnosis and treatment targets for 
people with uncomplicated hypertension. Similar standard thresholds are available for ambulatory and 
self measurements and the thresholds for treatment targets vary depending on co-morbidity, most 
notably for diabetes. We will use the office standard measurement as the reference from which to 
ascertain differences to ambulatory blood pressure, self monitored BP and research (see below) office 
measurements in order to ascertain whether such differences are similar in White, Black, South Asian 
and Irish populations and therefore whether or not the same diagnostic and treatment target 
thresholds are appropriate.  
 
Embedded study: Interactive Information Sheet (IIS) 
Those participants who have access to the internet, and are willing to do so, will be offered information 
electronically. Half will receive a .pdf file of the paper information sheet and the other half an 
interactive Internet information sheet (IIS), with three increasingly detailed levels of information, the 
second of which is identical to the .pdf file.   
 
Part 3 
Focus groups including patients from each ethnic group will consider patient preferences for and 
experiences of blood pressure measurement in each of the three ways considered by the study. 
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Study Methods 
1 Survey of blood pressure monitoring in representative White and minority ethnic Populations.  
Population and Rationale for sampling strategy,  
A postal questionnaire with telephone follow up where required by bi-lingual researcher(s) will be sent 
to a random sample of people who appear on the hypertension and general population registers of 
approximately twenty practices, from the Birmingham and Black Country Area (8000 individuals in 
total). Within each practice we will approach a random stratified sample of approximately 250 people 
with hypertension and an equivalent sized random population not known to be hypertensive to ensure 
that people with a range of blood pressures are included as well as diagnosed and undiagnosed 
hypertension. People whom the general practitioner feels that it would be inappropriate to approach, 
for example those with a terminal illness, acutely unwell with a severe mental illness or recent 
bereavement will be excluded. 
 
 
 
 
 
 
 
 
Search practice 
clinical system 
Random sample 
of 250 
All non 
hypertensive 
 
 
All hypertensive 
 
 
 
Random sample 
of 250 
 
500 potential 
participants for 
checking by GP 
 
Approx 475 sent 
survey 
 
 
250 responses 
 
 
 
Figure 1 Recruitment strategy for phase 1 
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The survey will be kept short (2 sides of A4 max). Practices will be chosen on the basis of census data 
for their practice area, and using specialist knowledge from previous research which include a majority 
of people from one or more of the four ethnic groups of interest. Patients will be targeted using 
practice ethnicity records (both to include and exclude potential participants) along with local 
knowledge with the aim of recruiting a sample including similar proportions of people of South Asian 
(ie Indian, Pakistani and Bangladeshi), Black African-Caribbean, Irish and White origin. The success 
of this sampling strategy will be reviewed as the study goes on and recruitment targeted with 
additional questionnaires towards under represented groups as necessary.   
 
 
Pilot/Previous Work  
Previous work in a general (largely white) population sample (2931 respondents) has shown that 
around 9% of adults have self monitored blood pressure and that a response rate to a simple 
questionnaire of around 60% is feasible. Pilot work (RCGP Scientific Board Small Grant, Baral S, 
McManus RJ 2007-8) surveyed self monitoring in people with hypertension, diabetes or both, again in 
a general population, and found a prevalence of between 15-30% varying with diagnosis. Work in 
ethnic minority populations has shown that additional measures are required in order to get 
reasonable response rates and hence generalisable populations: it is often stated that the responses 
to surveys by minority ethnic groups are low but this is not borne out by the extensive study by Bhopal 
et al who achieved a 68% response rate by engaging with the local communities, providing information 
in appropriate languages and using bilingual staff to answer any questions. These measures are 
currently being utilised in a large heart failure screening study that the BHF has recently funded (E-
Echoes – screening 3000 people from minority ethnic populations) and will be implemented in the 
proposed study. 
 
 
Method of data collection 
A survey, with covering letter translated into appropriate languages, will ascertain the blood pressure 
monitoring experience of respondents in the last year including prevalence of self monitoring as well 
as use of community pharmacies for monitoring and uptake of clinical professional monitoring at 
surgeries or outpatients. The questionnaire, developed from the previous and pilot work above, will in 
addition elicit basic socio-demographic characteristics (e.g. age, sex, ethnic group and employment 
status) as well as type of monitoring used in the case of self monitoring (wrist/upper arm, model if 
known). We will explicitly request permission to review practice records to corroborate professional 
monitoring responses and to allow inclusion of co-morbidities and medication history with the results of 
the survey. The investigators have a track record of linking survey results with multiple professional 
datasources. Lists will be verified by General Practitioners (GPs) from participating practices prior to 
being sent out to patients.  The survey will include an invitation for stage 2 (validation) of the study as 
a means to recruit participants. An email address will be requested so that participants can be invited 
to receive information about part 2 electronically as an alternative to the standard paper participant 
information sheet (PIS). 
 
Embedded Interactive Information Sheet (IIS) study methods 
Participants who choose to access information electronically can do so via the Bp-Eth website (see 
appendix one for the email invitation). Those participants who choose to take part in the embedded 
study will be randomised to either the .pdf file or the interactive information sheet (appendix two). 
Those participants who do not wish to take part will be sent the standard paper version.  The 
understanding, and satisfaction (appendices three & four) with the information provided, of all 
participants will be assessed and compared.  
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Figure 2 shows where the embedded study of electronic information fits into the Blood Pressure 
Monitoring Study. 
 
2 Comparison of acceptability and agreement of different measures of blood pressure in 
representative White and minority ethnic Populations.  
 
200 each of White, Black, Asian and Irish participants recruited from respondents to study 1 (half with 
diagnosed hypertension and half without known hypertension) will be invited to undergo blood 
pressure measurement by three methods: office measurement in both arms using a BP-Tru (BHS A/A 
rated) automated sphygmomanometer (BP measured three times: at the beginning, middle and the 
end of study period of eight days; this will be used to generate two sets of readings: standard office 
(mean of second and third readings on three occasions) and research office (mean of second to sixth 
readings on three occasions)), 24 hour ambulatory blood pressure x 1 (BHS validated monitor rated  
to record mean 24, mean day time and mean night time), and self monitoring consisting of paired 
readings taken twice daily for one week (28 readings in all stored in monitor memory) using a 
validated monitor (BHS validated). Office readings will be taken in both arms simultaneously at 
baseline and postural hypotension will be checked for by measurement after 1 minute standing.  All 
patients will have measurements taken in the following order: 
 
Day 1 Days 1-7 Day 7 Day 8 
Office 
Measurement 
Home 
Measurement 
Office 
Measurement  
Office 
Measurement 
Trained to do 
home readings 
 ABPM applied ABPM 
removed 
Table 1 Overview of measurements 
 
For both ambulatory and self monitoring, bespoke training developed by our team for previous projects 
and clinical work will be used and will be delivered to participants by the research nurses. Training will 
include timing, positioning, and setting of measurement with careful instruction on safe use of 
ambulatory monitoring including for instance care if the monitor starts when driving. Close cooperation 
between the research team and colleagues in the Wellcome Clinical Research Facility and MidReC 
will ensure that appropriate standard operating procedures and clinical supervision is available. Drs 
McManus and Martin will take responsibility for any clinical issues arising through the study and will 
liaise with individual’s GPs as required. 
 361 
 
 
Receive questionnaire 
through post 
Complete 
questionnaire 
Decline to complete 
questionnaire 
Accept invitation 
to participate in 
part 2 
[ePIS option] 
Decline invitation to 
participate in part 2 
Day 1: Attend initial meeting with research nurse: 
 
- Consent 
- Initial questionnaire 
- Office BP Measurement 
- Research BP Measurement 
- Participant trained re. home monitoring and issued with equipment 
 
Day 7: Second visit to research nurse: 
- Return home monitoring equipment having completed 7 days of 
monitoring 
- Office BP Measurement 
- Research BP Measurement 
- Participant counselled re. ambulatory monitoring and issued with 
equipment 
 
 
Day 8: Third visit to research nurse: 
- Return ambulatory monitoring equipment having completed 24 hours 
of recording 
- Office BP Measurement 
- Research BP Measurement 
- Final questionnaires 
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Figure 2 Overview of Phase 2 
In each case the differences between office and the other modes of measurement will be compared 
between the White British Group and the other minority ethnic groups. The order of home and 
ambulatory measurement undertaken within each group will be randomly varied. A further comparison 
will be between the study readings and routinely collected measurements from the practice clinical 
systems made by both GPs and nursing staff. Once all three modalities of measurement are complete, 
participants will be asked to complete a questionnaire assessing the acceptability of the various 
methods of blood pressure measurement. 
 
During the study it is likely that new cases of hypertension, poor control of treated hypertensives and 
the presence of other features including white coat hypertension and lack of nocturnal dipping will be 
detected. In view of this we will specifically report back the results of all modalities of monitoring with 
appropriate interpretation and/or recommendations to the GPs of participating patients in terms of the 
meaning of results and suggested further management and/or referral where indicated. Patients will 
also receive individualised reports. These are issues identified as important in our feasibility 
discussions with patients and local practices. 
 
Patients will be offered the opportunity to be seen in their own practices and/or the Wellcome Clinical 
Research Facility at the UHB hospital. Study nurses will liaise with practice staff and where 
appropriate service support costs for practices’ out of pocket expenses will be applied for from the 
relevant Comprehensive Research Network (CLRN). Participants travelling expenses will be 
reimbursed. An 0800 helpline number will be available for queries during office hours. 
All study data will be kept secure in accordance with university procedures and the Data Protection 
Act. 
 
3 Qualitative Component 
Participants will be asked to indicate in the questionnaires from phase 2 if they are willing to be 
contacted again to take part in a focus group.  Focus groups  will take place following the monitoring 
phase to provide richer outcome data regarding the acceptability of the various monitoring modalities.  
The emphasis will be on participants’ experiences of taking part in and satisfaction with monitoring, 
perceptions of the relative advantages and disadvantages of office, home and ambulatory monitoring 
(e.g. level of stress experienced, discomfort and inconvenience, length of time procedure takes, 
understanding and interpretation of differences in readings from different monitoring methods, 
preferences for and value of BP reading taken by Doctor, nurse, patient themselves). Focus groups 
will comprise 6-8 individuals and will include members of a single ethnicity and gender in any given 
group (i.e. 10 focus groups in total) as our previous experience has shown that participants are often 
more forthcoming in the presence of those with similar characteristics. To ensure inclusion of 
participants with limited English, two language specific focus groups will be held for South Asian 
participants. As the potential participants are  from ‘hard to reach’ groups in order to ensure we 
capture the views of the range of study subjects if some subjects of interest remain under represented, 
we will provide the option of individual interviews for people who want to contribute (e.g. working men) 
but who cannot make the times stated. A range of venues will be offered for the focus groups e.g. 
healthcare location, community location, university  They will be facilitated by two members of the 
study team, one will facilitate the group and the other will observe and take detailed field notes to note 
non-verbal interactions and proceedings will be taped with the permission of participants.   
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 White 
British 
White Irish African-
Caribbean  
Asian 
(language 
1)* 
Asian 
(language 
2)* 
Male      
Female      
Table 1 Grid showing make up of ten focus groups. (* language specific groups 
to be chosen depending on requirements of participants eg Urdu & Hindi) 
 
Analysis will be carried out by reading the transcripts and identifying emerging themes and categories 
with attention to the interaction between participants.  Each transcript will be independently analysed 
using the principles of thematic content analysis, by two of the researchers.  Additionally the co-
applicants from different disciplines will read and analyse some of the transcripts to allow the data to  
be considered from the range of perspectives within the study team. An overall summary of themes 
and categories emerging from the focus groups will be compiled as well as a summary for individual 
focus group which will allow for between focus group comparison and the identification of any 
similarities and differences.  
 
Duration of study period / follow up 
The initial survey will take approximately 10 minutes to complete.  The validation study will require 
each patient to participate for three visits to the research nurse over eight days. On each occasion it 
should take no more than 30 minutes to complete the follow up activities.  Focus groups are expected 
to last approximately 1 hour. 
 
Inclusion / exclusion criteria  
The study population will comprise people with both diagnosed hypertension and those not known to 
have hypertension recruited from primary care.   
 
Subject inclusion criteria. 
Eligibility criteria will be age between 40-74 and belonging to one of the four ethnic groups under 
investigation (White, Irish, Asian, African-Caribbean) .  
 
Subject exclusion criteria. 
Exclusion criteria will include inability to self monitor or use an ambulatory blood pressure monitor, 
pregnancy, inability to consent, terminal disease, or those felt by their GP not to be suitable. 
Subject withdrawal criteria: 
Subjects will be withdrawn from the study if they choose not to continue.  
 
Outcome Measures 
Part 1 
The primary outcome measure will be prevalence of self, professional (practice, pharmacy, outpatient) 
and ambulatory monitoring over the last 12 months in each ethnic group. Secondary outcomes will 
include preferences for types of monitoring. 
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Part 2 
The primary outcome will be the mean between difference in standard office (mean of second and 
third readings on three occasions) , ambulatory mean day time blood pressure, self monitored BP, 
office research (mean of second to sixth readings) and routine practice blood pressures (GP and 
practice nurses) in White, South Asian, Black African –Caribbean and Irish populations in people 
being treated for hypertension and in people not being treated for hypertension. Ambulatory 
monitoring will be treated as the reference standard with other measurements compared to it. The 
effect of these differences on diagnostic and treatment target thresholds will be evaluated. 
 
Interactive Information Sheet 
The primary outcome measure will be the proportion of eligible participants agreeing to participate in 
the blood pressure monitoring study.  Secondary outcomes include participant satisfaction, 
understanding and information needed to make a decision to participate 
 
Frequency / Duration of Follow up 
Each patient will be in the study for eight days (3 visits). Each follow up visit will be timetabled for no 
more than ½ hour. 
 
 
Measurement of Outcome measures 
The primary outcome measures of blood pressure will be measured using a validated electronic 
sphygmomanometer so as to reduce bias potentially introduced by the unblinded nature of the 
investigation. Secondary outcomes will be measured using validated questionnaires where 
appropriate or by collection of original data (weight and height) or extracted data from notes (past 
medical history).  
 
Methods for protecting against other forms of bias 
Because of the nature of the investigation, blinding will not be possible for patients taking part in the 
study. In order to minimise the effects of this, researchers measuring blood pressure for the end points 
will use validated automated electronic sphygmomanometers where measurement will not be affected 
by knowledge of allocation. 
 
Sample size and power calculation 
Part 1: 
Twenty practices with mean list size of 5000 adult patients (lower than normal to take into account the 
typical practices in majority ethnic population areas such as the inner city) with a conservative 
prevalence of hypertension of 10% will result in a potential sample of at least 10000 patients with 
hypertension and many times this without. We will send questionnaires to a random sample of 4000 
stratified by practice and ethnic group (where known) with a Read code for hypertension and 4000 
with no such Read code but who have at least one blood pressure recorded on the practice computer 
in the last 5 years- stratification will be based on ethnicity. A 50% response rate (realistic in this 
population from previous work) will mean 4000 responses.  We anticipate that a proportion of 
responses will fall outside of the four ethnic groups we are studying hence may need to send further 
questionnaires (up to 10000) in order to receive responses from 1000 individuals in each main ethnic 
group being studied, half of which will have hypertension and half not (see appendix 1). This will allow 
us to estimate the overall prevalence of the different types of monitoring with and without hypertension 
to within 2.7% assuming a 10% prevalence of monitoring in each case (the approximate community 
prevalence of self monitoring in a white population). 
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Part 2  
100 patients with and without hypertension will be recruited from each ethnic group.(see appendix 1) 
Based on previous work in a white population, 200 patients per ethnic group, ie 800 people in total, will 
be sufficient to detect a difference of 5mmHg in mean differences between any two populations (this is 
sufficient across the plausible range of standard deviations between 12-18 mmHg, power 80%). 
Differences of less than 5 mmHg are unlikely to be clinically significant given the day to day variation 
of blood pressure within individuals. A further approximately 5% will be recruited as required to take 
into account drop outs or equipment malfunction. 
 
Recruitment and Rationale for sampling strategy,  
Because we will have already identified potentially willing participants in study 1, any problems in 
recruitment for study 2 will be identified at an early stage. Patients will be identified from practices who 
are members of the Midlands Research Practice Consortium (MidReC) and/or the Central England 
Primary Care Research Network (PCRN-CE). MidReC includes around 300 practices in the West 
Midlands which have been shown to be generalisable to wider primary care. In the event of the 
responses from study 1 suggesting that recruitment may be difficult, then further practices will be 
recruited for study 2 and participants identified through invitation letter following further practice 
searches. The sampling strategy, is designed to recruit populations representative of the target ethnic 
groups with a range of blood pressure including both those receiving treatment and those not. 
 
Planned recruitment rate 
The study has a two year timetable (see Gant chart):   
The initial survey will be distributed in a stepped fashion covering 6 or 7 practices at a time allowing 
sufficient gaps between each tranche to undertake the measurement comparisons and avoiding long 
gaps between inviting a person to take part and undertaking the monitoring.  15 months of monitoring 
with a maximum of 20 patients per week and taking into account holidays will be sufficient for 1100 
patients to be monitored. Monitoring will occur within practices and/or the Welcome CRF facility as 
determined by patient preference. The study requires 800 (840 including 5% drop put) patients which 
allows leeway for clinics where not all places are filled.  Six months for analysis including 3 months for 
writing up provides a small contingency should slippage in time occur. 
 
20 patients per week: 5 x 24 hr monitors: Mon Tues Weds Thursday & Friday clinics with five –ten 
slots each for fitting and removal of 24 hour monitors and/or training for home monitoring.  The latter 
will need 20 x home monitors to be available, each for a week. We know from experience that 
practices have variable room availability which is taken into account in this schema.  
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Gant Chart Showing Study Plan 
Month 1-3 4-6 7-9 10-
12 
13-
15 
16-
18 
19-
21 
22-
24 
 
Recruit 
Practices,  
        
Survey 
 
        
Validation 
study 
        
Analyses 
 
        
Write up 
 
        
Steering 
groups 
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Potential problems with compliance 
Compliance in this study will comprise compliance to the protocol with respect to ambulatory and self 
monitoring. This will be monitored by self report and by review of self monitored blood pressures.  
Likely rate of loss to follow up 
 
The TASMINH1 and 2 studies with a similar group of patients achieved a 91% follow up rate of 
patients after 1 year. Once patients are recruited they will have three visits in short succession and so 
drop outs should be minimal. We have conservatively estimated a 5% drop out rate in our recruitment 
calculations but will aim to maintain less than this.  
 
Centres involved  
20 General Practices drawn from the Midlands Research Practice Consortium from within the 
Birmingham and Solihull area. For each site the relevant primary care physicians will retain direct 
medical responsibility for trial patients. 
 
Assessment of Safety 
Specification of safety parameters. 
Where office, ABPM or HBPM readings suggest a diagnosis of previously undetected hypertension or 
that increased or new medication may be required for blood pressure, a letter will be sent to the 
patients GP suggesting this and patients will be advised to make an appointment for review.  All 
patients’ results will be communicated to their GP in any case with Dr Una Martin providing specialist 
input where required. 
 
Procedures for eliciting reports of and for recording and reporting adverse event and intercurrent 
illnesses. 
We do not anticipate a high level of adverse events as this is an observational study.  Patients 
experiencing adverse events (eg discomfort from blood pressure monitoring) will be asked to contact 
the study helpline or their own primary care physician as appropriate.  
 
Analysis 
Part 1 
The prevalence of blood pressure monitoring will be estimated and the variation in prevalence 
between different age groups, sex, employment status and deprivation as measured by the Index of 
Multiple Deprivation as well as the association with ethnic group will be explored using logistic and 
multi level logistic regression  
 
Part 2 
Between groups, t tests will be used to compare mean differences in ambulatory vs office, home 
monitored and routine blood pressure between White, South Asian, African-Caribbean, Irish 
populations separately for people with a diagnosis of hypertension, and for people without a prior 
diagnosis of hypertension (ambulatory used as reference standard). Because we are interested in the 
differences between each ethnic minority groups and White British, each comparison is of interest and 
will be dealt with individually. Thus no adjustment for multiple comparisons is required. Within groups, 
repeated measures General Linear Modelling (GLM) and multi level models will be used to evaluate 
differences between the different methods of measurement and routinely collected BP data with post 
hoc tests where significant differences are found. Baseline covariates will be examined for similar 
age/gender/ blood pressure distribution and adjustment will be incorporated in the analysis where 
necessary. We will investigate whether differences or errors are related to level of blood pressure.  
 
Level of significance to be used. 
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P<0.05 
 
Procedure for accounting for missing, unused, and spurious data. 
A sensitivity analysis will examine the potential effect of missing data.  
 
Procedures for reporting any deviation(s) from the original analysis plan  
Any deviation from the original analysis plan will be described in the final report and publications. 
Frequency of analysis 
Analyses will be performed at the end of the study after all data has been collected. No interim 
analysis will be performed as this is an observational study.  
 
Planned sub group analysis 
Planned sub group analyses will be of diabetic vs non diabetic patients, older vs younger (65 as 
threshold), males vs females, higher vs lower blood pressure (threshold 150 systolic).  
 
Analysis for IIS part of study 
Analysis will be carried out based on intention to treat. 
 
Primary Outcome 
The primary outcome of this study is the proportion of eligible participants agreeing to participate in 
Bp-Eth.  The primary analysis will assess the impact of IIS on consent using a mixed model with a logit
 
link and binomial error accounting for baseline age and gender and with practice as random effects.  
Odds ratio 95% CI and p value will be presented. 
 
Secondary Outcomes: 
Exploratory analysis will be undertaken to assess patient satisfaction, understanding and the level of 
information needed to make a decision. The relationship between patient characteristics and these 
outcomes will be considered (age, gender, deprivation etc).   
 
 
Ethical Issues 
Ethical and R&D approval for the full study will be gained. Consideration will be given to the potential 
sensitivities of individuals from minority ethnic groups. Telephone contacts will be used to ensure that 
people from hard to reach groups are given appropriate opportunity to take part. Written consent will 
be sought from the patients for access to their medical records.  Any data stored about the patients 
The main ethical issues relating to the study are regarding confidentiality and data protection. Initial 
invitations will be sent by the practices. All of the research team with access to patient identifiable data 
will have honorary contracts with the relevant primary care organisations. All participating patients will 
be asked for permission to gain access to their medical records. The research project is registered 
with the Data Protection Commissioner via the University of Birmingham Data Protection Officer. 
It is possible that blood pressure monitoring may increase anxiety in participants but previous work by 
our team has not found this to be common.  Should an individual feel excessively anxious due to study 
procedures then they will be free to withdraw. 
 
For the interactive information sheet part of the study 
As this is an observational study (albeit electronic observation), we will not be able to inform 
participants that we will record the type and amount of information they access as this would bias 
results.  Participants will be informed of all aims that are not likely to invite bias into the study. They will 
know that the information provided online is to evaluate and pilot a new way of providing study 
information to participants. Our results will inform how future research participants receive information. 
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Study Management  
Day to day management 
The study will be managed on a day to day basis by the research team led by Dr RJ McManus. 
Responsibilities of Team Members 
Dr RJ McManus: overall responsibility for the study 
Dr Una Martin: specialist hypertension input 
Steering group: strategic direction for the study 
Research Nurses:  Research Clinics 
Study statistician 
Mr Roger Holder 
Study Steering Group 
Dr Richard McManus 
Dr Una Martin 
Dr Paramjit Gill 
Prof Jonathan Mant 
Mr Roger Holder 
Dr Jamie Coleman 
Dr Mohammed Mohammed 
Dr Sheila Greenfield 
Dr Sally Wood 
Dr Tehreem Butt 
Lay representatives 
 
Data Handling and Record Keeping 
Data will be recorded onto a combination of electronic and paper case record forms. In the case of 
electronic forms, underlying data will be stored in password protected files with strong patient 
identifiers kept separately from the rest of the data.   
 
Direct Access to Source Data/Documents 
The investigators will permit study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s), providing direct access to source data/documents as necessary.  
 
Quality Control and Quality Assurance 
Data for this study will be entered onto an electronic database which will have built in safeguards 
regarding data quality. All research staff and practice staff involved in the study will be subject to 
quality control checks by the Primary Care Clinical Trials Unit.  
 
The identification of any data to be recorded directly on the CRFs (i.e. no prior written or electronic 
record of data), and to be considered to be source data. 
 
Source data will consist of: 
Initial Survey Questionnaires 
Demographics and past medical history 
Current Medication 
Blood pressure readings 
Questionnaires from phase 2 
Qualitative transcripts from phase 3 
 
Financing and Insurance 
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The trial is funded by the NIHR Research from Patient Benefit Programme. Study insurance to cover 
negligent harm will be provided by the sponsors, the University of Birmingham. Individual medical 
indemnity insurance (typically by the MDU or MPS) will cover negligent harm arising from clinical care 
provided by participating primary care physicians. No funding is available for non negligent harm. 
Publication Policy 
The results from this study will be published in a peer reviewed journal. This publication and the data 
on which it will be based will remain independent of the funders. 
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9.5 ELECTRONIC INVITATION LETTER  
 
Dear participant, 
 
You have kindly filled in a questionnaire for this study and indicated that you would 
be happy for us to contact you again. 
 
We would like to invite you to attend a study clinic held by the research team here at 
the surgery on xyz days between a and b. This will initially involve further information 
about the study and a discussion as to whether you would like to take part in the 
research. If you do decide to take part your blood pressure will be measured in three 
different ways (by a nurse, at home and with an automatic machine) and we will ask 
you to attend clinics on two further occasions.  
 
Please read the patient information sheet which can be found at 
www.studyurl.bham.ac.uk that will tell you about the study and help you decide 
whether you may be interested in taking part.   
 
Your username for the website is  X 
 
  Because we value your potential participation and because we know that using 
electronic information sheets is a new way of giving out information, if we do not hear 
from you within 7 days of sending this email, we will send you a standard paper 
information sheet in the post. This is to ensure that you have got the information you 
have requested. 
 
 If you decide you would like to attend a study clinic at the surgery, could you please 
telephone the research study helpline on 0800 234 6 432 (not the surgery) to make 
an appointment. If you are not available at the times outlined above but would still 
like to take part then the researchers will do their best to make other arrangements. If 
you have any questions about the research and would like to talk to someone before 
deciding to attend a study clinic then please also telephone the study helpline (0800 
234 6 432). 
 
We would like to emphasise that you do not have to take part, and if you decide not 
to, your medical care will not be affected. It is also important for you to understand 
that even if you agree to attend the study clinic to find out more about the research, 
this does not commit you to taking part.  
 
Yours sincerely, 
 
Professor Richard McManus 
Chief Investigator 
 
 372 
 
9.6  PIS FOR INTERVIEWS WITH PARENT STUDY PILOT PARTICIPANTS AND 
RESEARCH NURSES 
 
 
Hub for Trial Methodology Research 
University of Birmingham 
Edgbaston 
Birmingham 
B15 2TT 
25
th
 March 2010 
 
Dear participant, 
 
 
I am a PhD student at the University of Birmingham, conducting research into the type and amount of 
information that participants want to know before they are able to make a decision about whether or 
not to take part in a research study.  You have been invited by the research nurse from the 
hypertension study you are taking part in / Dr Paramjit Gill to take part in an interview. 
 
This research is designed to look at the amount and type of information that potential research 
participants want to know before they agree or refuse to take part in a study. The information collected 
during these interviews will be used to design a new type of participant information sheet and to 
improve the way in which research participants are informed about research studies.   
 
If you agree to take part, the interviews will last approximately an hour and a half.  More detailed 
information about this study can be found in the participant information sheet, which is included with 
this letter. 
 
You have been asked by your research nurse/Dr Paramjit Gill and agreed that your contact details can 
be provided to me.  I will contact you in the next few days to ask if you are interested in taking part in 
an interview.  If you are willing to take part I will also arrange a suitable time and place for the 
interview. 
 
 
 
If you have any questions or prefer to contact me yourself, please ring Helen Kirkby on  
 
 
 
 
Thank you for your time, 
 
Yours sincerely,  
 
Miss Helen M Kirkby 
 
PhD Student, 
Hub for Trials Methodology Research, 
The University of Birmingham  
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9.7 PROPORTIONS OF PARTICIPANTS ACCESSING EACH LEVEL OF INFORMATION FOR EACH FAQ BY AGE, GENDER 
AND ETHNICITY 
 
Proportions of participants accessing each level of information for each FAQ by age 
 
 Level one 
 
Level two Level three 
Age group 
 
45-55 55-65 65+ 45-55 55-65 65+ 45-55 55-65 65+ 
Purpose of the 
study 
10/24 
(41.7%) 
6/14 
(42.9%) 
2/6  
(33.3%) 
3/24 
(12.5%) 
1/14  
(7.1%) 
0/6  
(0%) 
1/24 
(4.2%) 
1/14 
(7.1%) 
0/6  
(0%) 
Have to take 
part 
4/24 
(16.7%) 
2/14  
(14.3) 
2/6  
(33.3%) 
0/24  
(0%) 
0/14  
(0%) 
0/6  
(0%) 
0/24  
(0%) 
0/14  
(0%) 
0/6  
(0%) 
Why been 
chosen 
9/24  
(37.5) 
5/14 
(35.7%) 
4/6  
(66.7%) 
1/24  
(4.2%) 
2/14 
(14.3%) 
1/6  
(16.7%) 
0/24  
(0%) 
1/14 
(7.1%) 
0/6  
(0%) 
Expenses 
 
10/24 
(41.7%) 
8/14 
(57.1%) 
4/6 
(66.7%) 
1/24  
(4.2%) 
3/14 
(21.4%) 
1/6  
(16.7%) 
1/24 
(4.2%) 
1/14 
(7.1%) 
0/6  
(0%) 
What will 
happen 
10/24 
(41.7%) 
8/14 
(57.1%) 
4/6  
(66.7%) 
2/24  
(8.3%) 
1/14  
(7.1%) 
1/6  
(16.7%) 
1/24 
(4.2%) 
0/14  
(0%) 
0/6  
(0%) 
Risks 
 
10/24 
(41.7%) 
8/14 
(57.1%) 
4/6  
(66.7%) 
3/24 
(12.5%) 
3/14 
(21.4%) 
1/6  
(16.7%) 
1/24 
(4.2%) 
1/14 
(7.1%) 
0/6  
(0%) 
Benefits 
 
9/24 
(37.5%) 
8/14 
(57.1%) 
4/6  
(66.7%) 
2/24  
(8.3%) 
2/14 
(14.3%) 
1/6  
(16.7%) 
1/24 
(4.2%) 
0/14  
(0%) 
0/6  
(0%) 
Problems 
 
7/24 
(29.2%) 
6/14 
(42.9%) 
3/6 
(50%) 
1/24  
(4.2%) 
0/14  
(0%) 
0/6  
(0%) 
0/24  
(0%) 
0/14  
(0%) 
0/6  
(0%) 
Confidentiality 
 
4/24 
(16.7%) 
4/14 
(28.6%) 
2/6  
(33.3%) 
1/24  
(4.2%) 
0/14  
(0%) 
0/6  
(0%) 
0/24  
(0%) 
0/14  
(0%) 
0/6  
(0%) 
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Don’t want to 
carry on 
4/24 
(16.7%) 
2/14  
(14.3) 
1/6  
(16.7%) 
0/24  
(0%) 
0/14  
(0%) 
0/6  
(0%) 
0/24  
(0%) 
0/14  
(0%) 
0/6  
(0%) 
GP 
 
5/24 
(20.8%) 
6/14 
(42.9%) 
3/6  
(50%) 
1/24  
(4.2%) 
1/14  
(7.1%) 
1/6  
(16.7%) 
1/24 
(4.2%) 
0/14  
(0%) 
0/6  
(0%) 
Samples 
 
7/24 
(29.2%) 
4/14 
(28.6%) 
4/6  
(66.7%) 
      
Genetic tests 
 
5/24 
(20.8%) 
3/14 
(21.4%) 
2/6  
(33.3%) 
      
Results  
 
5/24 
(20.8%) 
4/14 
(28.6%) 
2/6  
(33.3%) 
2/24  
(8.3%) 
0/14  
(0%) 
1/6  
(16.7%) 
2/24 
(8.3%) 
0/14  
(0%) 
0/6  
(0%) 
Organising 
and funding 
 
7/24 
(29.2%) 
2/14  
(14.3) 
2/6  
(33.3%) 
2/24  
(8.3%) 
1/14  
(7.1%) 
1/6  
(16.7%) 
2/24 
(8.3%) 
0/14  
(0%) 
0/6  
(0%) 
Reviewed 
study 
 
4/24 
(16.7%) 
4/14 
(28.6%) 
3/6  
(50%) 
2/24  
(8.3%) 
1/14  
(7.1%) 
1/6  
(16.7%) 
2/24 
(8.3%) 
0/14  
(0%) 
0/6  
(0%) 
Further info 
and contact 
4/24 
(16.7%) 
4/14 
(28.6%) 
1/6  
(16.7%) 
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Proportions of participants accessing each level of information for each FAQ by gender 
 Level one Level two Level three 
 Male 
 
Female Male Female Male Female 
Purpose of the study 10/24 (41.7%) 8/20 (40.0%) 3/24 (12.5%) 1/20 (5.0%) 1/24 (4.2%) 1/20 (5.0%) 
Have to take part 3/24 (12.5%) 5/20 (25.0%) 0/24 (0%) 0/20 (0%) 0/24 (0%) 0/20 (0%) 
Why been chosen 9/24 (37.5%) 9/20 (45.0%) 1/24 (95.8%) 3/20 (15.0%) 0/24 (0%) 1/20 (5.0%) 
Expenses 13/24 (54.2%) 9/20 (45.0%) 3/24 (12.5%) 2/20 (10.0%) 1/24 (4.2%) 1/20 (5.0%) 
What will happen 13/24 (54.2%) 9/20 (45.0%) 3/24 (12.5%) 1/20 (5.0%) 0/24 (0%) 1/20 (5.0%) 
Risks 12/24 (50.0%) 10/20 (50.0%) 4/24 (16.7%) 3/20 (15.0%) 0/24 (0%) 2/20 (10.0%) 
Benefits 12/24 (50.0%) 9/20 (45.0%) 3/24 (12.5%) 2/20 (10.0%) 1/24 (4.2%) 0/20 (0%) 
Problems 7/24 (29.2%) 9/20 (45.0%) 0/24 (0%) 1/20 (5.0%) 0/24 (0%) 0/20 (0%) 
Confidentiality 4/24 (16.7%) 6/20 (30.0%) 0/24 (0%) 1/20 (5.0%) 0/24 (0%) 0/20 (0%) 
Don’t want to carry on 3/24 (12.5%) 4/20 (20.0%) 0/24 (0%) 0/20 (0%) 0/24 (0%) 0/20 (0%) 
GP 8/24 (33.3%) 6/20 (30.0%) 2/24 (8.3%) 1/20 (5.0%) 1/24 (4.2%) 0/20 (0%) 
Samples 8/24 (33.3%) 7/20 (35%)     
Genetic tests 6/24 (25.0%) 4/20 (20.0%)     
Results  7/24 (29.2%) 4/20 (20.0%) 2/24 (8.3%) 1/20 (5.0%) 1/24 (4.2%) 1/20 (5.0%) 
Organising and funding 6/24 (25.0%) 5/20 (25.0%) 2/24 (8.3%) 2/20 (10.0%) 1/24 (4.2%) 1/20 (5.0%) 
Reviewed study 8/24 (33.3%) 3/20 (15.0%) 2/24 (8.3%) 2/20 (10.0%) 1/24 (4.2%) 1/20 (5.0%) 
Further info and contact 6/24 (25.0%) 3/20 (15.0%)     
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Proportions of participants accessing each level of information for each FAQ by ethnicity 
 Level one Level two Level three 
Ethnic group 
 
WB SA BC WB SA BC WB SA BC 
Purpose of the 
study 
12/31 
(38.7%) 
1/2  
(50.0%) 
5/9  
(55.6%) 
2/31  
(6.5%) 
0/2  
(0%) 
2/9  
(22.2%) 
1/31  
(3.2%) 
0/2  
(0%) 
1/9  
(11.1%) 
Have to take 
part 
6/31 
(19.4%) 
1/2  
(50.0%) 
1/9  
(11.1%) 
0/31  
(0%) 
0/2  
(0%) 
0/9  
(0%) 
0/31  
(0%) 
0/2  
(0%) 
0/9  
(0%) 
Why been 
chosen 
14/31 
(45.2%) 
1/2  
(50.0%) 
3/9  
(33.3%) 
4/31  
(12.9%) 
0/2  
(0%) 
0/9  
(0%) 
1/31  
(3.2%) 
0/2  
(0%) 
0/9  
(0%) 
Expenses 15/31 
(48.4%) 
2/2  
(100%) 
5/9  
(55.6%) 
4/31  
(12.9%) 
0/2  
(0%) 
1/9  
(11.1%) 
1/31  
(3.2%) 
0/2  
(0%) 
1/9  
(11.1%) 
What will 
happen 
15/31 
(48.4%) 
1/2  
(50.0%) 
6/9  
(66.7%) 
3/31  
(9.7%) 
0/2  
(0%) 
1/9  
(11.1%) 
1/31  
(3.2%) 
0/2  
(0%) 
0/9  
(0%) 
Risks 16/31 
(51.6%) 
1/2  
(50.0%) 
5/9  
(55.6%) 
5/31  
(16.1%) 
0/2  
(0%) 
2/9  
(22.2%) 
2/31  
(6.5%) 
0/2  
(0%) 
0/9  
(0%) 
Benefits 16/31 
(51.6%) 
1/2  
(50.0%) 
4/9  
(44.4%) 
3/31  
(9.7%) 
0/2  
(0%) 
2/9  
(22.2%) 
0/31  
(0%) 
0/2  
(0%) 
1/9  
(11.1%) 
Problems 12/31 
(38.7%) 
1/2  
(50.0%) 
3/9  
(33.3%) 
1/31  
(3.2%) 
0/2  
(0%) 
0/9  
(0%) 
0/31  
(0%) 
0/2  
(0%) 
0/9  
(0%) 
Confidentiality 8/31 
(25.8%) 
0/2  
(0%) 
2/9  
(22.2%) 
1/31  
(3.2%) 
0/2  
(0%) 
0/9  
(0%) 
0/31  
(0%) 
0/2 
(0%) 
0/9  
(0%) 
Don’t want to 
carry on 
7/31 
(22.6%) 
0/2  
(0%) 
0/9  
(0%) 
0/31  
(0%) 
0/2  
(0%) 
0/9 (0%) 0/31  
(0%) 
0/2  
(0%) 
0/9  
(0%) 
GP 
 
11/31 
(35.5%) 
0/2  
(0%) 
3/9  
(33.3%) 
2/31  
(6.5%) 
0/2  
(0%) 
1/9 
(11.1%) 
0/31  
(0%) 
0/2  
(0%) 
1/9  
(11.1%) 
Samples 11/31 
(35.5%) 
0/2  
(0%) 
4/9  
(44.4%) 
      
Genetic tests 6/31 
(19.4%) 
0/2  
(0%) 
4/9  
(44.4%) 
      
Results  8/31 
(25.8%) 
0/2  
(0%) 
3/9  
(33.3%) 
2/31  
(6.5%) 
0/2  
(0%) 
1/9 
(11.1%) 
1/31  
(3.2%) 
0/2  
(0%) 
1/9  
(11.1%) 
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Organising 
and funding 
8/31 
(25.8%) 
1/2  
(50.0%) 
2/9  
(22.2%) 
3/31  
(9.7%) 
0/2  
(0%) 
1/9 
(11.1%) 
1/31  
(3.2%) 
0/2  
(0%) 
1/9  
(11.1%) 
Reviewed 
study 
9/31 
(29.0%) 
0/2  
(0%) 
2/9  
(22.2%) 
3/31  
(9.7%) 
0/2  
(0%) 
1/9 
(11.1%) 
1/31  
(3.2%) 
0/2  
(0%) 
1/9  
(11.1%) 
Further info 
and contact 
8/31 
(25.8%) 
0/2  
(0%) 
1/9  
(11.1%) 
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9.8 INFORMATION INCLUDED IN THE STREAMLINED PIS 
 
Bp-Eth 
Participant Invitation Sheet 
 
You are being invited to take part in a research study about the different ways of 
measuring blood pressure.  Please take time to read the following information 
carefully and discuss it with your friends and relatives if you wish.  Ask us if there is 
anything that is not clear or if you would like more information.    
 
If you decide to take part you will make three visits to your GP surgery over 10 days.  
During that time you will be asked to have a 24 hour blood pressure monitor and take 
your own blood pressure for a week.  The possible benefits of taking part are that 
your GP will be given the blood pressure measurements and offer you treatment if 
you need it.  The possible risks of taking part are that some people find it 
uncomfortable to have their blood pressure measured.  Any travel expenses you 
incur during this study will be refunded.  We would like to let your GP know that you 
are taking part.  Any problems you have during the study will be addressed. 
 
The study will involve 800 participants.  It is up to you to decide whether or not to 
take part and your decision will not affect your healthcare.  If you decide to take part 
you are able to withdraw your consent to participate at any time and this will not 
affect your healthcare.  You will be informed in a timely manner if information 
becomes available that may be relevant to your willingness to continue in the study. 
 
Your taking part in this study will be kept confidential and will not be made publically 
available.  If the results of the trial are published, your identity will remain confidential.  
Personal data (names and addresses) will be only accessible by authorised persons 
such as researchers and regulatory authorities.  
 
You can get more information about this study by:  
o Accessing the study website at www.studywebsite.co.uk 
o Contacting Professor Richard McManus’s study team on  to 
request a more detailed information sheet or to ask any specific questions that 
you have 
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9.9  APPENDIX 7 – MINUTES FROM MEETING WITH NRES EXPERT PANEL 
 
1. What do Potential Research Participants Want To Know? 
 
Received for information/discussion: A presentation by Ms Helen Kirkby (HK), Dr 
Melanie Calvert (MC), Professor Heather Draper (HDr) 
 
 Summary: “What do potential Research participants want to know?” 
 What potential research participants want to know about research: a 
systematic review  - BMJ Open 2012;2:e000509. doi:10.1136/bmjopen-
2011-000509 
 
The panel were invited to discuss the applications of the results of this study with the 
researchers 
 
Professor Draper explained that they would like to seek the panel's views on two 
issues: 
 
1. The format and use of the ‘reduced’ information sheet 
2. How to take this work forward 
 
SiWo explained that as a REC vice-chair his REC frequently advised researchers to 
produce information sheet similar to the "reduced" information sheet presented to the 
panel. However, he wondered how such a patient information sheet (PIS) would fit in 
to the overall informed consent process. Where did the PIS sit within this process. He 
noted that the GMC state that in taking consent researchers “must ensure that any 
individuals whom you invite to take part in research are given the information which 
they want or ought to know, and that is presented in terms and a form that they can 
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understand.”6 The question of what the participant ought to know is an area that 
RECs will have an opinion on. 
 
HDr asked, if we accept that the role of the consent interview is more important and 
takes precedence over the information provided in the PIS, what things must be 
patients know before deciding whether to take part in a piece of research. She also 
asked whether the "24-hour rule" might be reduced in appropriate circumstances. 
The panel informed HDr that allowing potential participants at least 24 hours to 
consider their participation had never been a "rule" nor stipulated in any guidance. 
 
SiWo stated that patients rely on many sources of knowledge some of which they 
have prior to being approached to take part in research e.g. knowledge gained from 
being a patient etc. AG agreed stating that RECs may not always take into account 
the prior knowledge of the intended audience. 
 
JS commented that the study population in the team’s research was probably 
younger than the average clinical research participant. HK acknowledged that one of 
their concerns was that the use of technology might not be appropriate for many 
older people. 
 
JS stated that the PIS was not as important as what is said verbally to potential 
participants and their relationship with the researcher/HCP. RT commented that 
whilst this was probably correct it highlighted the need for impartial written 
information to be provided. 
 
JS felt that the issue of gaining consent had parallels with the ‘paradox of enquiry’ 
presented in Plato's Meno: “…man cannot enquire either about that which he knows, 
                                            
6
 GMC, Research: The Role and Responsibilities of Doctors (2002) para 19. http://www.gmc-
uk.org/Research_the_role_and_responsibilities_of_doctors_2002.pdf_31588009.pdf  
 
(NB guidance withdrawn April 2010 and replaced by ’Good practice in research and Consent to 
research – supplementary guidance’ (04 May 2010) which now states: “You must give people the 
information they want or need in order to decide whether to take part in research. How much 
information you share with them will depend on their individual circumstances. You must not make 
assumptions about the information a person might want or need, or their knowledge and 
understanding of the proposed research project.”  
http://www.gmc-uk.org/static/documents/content/Research_guidance_FINAL.pdf  
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or about that which he does not know; for if he knows, he has no need to enquire; 
and if not, he cannot; for he does not know the, very subject about which he is to 
enquire.7” i.e. potential research participants do not know what it is they need to 
know. HDr agreed saying that there were circles of information: patient judgement 
was overlaid with what is required to be given to the patient. However, we do have a 
consent process whereby patients are verbally given information that it is considered 
necessary for them to know. 
 
AG commented that if a REC thinks there are a core number of items that potential 
participants should know then that REC has to decide what they are. It might be 
possible that the researcher or other person taking consent might then test the 
participant on those core items to ensure that they have taken in the essential 
information. HDr agreed but felt that there would then need to be guidance on what 
the core items should be. If a participant did not wish to know one of those pieces of 
information then they might be barred from the research. 
 
SiWo explained that he had been working recently on the concept of therapeutic 
misconception and noted that if patients do fail to perceive that research aims are 
different to the aims of treatment that at least the current governance framework 
means that we are dealing with well-defined and relatively "safe" research studies. 
Participants who took part in such studies even though they had an incomplete 
understanding of the true aims would at least be taking part in a relatively safe 
activity. 
 
RT noted that all medicines come with an information leaflet included in the box. If 
something untoward happens to the patient then they immediately go to the leaflet. 
He felt this was similar to research information sheets in that there needed to be a 
document that participants could refer to when needed. SiWo noted that there are 
occasions where clinical trials will have very serious side effects and asked whether 
we can really afford for patients not to be made aware about such things. RT agreed 
and felt that this is where the interview process comes in. 
 
RT felt one of the main issues was one of "trust". He felt that patients in this country 
particularly are still very trusting of their healthcare professionals, not as much as 
they once were still more than in other countries. This culture of trust was still very 
important factor in a patient’s decision to take part or not in research as they will tend 
to trust an invitation coming from their doctor or other healthcare professional. 
 
NT was concerned that the research presented to the panel involved a lower risk 
study and that there was a real danger in extrapolating from this to other higher risk 
studies. In addition, he felt that not everybody would be able to access the extra 
layers of information provided through the Internet. He stated that he felt the purpose 
of a PIS was for future referral and also as a "legal" document to prove that the 
researchers have provided the necessary information to the participant. 
                                            
7
 http://classics.mit.edu/Plato/meno.html  
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HDr asked whether the panel thought that RECs would be happy if the use of 
streamlined information was applied to higher risk studies. She added that the more 
complex the study the more likely patients are to return to the study information and 
that by using an Interactive Information Sheet (IIS) it would be possible to track 
exactly what information they are accessing and how often. 
 
NT stated that he understood where Prof Draper's team were coming from but felt it 
was important to note that RECs do constantly ask for information sheets to be 
simplified. FW agreed but felt that information sheets still required a number of 
essential items. NT agreed but felt that these could be much shorter for low-risk 
information sheets. 
 
AT stated that in his opinion information sheets are primarily intended to provide 
protection for the pharmaceutical industry. The reason that 20 page information 
sheets are produced by pharma companies was so that they can avoid being sued 
for not providing sufficient information. 
 
AG noted that RECs would often use the information sheet as a test of whether the 
researcher was able to communicate effectively. An incomprehensible information 
sheet would invite the REC to question whether the researcher would be able to 
communicate the necessary information to the patient verbally. 
 
HD congratulated the team on the work and stated that he would be very happy to 
work with them to take this work forward. He suggested that at this stage it might be 
sensible to collect more data in high risk studies regarding what information patients 
are actually using before going on to conduct a randomised trial of different PIS 
formats. He also thought that they might usefully talk to Pfizer as they were currently 
in the process of setting up studies using Internet-based information. HD also noted 
that Jane Kaye was looking at similar areas and referred Prof Draper's team to her 
recent article in ‘Nature Reviews Genetics 13, 371-376 (May 2012), 
doi:10.1038/nrg3218 “From patients to partners: participant-centric initiatives in 
biomedical research”8 he also felt it might be useful to discuss this with the EFGCP in 
order to investigate proceeding with this work as there were a large number of people 
in Europe who would be interested. He suggested they contact Jan Geissler at 
EFGCP (http://www.efgcp.be/Bio.asp?membid=753). 
 
RT also suggested that they might like to talk to INVOLVE about this work and how 
to take it forward. 
 
HDr asked whether the panel thought they would be able to get REC approval for 
such studies.AG felt that the use of IISs might be extended to higher risk studies 
provided that appropriate safeguards were put in place such to ensure that all 
participants have real access to the full information if they required it. An easy way to 
                                            
8
 http://www.nature.com/nrg/journal/v13/n5/abs/nrg3218.html 
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initially simplify and stratify information provided would be to separate the information 
along the lines of the current part one and part two sections of the NRES standard 
information sheet format. Information regarding insurance, confidentiality etc might 
be separated out into a separate layer of information that could be accessed if 
required. AG felt that whilst there was clearly a risk in trialling the use of reduced 
information he also noted that it was in line with NRES’ wish to produce more 
evidence-based guidance.  
 
HD suggested that it might be useful if they attend the EFGCP Annual Conference in 
Brussels on 29 & 30 January 2013 entitled "Virtual Future: what are the ethical 
dimensions of using emerging 
technologies in clinical trials and research?”. 
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